Heparin-Associated Polypeptides and Uses Thereof

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said copy, created on Aug. 10, 2023, is named 54275-702_302_SL.xml and is 108,873 bytes in size.

BACKGROUND

As the average life span increases, increasing emphasis is placed upon “healthy aging.” Individuals would like to live more active lifestyles as they age, and as a result, many aging disorders can have a significant impact on the quality of life of aging individuals. Treatments directed to regenerative ends have utility for treating aging diseases. Additionally, many treatments for aging disorders can be applicable to younger individuals who have suffered illness, injury, or who possess genetic or developmental defects leading to premature tissue loss, wasting, or weakening.

SUMMARY

As individuals age, tissue progenitor cells lose their regenerative potential. Described herein, in certain aspects, are heparin-associated polypeptides that can restore some or all of this regenerative potential, and are thus useful in the treatment of aging disorders that result in tissue loss or underperformance, and rehabilitation from injury. Described herein are therapeutic compositions comprising heparin-associated polypeptides and methods of treating disorders associated with aging, injury, or illness. In certain embodiments, the therapeutic compositions comprise one or more heparin-associated polypeptides that possess mitogenic (i.e., regenerative) and/or fusion promoting activity to a somatic cell, such as a tissue progenitor cell. In certain embodiments, the therapeutic compositions have activity towards muscle and soft tissue progenitor cells. In certain embodiments these compositions possess utility in treating sarcopenia, cachexia, muscular dystrophy, acute and chronic muscle wasting diseases, and muscle, ligament, or tendon injury, or any combination of these diseases or conditions.

In one aspect, described herein is a composition comprising: (a) a first therapeutic polypeptide comprising a first polypeptide of Table 2, and (b) a second therapeutic polypeptide comprising a second polypeptide of Table 2. In certain embodiments, the first polypeptide of Table 2 is a first polypeptide of Table 1 and/or the second polypeptide of Table 2 is a second polypeptide of Table 1. In certain embodiments, the first polypeptide of Table 2 comprises THBS1, THBS2, THBS4, FGF17, VTN, POSTN, IGF2, or IL-15, or any combination thereof. In certain embodiments, the second polypeptide of Table 2 comprises THBS1, THBS2, THBS4, FGF17, VTN, POSTN, IGF2, or IL-15, or any combination thereof.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises THBS2 and/or a sequence comprising at least about 90% homology to amino acids 19-1172 of SEQ ID NO: 4.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11.

In certain embodiments, the first polypeptide of Table 2 comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9; and the second polypeptide of Table 2 comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10.

In certain embodiments, the first polypeptide of Table 2 comprises THBS2 and/or a sequence comprising at least about 90% homology to amino acids 19-1172 of SEQ ID NO: 4; and the second polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8. In certain embodiments, the composition further comprises IL-15 and/or a polypeptide comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10. In certain embodiments, the composition further comprises IGF2 and/or a polypeptide comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11.

In certain embodiments, the first polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8; and the second polypeptide of Table 2 comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7.

In certain embodiments, the first polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8; and the second polypeptide of Table 2 comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1.

In certain embodiments, the first polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8; and the second polypeptide of Table 2 comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6.

In certain embodiments, the first polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acid s 27-961 of SEQ ID NO: 8; and the second polypeptide of Table 2 comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11.

In certain embodiments, the first polypeptide of Table 2 comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8; and the second polypeptide of Table 2 comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10.

In certain embodiments, the first polypeptide of Table 2 comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7; and the second polypeptide of Table 2 comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1.

In certain embodiments, the first polypeptide of Table 2 comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7; and the second polypeptide of Table 2 comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6.

In certain embodiments, the first polypeptide of Table 2 comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7; and the second polypeptide of Table 2 comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11.

In certain embodiments, the first polypeptide of Table 2 comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7; and the second polypeptide of Table 2 comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10.

In certain embodiments, the first polypeptide of Table 2 comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1; and the second polypeptide of Table 2 comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6.

In certain embodiments, the first polypeptide of Table 2 comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1; and the second polypeptide of Table 2 comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11.

In certain embodiments, the first polypeptide of Table 2 comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1; and the second polypeptide of Table 2 comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10.

In certain embodiments, the first polypeptide of Table 2 comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6; and the second polypeptide of Table 2 comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11.

In certain embodiments, the first polypeptide of Table 2 comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6; and the second polypeptide of Table 2 comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10.

In certain embodiments, the first polypeptide of Table 2 comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11; and the second polypeptide of Table 2 comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10.

In certain embodiments, the first therapeutic polypeptide has been recombinantly produced, the second polypeptide has been recombinantly produced, or both the first and second therapeutic polypeptides have been recombinantly produced. In certain embodiments, the first therapeutic polypeptide has been produced in a mammalian, yeast, insect or bacteria cell, the second polypeptide has been produced in a mammalian, yeast, insect or bacteria cell, or both the first and second therapeutic polypeptides have been produced in a mammalian, yeast, insect or bacteria cell. In certain embodiments, the first therapeutic polypeptide and/or the second therapeutic polypeptide have been produced in a mammalian cell and the mammalian cell is a human cell. In some cases the human cell is a human embryonic kidney-derived epithelial cell (e.g., HEK293 cell). In certain embodiments, the first therapeutic polypeptide has been produced in a mammalian cell and the mammalian cell is a Chinese Hamster Ovary (CHO) cell or mouse myeloma cell. In certain embodiments, the second therapeutic polypeptide has been produced in a mammalian cell and the mammalian cell is a Chinese Hamster Ovary (CHO) cell or mouse myeloma cell. In certain embodiments, the first therapeutic polypeptide and/or the second therapeutic polypeptide has been purified from a human biological sample. In some cases, the human biological sample is human plasma. In certain embodiments, the composition further comprises a pharmaceutically acceptable excipient. In certain embodiments, the composition is formulated for administration by injection. In certain embodiments, the injection is intramuscular. In certain embodiments, the injection is subcutaneous. In certain embodiments, the injection is intravenous.

In another aspect, described herein is a composition comprising a polypeptide of Table 2 and a pharmaceutically acceptable excipient. In certain embodiments, the polypeptide comprises VTN and/or a sequence comprising at least about 90% homology to amino acids 20-478 of SEQ ID NO: 1. In certain embodiments, the polypeptide comprises POSTN and/or a sequence comprising at least about 90% homology to amino acids 22-836 of SEQ ID NO: 6. In certain embodiments, the polypeptide comprises FGF17 and/or a sequence comprising at least about 90% homology to amino acids 23-2165 of SEQ ID NO: 7. In certain embodiments, the polypeptide comprises THBS2 and/or a sequence comprising at least about 90% homology to amino acids 19-1172 of SEQ ID NO: 4. In certain embodiments, the polypeptide comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8. In certain embodiments, the polypeptide comprises THBS1 and/or a sequence comprising at least about 90% homology to amino acids 19-1170 of SEQ ID NO: 9. In certain embodiments, the polypeptide comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10. In certain embodiments, the polypeptide comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11. In certain embodiments, the polypeptide has been produced in a mammalian cell and the mammalian cell is a human cell. In some cases the human cell is a human embryonic kidney-derived epithelial cell (e.g., HEK293 cells). In certain embodiments, the polypeptide has been expressed from a Chinese Hamster Ovary (CHO) cell, or mouse myeloma (NS0) cell, insect, or a bacterial cell. In some cases the bacterial cell is an E. coli cell. In certain embodiments, the polypeptide has been purified from a human biological sample. In some cases, the human biological sample is human plasma. In certain embodiments, the polypeptide is synthetically produced. In certain embodiments, the polypeptide possesses mitogenic and/or fusion promoting activity. Further described is a nucleic acid encoding the polypeptide described herein. Further described is a cell line comprising the nucleic acid.

Further described herein is a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a composition described herein. In certain embodiments, the disease or condition comprises an aging disorder, muscle wasting disorder, muscle injury, or injury to connective tissue, or a combination thereof. In certain embodiments, the subject has the aging disorder and the aging disorder comprises sarcopenia. In certain embodiments, the subject has the muscle wasting disorder and the muscle wasting disorder comprises muscular dystrophy. In certain embodiments, the subject has the muscle wasting disorder and the muscle wasting is a result of obesity, disease progression, metabolic disorder, or therapeutic treatment, or a combination thereof. In certain embodiments, the metabolic disorder is diabetes. In some cases the diabetes is Type 2 Diabetes. In certain embodiments, the subject has the muscle wasting disorder and the muscle wasting is cachexia, e.g., muscular cachexia.

In another aspect, described herein is a composition comprising: (a) a first therapeutic polypeptide comprising THBS1, THBS2, THBS4, FGF17, VTN, POSTN, IGF2, or IL-15, and (b) a second therapeutic polypeptide comprising THBS1, THBS2, THBS4, FGF17, VTN, POSTN, IGF2, or IL-15. In certain embodiments, the first therapeutic polypeptide has been recombinantly produced, the second polypeptide has been recombinantly produced, or both the first and second therapeutic polypeptides have been recombinantly produced. In certain embodiments, the first therapeutic polypeptide has been produced in a mammalian, yeast, insect or bacteria cell, the second polypeptide has been produced in a mammalian, yeast, insect or bacteria cell, or both the first and second therapeutic polypeptides have been produced in a mammalian, yeast, insect or bacteria cell. In certain embodiments, the polypeptide has been produced in a mammalian cell and the mammalian cell is a human cell. In some cases the human cell is a human embryonic kidney-derived epithelial cell (e.g., HEK293 cells). In certain embodiments, the first therapeutic polypeptide has been produced in a mammalian cell and the mammalian cell is a Chinese Hamster Ovary (CHO) cell or mouse myeloma cell. In certain embodiments, the second therapeutic polypeptide has been produced in a mammalian cell and the mammalian cell is a Chinese Hamster Ovary (CHO) cell or mouse myeloma cell. In certain embodiments, the polypeptide has been purified from a human biological sample. In some cases, the human biological sample is human plasma.

In certain embodiments, the first therapeutic polypeptide comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10; and the second therapeutic polypeptide comprises THBS2 and/or a sequence comprising at least about 90% homology to amino acids 19-1172 of SEQ ID NO: 4. In certain embodiments, the first therapeutic polypeptide comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10; and the second therapeutic polypeptide comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8. In certain embodiments, the first therapeutic polypeptide comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11; and the second therapeutic polypeptide comprises THBS2 and/or a sequence comprising at least about 90% homology to amino acids 19-1172 of SEQ ID NO: 4. In certain embodiments, the first therapeutic polypeptide comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11; and the second therapeutic polypeptide comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8. In certain embodiments, the first therapeutic polypeptide comprises THBS4 and/or a sequence comprising at least about 90% homology to amino acids 27-961 of SEQ ID NO: 8; and the second therapeutic polypeptide comprises THBS2 and/or a sequence comprising at least about 90% homology to amino acids 19-1172 of SEQ ID NO: 4. In certain embodiments, the composition further comprises IL-15 and/or a sequence comprising at least about 90% homology to amino acids 49-162 of SEQ ID NO: 10. In certain embodiments, the composition further comprises IGF2 and/or a sequence comprising at least about 90% homology to amino acids 25-91 of SEQ ID NO: 11. In certain embodiments, the composition further comprises a pharmaceutically acceptable excipient. In certain embodiments, the composition is formulated for administration by injection. In certain embodiments, the injection is intramuscular. In certain embodiments, the injection is subcutaneous. In certain embodiments, the injection is intravenous.

In certain embodiments, described herein is a composition comprising THBS2 and THBS4. The composition may comprise VTN. The composition may comprise ANOS1. The composition may comprise IL-15. The composition may comprise IGF2. In certain embodiments, the composition comprises THBS2, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, THBS4, and ANOS1. In certain embodiments, the composition comprises THBS2, THBS4, and IL-15. In certain embodiments, the composition comprises THBS2, THBS4, and IGF2. In certain embodiments, the composition further comprises a pharmaceutically acceptable excipient. In certain embodiments, the composition is formulated for administration by injection. In certain embodiments, the injection is intramuscular. In certain embodiments, the injection is subcutaneous. In certain embodiments, the injection is intravenous.

In certain embodiment, described herein is a composition comprising THBS1 and FGF17. In certain embodiment, described herein is a composition comprising THBS2 and VTN. In certain embodiment, described herein is a composition comprising THBS1 and VTN. In certain embodiment, described herein is a composition comprising THBS1 and THBS2. In certain embodiment, described herein is a composition comprising THBS2 and FGF17. In certain embodiment, described herein is a composition comprising THBS1 and THBS4. In certain embodiment, described herein is a composition comprising VTN and FGF17. In certain embodiment, described herein is a composition comprising THBS4 and VTN. In certain embodiment, described herein is a composition comprising THBS4 and FGF17. In certain embodiments, the composition further comprises a pharmaceutically acceptable excipient. In certain embodiments, the composition is formulated for administration by injection. In certain embodiments, the injection is intramuscular. In certain embodiments, the injection is subcutaneous. In certain embodiments, the injection is intravenous.

Further described is a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a composition described herein. In certain embodiments, the disease or condition comprises an aging disorder, muscle wasting disorder, muscle injury, or injury to connective tissue, or a combination thereof. In certain embodiments, the subject has the aging disorder and the aging disorder comprises sarcopenia. In certain embodiments, the subject has the muscle wasting disorder and the muscle wasting disorder comprises muscular dystrophy. In certain embodiments, the subject has the muscle wasting disorder and the muscle wasting is a result of obesity, metabolic disorder, disease progression, or therapeutic treatment, or a combination thereof. In certain embodiments, the metabolic disorder is diabetes. In some cases the diabetes is Type 2 Diabetes. In certain embodiments, the subject has the muscle wasting disorder and the muscle wasting is cachexia, e.g., muscular cachexia.

In a certain aspect, described herein, is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the polypeptide is a heparin-associated polypeptide secreted from a stem cell or a transformed cell line, wherein the heparin-associated polypeptide possesses mitogenic and/or fusion promoting activity. In certain embodiments, the composition comprises a plurality of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the plurality comprises two, three, four, five, six, seven, eight, nine, ten or more polypeptides. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly produced. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. In certain embodiments, the stem cell is a pluripotent stem cell. In certain embodiments, the stem cell is an induced pluripotent stem cell. In certain embodiments, the mitogenic activity comprises the ability to increase proliferation in a somatic cell and/or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. In certain embodiments, the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells and/or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. In certain embodiments, the somatic cell is a muscle, muscle progenitor cell, tenocyte, or tenocyte precursor. In certain embodiments, the somatic cell is a mammalian cell. In certain embodiments, the somatic cell is a human cell. In certain embodiments, any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are produced in a heterologous cellular production system. In certain embodiments, any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are synthetically produced. In certain embodiments, the polypeptides are purified from human plasma. In certain embodiments, the polypeptides are purified from a mammalian cell, insect cell, or bacterial cell. The mammalian cell may be a human cell. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprises one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system, or any combination thereof. In certain embodiments, the modification is an alteration of one or more amino acids in the polypeptide sequence of mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. In certain embodiments, the mitogenic and/or fusion promoting polypeptide(s) are encoded by a nucleic acid. In certain embodiments, the cell line comprises the nucleic acid encoding the mitogenic and/or fusion promoting polypeptide(s). In certain embodiments, the cell line is a eukaryotic cell line. In certain embodiments, the composition comprises the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, the composition is formulated in injectable form. In certain embodiments, the composition is for use in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or any combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of treating an individual with aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or any combination thereof, the method comprising administering to the individual the composition of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of producing a composition suitable for the treatment of an aging disorder comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides described herein. In certain embodiments, described herein, is a method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing a cell line comprising a nucleic acid expressing a mitogenic and/or fusion promoting polypeptide under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

In another aspect, described herein, is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide is identified by: (a) identifying at least one polypeptide in a mixture of a plurality of polypeptides secreted from a stem cell or a transformed cell line that can be purified with heparin coated matrix; and (b) determining the mitogenic and/or fusion promoting activity of the at least one polypeptide for a somatic cell, wherein the at least one polypeptide is identified as a mitogenic and/or fusion promoting polypeptide if the at least one polypeptide exhibits mitogenic and/or fusion promoting activity. In certain embodiments, the composition comprises a plurality of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the plurality comprises three, four, five, six, seven, eight, nine, ten or more polypeptides. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly produced. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. In certain embodiments, the stem cell is a pluripotent stem cell. In certain embodiments, the stem cell is an induced pluripotent stem cell. In certain embodiments, the mitogenic and/or fusion promoting activity comprises the ability to increase proliferation in a somatic cell or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. In certain embodiments, the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. In certain embodiments, the somatic cell is a muscle, muscle progenitor cell, tenocyte, or tenocyte precursor. In certain embodiments, the somatic cell is a mammalian cell. In certain embodiments, the somatic cell is a human cell. In certain embodiments, any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are produced in a heterologous cellular production system. In certain embodiments, any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are synthetically produced. In certain embodiments, the polypeptides are purified from human plasma. In certain embodiments, the polypeptides are purified from a mammalian cell, insect cell, or bacterial cell. The mammalian cell may be a human cell. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprises one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. In certain embodiments, the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. In certain embodiments, the mitogenic and/or fusion promoting polypeptide(s) are encoded by a nucleic acid. In certain embodiments, the cell line comprises the nucleic acid encoding the mitogenic and/or fusion promoting polypeptide(s). In certain embodiments, the cell line is a eukaryotic cell line. In certain embodiments, the composition comprises the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, the composition is formulated in injectable form. In certain embodiments, the composition is for use in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or any combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of treating an individual with aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or any combination thereof, the method comprising administering to the individual the composition of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of producing a composition suitable for the treatment of an aging disorder comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides described herein. In certain embodiments, described herein, is a method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing a cell line comprising a nucleic acid expressing a mitogenic and/or fusion promoting polypeptide under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

In another aspect, described herein, is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide comprises ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, RPL29, a protein listed in Table 2, or a protein listed in Table 1, or any combination thereof. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises VTN, STC2, AGRN, POSTN, FGF17, THBS2, FST, THBS4, IGF2, IL-15, or THBS1, or a combination thereof. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises one or more of VTN, POSTN, FGF17, THBS2, IGF2, IL-15, THBS1, and THBS4. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises VTN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises STC2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises AGRN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises FST. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises POSTN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises FGF17. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS4. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises IGF2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises IL-15. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS1. In certain embodiments, the composition comprises a plurality of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the plurality comprises three, four, five, six, seven, eight, nine, ten or more polypeptides. The plurality of polypeptides may comprise one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 2. The plurality of polypeptides may comprise one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 1. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises IGF2, THBS2, and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises IL-15, THBS2, and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and ANOS1. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and IL-15. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and IGF2. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and THBS2. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises VTN and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS4 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS4 and FGF17. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly produced. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. In certain embodiments, the stem cell is a pluripotent stem cell. In certain embodiments, the stem cell is an induced pluripotent stem cell. In certain embodiments, the mitogenic activity comprises the ability to increase proliferation in a somatic cell or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. In certain embodiments, the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells and/or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. In certain embodiments, the somatic cell is a muscle, muscle progenitor cell, tenocyte, or tenocyte precursor. In certain embodiments, the somatic cell is a mammalian cell. In certain embodiments, the somatic cell is a human cell. In certain embodiments, any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are produced in a heterologous cellular production system. In certain embodiments, any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are synthetically produced. In certain embodiments, the polypeptides are purified from human plasma. In certain embodiments, the polypeptides are purified from a mammalian cell, insect cell, or bacterial cell. The mammalian cell may be a human cell. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprises one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. In certain embodiments, the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. In certain embodiments, the mitogenic and/or fusion promoting polypeptide(s) are encoded by a nucleic acid. In certain embodiments, the cell line comprises the nucleic acid encoding the mitogenic and/or fusion promoting polypeptide(s). In certain embodiments, the cell line is a eukaryotic cell line. In certain embodiments, the composition comprises the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, the composition is formulated in injectable form. In certain embodiments, the composition is for use in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of treating an individual with aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof, the method comprising administering to the individual the composition of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of producing a composition suitable for the treatment of an aging disorder comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides described herein. In certain embodiments, described herein, is a method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing a cell line comprising a nucleic acid expressing a mitogenic and/or fusion promoting polypeptide under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

In another aspect, described herein, is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide comprises VTN, STC2, AGRN, POSTN, FGF17, THBS2, FST, THBS4, IGF2, IL-15, or THBS1, or a combination thereof. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises one or more of VTN, POSTN, FGF17, THBS2, THBS4, IGF2, IL-15, and THBS1. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises VTN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises STC2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises AGRN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises FST. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises POSTN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises FGF17. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS4. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises IGF2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises IL-15. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS1. In certain embodiments, the composition comprises a mixture of a plurality of different mitogenic and/or fusion promoting polypeptides. In certain embodiments, the plurality of different mitogenic and/or fusion promoting polypeptides comprise three, four, or five different mitogenic and/or fusion promoting polypeptides. The plurality of polypeptides may comprise one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 2. The plurality of polypeptides may comprise one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 1. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises IGF2, THBS2, and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises IL-15, THBS2, and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and ANOS1. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and IL-15. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and IGF2. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and THBS2. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises VTN and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS4 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS4 and FGF17. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly or synthetically produced. In certain embodiments, the polypeptides are purified from human plasma. In certain embodiments, the polypeptides are purified from a mammalian cell, insect cell, or bacterial cell. The mammalian cell may be a human cell. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. In certain embodiments, the stem cell is a pluripotent stem cell. In certain embodiments, the stem cell is an induced pluripotent stem cell. In certain embodiments, the mitogenic activity comprises increasing proliferation in a muscle cell precursor. In certain embodiments, the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells and/or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. In certain embodiments, the muscle cell precursor is a myoblast. In certain embodiments, the somatic cell is a mammalian cell. In certain embodiments, the somatic cell is a human cell. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprise one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. In certain embodiments, the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. In certain embodiments, the modification is a fusion of a mitogenic and/or fusion promoting polypeptide to a non-mitogenic or fusion promoting polypeptide. In certain embodiments, the non-mitogenic or fusion promoting polypeptide comprises an immunoglobulin Fc region or serum albumin. In certain embodiments, the non-mitogenic or fusion promoting polypeptide is a human polypeptide. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are concatemerized. In certain embodiments, the concatemerized polypeptides are separated by a polypeptide linker. In certain embodiments, the concatemerized polypeptides are the same polypeptide. In certain embodiments, the concatemerized polypeptides are different polypeptides. In certain embodiments, the concatemerized polypeptides are covalently concatemerized through a non-peptide linkage. In certain embodiments, the concatemerized polypeptides are non-covalently concatemerized. In certain embodiments, a nucleic acid encodes the mitogenic and/or fusion promoting polypeptide. In certain embodiments, a cell line comprises the nucleic acid. In certain embodiments, the cell line is a eukaryotic cell line. In certain embodiments, the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprises a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, the pharmaceutically acceptable excipient, carrier, or diluent increases the function of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the function comprises increasing proliferation in a muscle cell precursor, increasing stability of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides, or increasing bioavailability of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides. In certain embodiments, the composition is for subcutaneous, intravenous, intramuscular, or topical administration. In certain embodiments, the composition is for use in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In certain embodiments, described herein, is a method of treating an individual with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof, the method comprising administering to the individual the composition. In certain embodiments, described herein, is a method of increasing proliferation of a muscle cell or connective tissue cell precursor in an individual comprising administering to the individual the composition. In certain embodiments, the individual is afflicted with or suspected of being afflicted with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia.

Also described is a method of producing a composition suitable for the treatment of an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof, the method comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides. Also described is a method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing a cell line comprising a nucleic acid encoding mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features described herein are set forthwith particularity in the appended claims. A better understanding of the features and advantages of the features described herein will be obtained by reference to the following detailed description that sets forth illustrative examples, in which the principles of the features described herein are utilized, and the accompanying drawings of which:

FIG. 1 shows histology and immunofluorescence staining of injured and regenerated muscle tissue from aged mice treated with heparin-associated polypeptides or vehicle control.

FIG. 2A shows time-points for dosing and analysis of the effects of the entire pool of heparin-associated polypeptides in an acute injury model in aged mice. Squares denote injury inducing intramuscular injection (IM) with Barium Chloride; circles denote administration of treatment or vehicle.

FIG. 2B shows the results of the experiment outlined in FIG. 2A. Administration of hPSC derived factors resulted in improved new fiber formation (regenerative index, left) and reduced scaring (fibrotic index, right) in aged mice to levels similar to those in young mice, both of which were markedly better than vehicle-treated old mice. Stars indicate degree of significance from one-way ANOVA tests.

FIG. 2C shows time-points for dosing and analysis of the effects of the entire pool of heparin-associated polypeptides in an acute injury model in transgenic mice prone to obesity. Squares denote injury inducing intramuscular injection (IM) with Barium Chloride; circles denote administration of treatment or vehicle.

FIG. 2D shows the results of the experiment outlined in FIG. 2C. Administration of hPSC derived factors resulted in improved new fiber formation (regenerative index, left, p<3.5E-6) and reduced scaring (fibrotic index, right, p<8.44E-3) in transgenic obese mice to levels similar to those in positive control (8ngFGF19) treated mice (p<2.3E-5 and p<2.32E-2, respectively), both of which were markedly better than vehicle-treated transgenic obese mice. Stars indicate degree of significance from one-way ANOVA tests.

FIG. 3A-FIG. 3E show heparin-column enrichment of secreted factors from hESC and differentiated cells can be deeply profiled in an unbiased way using isobaric labeling, online reverse phase fractionation, an SPS-MS3 instrument method, and Principle Component Analysis. FIG. 3A depicts the methodology for targeted heparin purification of secreted proteins from media supernatant, isobaric labeling, reverse phase fractionation, and SPS-MS3 mass spectrometry instrument method. FIG. 3B depicts a silver stain gel of heparin purified proteins (left two lanes) compared to buffer only (right most lane), demonstrating enrichment of many protein species by their molecular weight. FIG. 3C depicts a 2D heat map of the intensity (color) of peptides separated by m/z (y-axis) compared to elution from reverse phase nHPLC separation (x-axis). FIG. 3D depicts a K-means clustered heat map of all proteins found in a representative experiment demonstrating the differential abundance of many proteins specifically in the secretome of undifferentiated hPSCs. FIG. 3E depicts Principle Component Analysis of proteins from the same run demonstrating again the differential expressionless (PC1) as well as a high relative degree of reproducibility from undifferentiated hPSCs compared to differentiated cells.

FIG. 4A-FIG. 4B illustrate representative results from an in vitro assay useful to validate the regenerative capacity of factors identified by mass spectroscopy. FIG. 4A shows representative micrographs taken from cells treated with fusion media (neg. control), defined growth media (pos. control), Optimem, supernatant from differentiated hESC, supernatant from undifferentiated hESC, heparin binding proteins eluted from supernatant of undifferentiated hESC under two different conditions, and supernatant of undifferentiated hESC that has been depleted of heparin binding proteins. FIG. 4B shows data expressed as % of nuclei stained with BrdU or % cells stained for embryonic myosin heavy chain (eMyHC).

FIG. 5A-FIG. 5C show quantitation and representative images demonstrating the proliferation effect of IGFBP7 (330 ng/mL), POSTN (330 ng/mL), SPON1 (330 ng/mL), MST1 (330 ng/mL), and RARRES2 (330 ng/mL) (FIG. 5A); and VTN (10 ug/mL), FGF17 (500 ng/mL), IGF2 (2 ug/mL), FGF4 (500 ng/mL), FGF1 (500 ng/mL), FGF6 (1 ug/mL) (FIG. 5B) in injury activated primary mouse myoblasts grown in vitro, and cellular fusion effect. FIG. 5C shows quantitation and representative images demonstrating the increased cellular fusion effect of THBS1 (330 ng/mL), THBS2 (330 ng/mL), and STC2 (875 ng/mL) in injury activated primary mouse myoblasts grown in vitro.

FIG. 6A-FIG. 6E show quantitation and representative immunofluorescent stained cell images demonstrating the proliferation effect specific heparin-associated polypeptides. FIG. 6A shows the effect of IGFBP5 at 1 ug/mL, FIG. 6B show the effect of THBS4 at 1 ug/mL, FIG. 6C shows the effect of VTN at 10 ug/mL, FIG. 6D shows the effect of FGF17 at 250 ng/mL, and FIG. 6E shows the effect of IGFBP7 at 500 ng/mL—all demonstrated notable effects in injury activated primary human myoblasts, young (18 years old) and aged (both 68 years old), grown in vitro.

FIG. 6F-FIG. 6H, show quantitation and representative images demonstrating the increased cellular fusion effect of SPON1 (1 ug/mL) (FIG. 6F), POSTN (1 ug/mL) (FIG. 6G), PDGFRL (5 ug/mL) (FIG. 6H) in injury activated primary human myoblasts, young (18 years) and old (both 69 years old), grown in vitro.

FIG. 7A provides an exemplary proliferative dose response of mouse myoblasts cultured with hPSC-derived factors Thrombospondin 1 (THBS1) applied at 125 ng/mL, 250 ng/mL, and 500 ng/mL, 1000 ng/ml and 200 ng/ml, and Fibroblast growth factor 17 (FGF17) applied at 12.5 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, and 200 ng/ml.

FIG. 7B shows that while THBS1 showed nonsignificant effects on proliferation of myoblasts (top), FGF17 produced a linear dose-dependent increase in proliferation of myoblasts (bottom).

FIG. 7C shows that the combination of the two produced potentiation type synergy (CI<0.68, p<7.92E-7).

FIG. 7D-FIG. 7M provide examples of synergistic combinations of heparin-associated polypeptides relative to the vehicle only control (_FM) or to treatment with either of the individual heparin-associated polypeptides. Combination Index (CI) values and probability values (p-values) from statistical tests for the synergy models are reported in Table 10. FIG. 7D shows the synergistic effects of THBS1 with VTN. FIG. 7E shows the synergistic effects of THBS1 with THBS2. FIG. 7F shows the synergistic effects of THBS1 with THBS4. FIG. 7G shows the synergistic effects of lower concentrations of THBS2 with varying concentrations of THBS4. FIG. 7H shows the synergistic effects higher concentrations of THBS2 with varying concentrations of THBS4. FIG. 7I shows the synergistic effects of THBS2 with VTN. FIG. 7J shows the synergistic effects of THBS2 with FGF17. FIG. 7K shows the synergistic effects of THBS4 with VTN. FIG. 7L shows the synergistic effects of THBS4 with FGF17. FIG. 7M shows the synergistic effects of VTN with FGF17.

FIG. 8 shows an example of the dose dependent increasing cellular fusion of mouse myoblasts cultured with a heparin-associated polypeptide. In this case Platelet derived growth factor-like (PDGFRL) proteins were applied at 625 ng/mL, 1250 ng/mL, 2500 ng/mL, 5000 ng/mL, and 10000 ng/mL.

FIG. 9A shows the experimental schematic of time-points for dosing and analysis using an acute injury model in aged mice of the effects of individual heparin-associated polypeptides with proliferative effects in vitro. Squares denote injury inducing intramuscular injection (IM) with Barium Chloride; circles denote administration of treatment or vehicle.

FIG. 9B shows the results of the experiment outlined in FIG. 9A. Administration of 20 ul of heparin-associated polypeptides FGF17 (500 ng/mL, p<2.23E-4), THBS1 (2 ug/mL, p<5.83E-5), THBS2 (2 ug/mL, p<2.67E-4), and VTN (10 ug/mL, p<1.13E-2) resulted in improved new fiber formation (regenerative index) in aged mice compared to vehicle-treated aged mice to levels similar or better than young mice. Stars indicate degree of significance from one-way ANOVA tests.

FIG. 9C Representative images of immunofluorescence staining of sectioned mouse muscle (tibialis anterior) demonstrated increased muscle regeneration for injured, aged mouse muscle treated with THBS1 (2 ug/mL) compared to young and vehicle-treated, aged mouse muscle.

FIG. 9E shows the results of the experiment outlined in FIG. 9D. Administration of 20 ul of heparin-associated polypeptides PPDGFRL (5 ug/mL, p<3.85E-2) and IGFBP7 (1 ug/mL, p<6.63E-3) resulted in improved new fiber formation (regenerative index compared to vehicle-treated aged mice. Stars indicate degree of significance from one-way ANOVA tests.

FIG. 9F provides representative images of immunofluorescence staining of sectioned mouse muscle (tibialis anterior) demonstrating increased muscle regeneration for injured, aged mouse muscle treated with POSTN (1 ug/mL) or IGFBP7 (1 ug/mL) compared to vehicle-treated, aged mouse muscle.

FIG. 10A shows the experimental schematic of time-points for in vivo injury and individual heparin-associated polypeptide administration followed by muscle excision, dissociation, ex vivo culturing of activated myoblasts and quantitation by chemical and immunofluorescent labelling.

FIG. 10B provides resulting quantitation that demonstrates the regenerative effect of heparin-associated polypeptide administration (FGF17) of 20 ul at 500 ng/ml improved the regeneration of new myoblasts in aged mice above the vehicle-treated aged mice (p<7.57E-8) to a level similar to those seen in young mice.

FIG. 10C provides representative immunofluorescence images for ex vivo cultured, injury activated myoblasts used for quantitative evaluation of factor efficacy.

FIG. 11A shows the experimental schematic of time-points for in vivo injury followed by muscle excision, dissociation, ex vivo culturing of activated myoblasts, then individual heparin-associated polypeptide administration and quantitation by chemical and immunofluorescent labelling.

FIG. 11B provides resulting quantitation that demonstrates the regenerative effect of administration of heparin-associated polypeptides FGF17 (500 ng/ml) and THBS4 (2 ug/mL)—each improved the regeneration of new myoblasts in aged mice above the vehicle-treated aged mice (p<1.57E-2, 4.64E-2 respectively, one-sided test) compared to vehicle treated control.

FIG. 11C provides representative immunofluorescence images for ex vivo cultured, injury activated myoblasts used for quantitative evaluation of factor efficacy.

FIG. 12A provides representative quantitation of immunofluorescence images demonstrating the proliferation enhancing effects of heparin-associated polypeptides administration at various does on primary human myoblasts derived from a patient with type 1 myotonic dystrophy.

FIG. 12B provides representative quantitation of immunofluorescence images demonstrating the hypertrophy enhancing effects of heparin-associated polypeptides administration at various does on primary human myoblasts derived from a patient with type 1 myotonic dystrophy.

DETAILED DESCRIPTION

In one aspect, described herein is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide is identified by: (a) identifying at least one polypeptide in a mixture of a plurality of polypeptides secreted from a stem cell or a transformed cell line that can be enriched through association of the mixture with heparin-conjugated beads; and (b) determining the mitogenic and/or fusion promoting activity of the at least one polypeptide for a somatic cell, wherein at least one polypeptide is identified as a mitogenic and/or fusion promoting polypeptide if at least one polypeptide exhibits mitogenic and/or fusion promoting activity.

In another aspect, described herein is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the polypeptide is a heparin-associated polypeptide secreted from a stem cell or a transformed cell line, wherein the heparin-associated polypeptide possesses mitogenic and/or fusion promoting activity. In certain embodiments, the composition is for use in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof. In certain embodiments, the composition is for use in a method of increasing proliferation of a muscle cell or connective tissue cell precursor in an individual. In certain embodiments, the individual is afflicted with or suspected of being afflicted with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia. In another aspect, described herein, is a composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide comprises ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, RPL29, a protein listed in Table 2, or a protein listed in Table 1, or any combination thereof. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises one or more of VTN, POSTN, FGF17, THBS2, THBS4, IGF2, IL-15, and THBS1. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises VTN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises POSTN. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises FGF17. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS4. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises IGF2. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises IL-15. In certain embodiments, the mitogenic and/or fusion promoting polypeptide comprises THBS1. In certain embodiments, the composition comprises a mixture of a plurality of different mitogenic and/or fusion promoting polypeptides. In certain embodiments, the plurality of different mitogenic and/or fusion promoting polypeptides comprise three, four, or five different mitogenic and/or fusion promoting polypeptides. The plurality of polypeptides may comprise one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 2. The plurality of polypeptides may comprise one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 1. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises IGF2, THBS2, and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises IL-15, THBS2, and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and ANOS1. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and IL-15. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2, THBS4, and IGF2. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and THBS2. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS2 and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS1 and THBS4. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises VTN and FGF17. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS4 and VTN. In certain embodiments, the plurality of mitogenic and/or fusion promoting polypeptides comprises THBS4 and FGF17. In certain embodiments, the composition is for use in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or any combination thereof. In certain embodiments, the composition is for use in a method of increasing proliferation of a muscle cell and/or connective tissue cell precursor in an individual. In certain embodiments, the individual is afflicted with or suspected of being afflicted with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue, or a combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is muscular dystrophy. In certain embodiments, the muscle wasting disorder is cachexia, e.g., muscular cachexia.

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the embodiments provided may be practiced without these details. Unless the context requires otherwise, throughout the specification and claims that follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.

As used herein a composition that is “consisting essentially” of the recited components is a composition that only has the recited elements as active ingredients, but can comprise other non-active components that do not appreciably modify the function or activity of the recited components. Any list disclosed herein that is recited as “comprising” can be recited as “consisting essentially,” to exclude non-recited polypeptide or protein components.

As used herein “heparin-associated polypeptide” means any polypeptide that directly binds to heparin with a KD of less than 1 micromolar, or any polypeptide that associates with one or more polypeptides that bind directly to heparin with a KD of less than 1 micromolar. This KD can be measured using a method such as surface plasmon resonance. See e.g., Nguyen et al., “Surface plasmon resonance: a versatile technique for biosensor applications.” Sensors (Basel). 2015 May 5; 15(5):10481-510. Alternatively, a heparin-associated polypeptide is one that is enriched by a factor of at least 5-fold, 10-fold, 100-fold, or 1,000 from a complex mixture of polypeptides (e.g., a cell supernatant) by the use of heparin bound to a bead or other matrix support, or co-purifies with such a polypeptide.

As used herein “heparin-binding polypeptide” means any polypeptide that directly binds to heparin with a KD of less than 1 micromolar. Heparin-binding polypeptides can interact with heparin at steady-state under normal growth conditions, but in other instances heparin-binding polypeptides may interact with heparin transiently under normal growth conditions or only under certain conditions as a result of a signaling or environmental stimulus. Heparin binding-polypeptides may interact with heparin as a result of post-translational modifications such as phosphorylation, dephosphorylation, acetylation, deacetylation, lipidation, delipidation, glycosylation, or deglycosylation, or combinations thereof.

As used herein “pluripotent stem cell” or “pluripotent cell” (PSC) means a cell that has the ability to differentiate into several different cell types that are derivatives of all of the three germinal layers (endoderm, mesoderm, and ectoderm). Pluripotent stem cells are capable of forming teratomas. Examples of pluripotent stem cells are embryonic stem cells (ESCs), embryonic germ stem cells (EGCs), embryonic Carcinoma Cells (ECCs), and induced pluripotent stem cells (iPSCs). PSC may be from any organism of interest, including, primate, human; canine; feline; murine; equine; porcine; avian; camel; bovine; ovine, and so on.

As used herein “somatic cell” means any cell of an organism that, in the absence of experimental manipulation, does not ordinarily give rise to all types of cells in an organism. In other words, somatic cells are cells that have differentiated sufficiently that they will not naturally generate cells of all three germ layers of the body, i.e., ectoderm, mesoderm and endoderm. For example, somatic cells would include muscle cells and muscle progenitor cells, the latter of which may be able to self-renew and naturally give rise to all or some cell types of the skeletal, cardiac, or smooth muscle but cannot give rise to cells of the ectoderm or endoderm lineages.

As used herein the term “about” refers to an amount that is near the stated amount by 10% or less.

As used herein the terms “individual” “subject,” and “patient” are interchangeable. The individual can be mammal such as a horse, cow, pig, chicken, goat, rabbit, mouse, rat, dog, or cat. In certain embodiments, the individual is a human person.

The terms “polypeptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues. Polypeptides, including the provided polypeptide chains and other peptides, e.g., linkers and binding peptides, may include amino acid residues including natural and/or non-natural amino acid residues. The terms also include post-translational modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. In some aspects, the polypeptides may contain modifications with respect to a native or natural sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts that produce the proteins, errors due to PCR amplification, or errors in protein translation.

In some embodiments, a recombinant protein is a protein expressed in a system other than a human, e.g., the protein is expressed from bacteria, yeast, or mammalian cells in culture. In some cases, the protein is expressed from Chinese Hamster Ovary cells (CHO cells). In some cases, the protein is expressed from mouse myeloma cells, e.g., (NS0) cells. In some cases, the protein is expressed from E. coli.

Percent (%) sequence identity with respect to a reference polypeptide sequence is the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences are able to be determined, including algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

“Exogenous” with respect to a nucleic acid or polynucleotide indicates that the nucleic acid is part of a recombinant nucleic acid construct, or is not in its natural environment. For example, an exogenous nucleic acid can be a sequence from one species introduced into another species, i.e., a heterologous nucleic acid. Typically, such an exogenous nucleic acid is introduced into the other species via a recombinant nucleic acid construct. An exogenous nucleic acid also can be a sequence that is native to an organism and that has been reintroduced into cells of that organism. An exogenous nucleic acid that includes a native sequence can often be distinguished from the naturally occurring sequence by the presence of non-natural sequences linked to the exogenous nucleic acid, e.g., non-native regulatory sequences flanking a native sequence in a recombinant nucleic acid construct. In addition, stably transformed exogenous nucleic acids typically are integrated at positions other than the position where the native sequence is found. The exogenous elements may be added to a construct, for example using genetic recombination. Genetic recombination is the breaking and rejoining of DNA strands to form new molecules of DNA encoding a novel set of genetic information. Often exogenous nucleic acids will include a translatable sequence lacking introns that has been cloned from a cDNA.

As described herein a “mitogenic polypeptide” is one that induces one or more stages of mitosis, including interphase, prophase, metaphase, anaphase, and telophase. In certain embodiments, a mitogenic polypeptide is one that induces mitosis in any one or more of a soft-tissue cell, a soft-tissue precursor cell, a muscle cell, a muscle precursor cell, or a tenocyte.

As described herein a “fusion promoting” polypeptide is one that promotes fusion of muscle cells or muscle cell precursors. Fusion of muscle precursors like C2C12 cells is an experimental marker of differentiation and can be monitored by increases in eMyHC or increased number of nuclei per eMyHC positive cell a by a statistically measurable change of at least 25% magnitude (p<0.05) relative to vehicle treated cells grown in otherwise identical conditions.

In some embodiments, reference to a fusion, fusion polypeptide, or fusion protein refers to a synthetically and/or recombinantly produced molecule in which two or more amino acid sequences are connected, e.g., by a peptide bond and/or linker. In some cases, the two or more amino acid sequences are linked via a linker comprising one or more amino acids. In other cases, the two or more amino acid sequences are not linked via a linker, e.g., the two sequences are directly connected by a peptide bond. In some cases, at least one of the two or more amino acid sequences comprises a polypeptide described herein. For example, the polypeptide described herein is a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS4, THBS1, IL-15, or IGF2, or a combination thereof.

In some embodiments, reference to a conjugate, polypeptide conjugate, or protein conjugate refers to a synthetically and/or recombinantly produced molecule comprising a chemical entity covalently bound to one or more amino acids of an amino acid sequence. In some cases, the conjugation is selective such that the chemical entity is connected to a specific amino acid of the amino acid sequence. In some embodiments, the amino acid sequence comprises a polypeptide described herein. For example, the polypeptide described herein is a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS4, THBS1, IL-15, or IGF2, or a combination thereof.

In some embodiments, a polypeptide described herein is a proteoform of a protein listed in Table 2. In some embodiments, as used herein a proteoform describes a molecular form of a protein product arising from a gene encoding a protein, such as a protein listed in Table 2. In some cases, a proteoform includes proteins that arise from the same gene as a result of genetic variation, alternatively spliced RNA transcripts, post-translational modifications, or polypeptide cleavage event.

Heparin-Associated Polypeptides

In one aspect, polypeptides described herein that are useful for treating an aging disease or injury comprise one or more polypeptides secreted from an induced pluripotent stem cell, an embryonic stem cell, a tissue progenitor cell, or a transformed cell line that bind to heparin. In certain embodiments, a plurality of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more heparin-associated polypeptides are included in a composition comprising a pharmaceutically acceptable excipient, carrier, or diluent. In some cases the composition comprises one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 2. In some cases the composition comprises one, two, three, four, five, six, seven, eight, nine, ten or more polypeptides of Table 1.

In certain aspects, there are three biochemical features that are common across all potential therapeutic heparin-associated polypeptides: 1) they are secreted by human pluripotent stem cells; 2) they can be purified by heparin agarose beads from a complex mixture, and 3) their molecular weight equals or exceeds 3.5 kDa.

In certain aspects, there are certain structure-function relationships that potentially link disparate therapeutic polypeptides into a genus of heparin-associated therapeutic polypeptides. Included among these are the ability to be secreted, which may require: 1) an N-terminal signal sequence (approx. 15-30 amino acids in length); and/or 2) the presence of one or more post translational modifications added in the Endoplasmic Reticulum or the Golgi apparatus to promote stability, such as glycosylation or the presence of disulfide bonds. It is estimated that 2,000 to 3,000 polypeptides encoded by the human genome can be secreted by one or more cell types. In addition to being secretory polypeptides the therapeutic polypeptides may comprise a heparin-binding domain, or, alternatively associate with heparin-binding domain comprising polypeptides. Heparin is a linear polymer of saccharides in 1-4 alpha linkages that form a spiraling chain, commonly associated with its role in binding plasma proteins to reduce clotting (See Capila and Lindhart, “Heparin-protein interactions” Angew Chem Int Ed Engl. 2002 Feb. 1; 41(3):391-412). Currently, predicting heparin-binding from protein sequence alone is a challenge for the field due to the structural heterogeneity of heparin polymers and the large and variable number of shallow binding pockets thought to be important for stabilizing the interaction. Several hundred heparin-associated polypeptides have been empirically tested for heparin binding, using a few heparin chain configurations. Based on these studies many binding motifs have been proposed, but none have been proven necessary and sufficient. One common motif appears to be a sequence of repeating basic residues that orient onto a common surface of the secondary structure for interacting with the matching pattern of sulfate groups on heparin chains. Therefore many heparin-binding therapeutic polypeptides may contain patterns of basic residues (arginine or lysine) clustered in some part of the protein, though agnostic to the exact sequence.

In certain embodiments, the heparin-associated therapeutic polypeptide is a secreted polypeptide. In certain embodiments, the heparin-associated therapeutic polypeptide is a secreted polypeptide that comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more disulfide bonds. In certain embodiments, the heparin-associated therapeutic polypeptide is a secreted polypeptide that comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or N-liked or O-linked glycans. In certain embodiments, the heparin-associated therapeutic polypeptide is greater than about 3.5 kilodaltons. In other embodiments, the heparin-associated is greater than about 5, 7.5, 10, 15, or 20 kilodaltons. In certain embodiments, the heparin-associated therapeutic polypeptide is one that comprises a region exhibiting enrichment for basic amino acids arginine or lysine. The region can be about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length, and comprise an amount of basic residues that is greater than would be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 100%, 150%, or 200% greater than expected given random chance. In certain embodiments, the heparin-associated therapeutic polypeptide does not comprise a basic DNA binding motif, such as those found in bZIP transcription factors. In a certain embodiment, the heparin-associated polypeptide is heparin binding polypeptide.

The heparin-associated polypeptides, described herein, can comprise one or more amino acid modifications that promote stability and/or facilitate production. In certain embodiments, the polypeptide can comprise one or more covalent modifications that promote stability (e.g., PEGylation). Other modifications of the heparin-associated polypeptide(s) are contemplated herein. For example, the heparin-associated polypeptide(s) may be linked to one of a variety of non-proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide may be fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the heparin-associated polypeptide may be a fusion with an Fc region of an immunoglobulin or with serum albumin.

The heparin-associated polypeptides described herein can be encapsulated in nanospheres or nanoparticles to increase stability. In certain embodiments, the nanospheres or nanoparticles are biodegradable or bioabsorbable. Certain types of nanospheres can be deployed such as polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA) microspheres or nanospheres. In certain embodiments, the heparin-associated polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, the heparin-associated-polypeptide may be concatemerized to increase stability and or bioavailability. In certain embodiments, the heparin-associated polypeptide(s) comprises concatemers of the same or of different heparin-associated binding polypeptides. Concatemers can be separated by polypeptide linkers, for example a Gly-Ser linker of any suitable length. In certain embodiments, the Gly-Ser liker comprises a G4S1 linker. In certain embodiments, the concatemers comprise 1, 2, 3, 4, 5 or more of the same heparin-associated polypeptide as a single polypeptide separated by a Gly-Ser linker. In certain embodiments, the concatemers comprise 1, 2, 3, 4, 5 or more different heparin-associated polypeptides as a single polypeptide separated by a Gly-Ser linker. In certain embodiments, the concatemers comprise 1, 2, 3, 4, 5 or more of the same heparin-associated polypeptide covalently linked through a non-peptide linkage, such as for example a disulfide bridge. In certain embodiments, the concatemers comprise 1, 2, 3, 4, 5 or more different heparin-associated polypeptides covalently linked through a non-peptide linkage, such as for example a disulfide bridge. In certain embodiments, the concatemers comprise 1, 2, 3, 4, 5 or more of the same heparin-associated polypeptide non-covalently linked, such as for example, by a streptavidin-biotin interaction or protein-protein interaction. In certain embodiments, the concatemers comprise 1, 2, 3, 4, 5 or more different heparin-associated polypeptides non-covalently linked such as for example, by a streptavidin-biotin interaction or protein-protein interaction.

Additional modifications to heparin-associated polypeptide comprise deletions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 amino acids from the N-terminal or C-terminal ends of the heparin-associated polypeptide. In certain embodiments, the heparin-associated polypeptide comprises the deletion of known inhibitory domains or deletion of domains not associated with the heparin-associated-poly peptides functions in inducing proliferation of muscle, connective, or soft-tissue cell precursors.

The heparin-associated polypeptides herein can comprise cleavage products of a pro-protein. Cleavage of a pro-protein can result in activation or higher activity of said pro-protein. In certain embodiments, heparin-associated polypeptides are produced that correspond to a cleaved or active form of the pro-protein. In certain embodiments, the heparin-associated polypeptides comprise only the active domain of a heparin associated pro-protein (e.g., the minimal portion sufficient to create a biological effect).

In certain embodiments, the heparin-associated polypeptide comprises one or more of the polypeptides listed in Table 1 and/or Table 2. In certain embodiments, the polypeptide is at least about 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to a polypeptide listed in Table 1 and/or Table 2, or an isoform thereof. In certain embodiments, the polypeptide is at least about 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to a sequence selected from SEQ ID NOS: 1-44, 55, 56, and 58-70.

TABLE 1

Exemplary Therapeutic Polypeptides

SEQ

Polypeptide
ID
Modified Amino Acid Sequences Tested

Vitronectin (VTN)
1
Asp20 to Leu478, purified from Human plasma-derived

Periostin (POSTN)
6
Asn22 to Gln836, with a C-terminal 6-His tag (SEQ ID

NO: 69), purified from Mouse myeloma cell line, NS0

Thrombospondin 2
4
Gly19 to Ile1172, with a C-terminal 10-His tag (SEQ ID

(THBS2)

NO: 70), purified from Mouse myeloma cell line, NS0

Thrombospondin 4
8
Ala22 to Asn961, with a C-terminal 10-His tag (SEQ ID

(THBS4)

NO: 70), purified from Chinese Hamster Ovary cell line

Fibroblast growth factor
12
Pro143 to Ser288, purified E. coli

2 (FGF 2)

Fibroblast growth factor
13
Leu25 to Lys216, purified from E. coli

19 (FGF 19)

Angiogenin (ANG)
14
Gln25 to Pro147, purified from E. coli

Probetacellulin (BTC)
15
Asp32 to Tyr111, purified from E. coli

Interleukin -13 receptor
16
Arg21 to Ala228, purified from mouse myeloma cell line,

alpha 2

NS0

Siglec-5/CD170
17
Glu17 to Thr434, purified from mouse myeloma cell line,

NS0

Interleukin-15
10
Asn49 to Ser162, purified from E. coli

Apelin receptor (APJ)
18

Insulin-like growth
19
Glu40 to Gln328, purified from mouse myeloma cell line,

factor- binding protein 2

NS0

(IGFBP-2)

Chordin-Like 1
20
Glu22-Cys450, purified from mouse myeloma cell line,

(CHRDL1)

NS0

WAP, Kazal,
21
Leu35 to His 576, purified from mouse myeloma cell line,

immunoglobulin, Kunitz

NS0

and NTR domain-

containing protein 2

Membrane frizzled-
22
Ser101 to Pro579, purified from mouse myeloma cell line,

related protein (MFRP)

NS0

Interleukin -10 receptor
23
His22 to Asn235, purified from human cell line HEK293

alpha

Chemokine like receptor
24

1, Chemerin Receptor 23

(Chem R23)

HB-EGF
25
Asp63 to Leu148, purified from insect cells

fibroblast growth factor
26
Gly67 to Ile208, purified from E. coli

6

Hepatocyte Growth
27
Gln32 to Ser728, purified from insect cells

Factor

Interleukin-16
28
Pro2 to Ser130, purified from E. coli

Interleukin-7 receptor
29
Glu21 to Lys261, purified from mouse myeloma cell line,

alpha

NS0

Tumor necrosis factor
30
Ala26 to Ala221, purified from mouse myeloma cell line,

receptor superfamily

NS0

member 10C

Bone morphogenetic
31
Gln382 to His51, 3 purified from E. coli

protein 6

Interleukin-36 gamma
32
Ser18 to Asp169, purified from E. coli

interleukin-1 receptor
33
Val2 to Asp155, purified from E. coli

antagonist (IL-1RA)

Kremen protein 2
34
Gln19 to Ala364, purified from mouse myeloma cell line,

NS0

Tumor necrosis factor
35

receptor superfamily

member 10D

C-X-C chemokine
36

receptor type 1

C-C motif chemokine 23
37

Catenin, Beta
38

Fibroblast growth factor
39

13, 1B

Tumor necrosis factor
40
Glu108 to Leu261, purified from E. coli

ligand superfamily

member 10

C-C motif chemokine 14
41
Ser35 to Glu111, purified from E. coli

Thrombospondin 1
9
Asn19-Pro1170, with Thr523Ala substitution plus 10His tag

(THBS1)

purified from mouse myeloma cell line, NS0

Insulin-like growth
42
Asp30 to Leu282 with a K95R mutation with an N-terminal

factor binding protein 7

10-His tag (SEQ ID NO: 70), purified from Mouse myeloma

cell line, NS0

Fibroblast growth factor
43
Ser54 to Leu206, purified from E. coli

4

Fibroblast growth factor
7
Thr23 to Thr216, purified from E. coli

17 (FGF17)

Fibroblast growth factor
44
Gln23 to Arg204, purified from E. coli

8

Insulin-like growth
11
Ala25 to Glu91, purified from E. coli

factor 2 (IGF2)

THBS1 isoform 2
58

FGF17 isoform 2
59

POSTN isoform 2
60

POSTN isoform 3
61

POSTN isoform 4
62

POSTN isoform 5
63

POSTN isoform 6
64

POSTN isoform 7
65

IGF2 isoform 2
66

IGF2 isoform 3
67

IL15 isoform 2
68

STC2
2

AGRN
3

FST
5

PDGFRL
55
Gln22 to Ser375, purified from HEK293 cells

ANOS1
56
Ala25 to Tyr680, purified from CHO cells

TABLE 2

Factors enriched in the supernatants of undifferentiated

human pluripotent stem cells.

Entrez

Peptide

Gene Name
Uniprot ID
Gene ID
Ensembl ID
No.

A1BG
P04217
1
ENSG00000121410
1

A2M
P01023
2
ENSG00000175899
2

ABCF1
Q8NE71
23
ENSG00000204574
3

ACADVL
P49748
37
ENSG00000072778
4

ACLY
P53396
47
ENSG00000131473
5

ACP1
P24666
52
ENSG00000143727
6

ACP5
P13686
54
ENSG00000102575
7

ACTG1
P63261
71
ENSG00000184009
8

ACTN1
P12814
87
ENSG00000072110
9

ACTR3
P61158
10096
ENSG00000115091
10

ADAMTS1
Q9UHI8
9510
ENSG00000154734
11

ADAMTS12
P58397
81792
ENSG00000151388
12

ADAMTS19
Q8TE59
171019
ENSG00000145808
13

ADAMTS7
Q9UKP4
11173
ENSG00000136378
14

ADAMTS8
Q9UP79
11095
ENSG00000134917
15

ADRM1
Q16186
11047
ENSG00000130706
16

AEBP1
Q8IUX7
165
ENSG00000106624
17

AFM
P43652
173
ENSG00000079557
18

AFP
P02771
174
ENSG00000081051
19

AGPS
O00116
8540
ENSG00000018510
20

AGRN
O00468
375790
ENSG00000188157
21

AGT
P01019
183
ENSG00000135744
22

AHCYL2
Q96HN2
23382
ENSG00000158467
23

AHSG
P02765
197
ENSG00000145192
24

AIMP1
Q12904
9255
ENSG00000164022
25

ALB
P02768
213
ENSG00000163631
26

ALCAM
Q13740
214
ENSG00000170017
27

ALDH9A1
P49189
223
ENSG00000143149
28

ALDOA
P04075
226
ENSG00000149925
29

ALPL
P05186
249
ENSG00000162551
30

AMBP
P02760
259
ENSG00000106927
31

ANG
P03950
283
ENSG00000214274
32

ANGPTL4
Q9BY76
51129
ENSG00000167772
33

ANOS1
P23352
3730
ENSG00000011201
34

ANXA1
P04083
301
ENSG00000135046
35

ANXA2
P07355
302
ENSG00000182718
36

ANXA2P2
A6NMY6

37

AOC1
P19801
26
ENSG00000002726
38

AP2A1
O95782
160
ENSG00000196961
39

AP2A2
O94973
161
ENSG00000183020
40

AP3D1
O14617
8943
ENSG00000065000
41

APLP2
Q06481
334
ENSG00000084234
42

APOA1
P02647
335
ENSG00000118137
43

APOA2
P02652
336
ENSG00000158874
44

APOB
P04114
338
ENSG00000084674
45

APOC3
P02656
345
ENSG00000110245
46

APOD
P05090
347
ENSG00000189058
47

APOE
P02649
348
ENSG00000130203
48

APOH
P02749
350
ENSG00000091583
49

APOM
O95445
55937
ENSG00000204444
50

ARCN1
P48444
372
ENSG00000095139
51

ARHGEF1
Q92888
9138
ENSG00000076928
52

ARHGEF28
Q8N1W1
64283
ENSG00000214944
53

ARPC1B
O15143
10095
ENSG00000130429
54

ARRB1
P49407
408
ENSG00000137486
55

ARSK
Q6UWY0
153642
ENSG00000164291
56

ART4
Q93070
420
ENSG00000111339
57

ASNA1
O43681
439
ENSG00000198356
58

ASNS
P08243
440
ENSG00000070669
59

ATP6AP2
O75787
10159
ENSG00000182220
60

ATRN
O75882
8455
ENSG00000088812
61

AZGP1
P25311
563
ENSG00000160862
62

B3GALT6
Q96L58
126792
ENSG00000176022
63

B3GNT7
Q8NFL0
93010
ENSG00000156966
64

B4GALT1
P15291
2683
ENSG00000086062
65

B4GALT4
O60513
8702
ENSG00000121578
66

B4GAT1
O43505
11041
ENSG00000174684
67

BCAM
P50895
4059
ENSG00000187244
68

BGN
P21810
633
ENSG00000182492
69

BLVRB
P30043
645
ENSG00000090013
70

BMP1
P13497
649
ENSG00000168487
71

BMP7
P18075
655
ENSG00000101144
72

BOC
Q9BWV1
91653
ENSG00000144857
73

BRD3
Q15059
8019
ENSG00000169925
74

BSG
P35613
682
ENSG00000172270
75

BTBD17
A6NE02
388419
ENSG00000204347
76

BTD
P43251
686
ENSG00000169814
77

BZW2
Q9Y6E2
28969
ENSG00000136261
78

C11orf24
Q96F05
53838
ENSG00000171067
79

C1QA
P02745
712
ENSG00000173372
80

C1QBP
Q07021
708
ENSG00000108561
81

C1QC
P02747
714
ENSG00000159189
82

C1QTNF3
Q9BXJ4
114899
ENSG00000082196
83

C1QTNF3-
E9PGA6

ENSG00000273294
84

AMACR

C1QTNF4
Q9BXJ3
114900
ENSG00000172247
85

C1RL
Q9NZP8
51279
ENSG00000139178
86

C1S
P09871
716
ENSG00000182326
87

C20orf27
Q9GZN8
54976
ENSG00000101220
88

C3
P01024
718
ENSG00000125730
89

C4A
P0C0L4
720
ENSG00000206340
90

C4B
A0A140TA29

ENSG00000236625
91

C4BPA
P04003
722
ENSG00000123838
92

C5
P01031
727
ENSG00000106804
93

C7
P10643
730
ENSG00000112936
94

C8B
P07358
732
ENSG00000021852
95

C9
P02748
735
ENSG00000113600
96

CA11
O75493
770
ENSG00000063180
97

CALM2
P0DP24
801
ENSG00000143933
98

CALR
P27797
811
ENSG00000179218
99

CALU
O43852
813
ENSG00000128595
100

CAND1
Q86VP6
55832
ENSG00000111530
101

CANT1
Q8WVQ1
124583
ENSG00000171302
102

CANX
P27824
821
ENSG00000127022
103

CAPG
P40121
822
ENSG00000042493
104

CAPN1
P07384
823
ENSG00000014216
105

CAPZA2
P47755
830
ENSG00000198898
106

CARM1
Q86X55
10498
ENSG00000142453
107

CARS
P49589
833
ENSG00000110619
108

CBL
P22681
867
ENSG00000110395
109

CBX3
Q13185
11335
ENSG00000122565
110

CCAR2
Q8N163
57805
ENSG00000158941
111

CCBE1
Q6UXH8
147372
ENSG00000183287
112

CCDC80
Q76M96
151887
ENSG00000091986
113

CCK
P06307
885
ENSG00000187094
114

CCT2
P78371
10576
ENSG00000166226
115

CCT4
P50991
10575
ENSG00000115484
116

CCT7
Q99832
10574
ENSG00000135624
117

CD5
P06127
921
ENSG00000110448
118

CDC40
O60508
51362
ENSG00000168438
119

CDH1
P12830
999
ENSG00000039068
120

CDH9
Q9ULB4
1007
ENSG00000113100
121

CDON
Q4KMG0
50937
ENSG00000064309
122

CDSN
Q15517
1041
ENSG00000137197
123

CENPV
Q7Z7K6
201161
ENSG00000166582
124

CFB
P00751
629
ENSG00000241253
125

CFC1
P0CG37
55997
ENSG00000136698
126

CFD
P00746
1675
ENSG00000197766
127

CFH
P08603
3075
ENSG00000000971
128

CFI
P05156
3426
ENSG00000205403
129

CHAD
O15335
1101
ENSG00000136457
130

CHD4
Q14839
1108
ENSG00000111642
131

CHD8
Q9HCK8
57680
ENSG00000100888
132

CHGA
P10645
1113
ENSG00000100604
133

CHID1
Q9BWS9
66005
ENSG00000177830
134

CHRDL1
Q9BU40
91851
ENSG00000101938
135

CHST11
Q9NPF2
50515
ENSG00000171310
136

CHST6
Q9GZX3
4166
ENSG00000183196
137

CHSY1
Q86X52
22856
ENSG00000131873
138

CHSY3
Q70JA7
337876
ENSG00000198108
139

CILP2
Q8IUL8
148113
ENSG00000160161
140

CKAP5
Q14008
9793
ENSG00000175216
141

CKMT1A
C9J8F6

ENSG00000223572
142

CKMT2
P17540
1160
ENSG00000131730
143

CLDN6
P56747
9074
ENSG00000184697
144

CLEC3B
P05452
7123
ENSG00000163815
145

CLPX
O76031
10845
ENSG00000166855
146

CLSTN3
Q9BQT9
9746
ENSG00000139182
147

CLTC
Q00610
1213
ENSG00000141367
148

CLU
P10909
1191
ENSG00000120885
149

CNOT1
A5YKK6
23019
ENSG00000125107
150

COCH
O43405
1690
ENSG00000100473
151

COL11A1
P12107
1301
ENSG00000060718
152

COL11A2
P13942
1302
ENSG00000227801
153

COL12A1
Q99715
1303
ENSG00000111799
154

COL14A1
Q05707
7373
ENSG00000187955
155

COL16A1
Q07092
1307
ENSG00000084636
156

COL18A1
P39060
80781
ENSG00000182871
157

COL1A1
P02452
1277
ENSG00000108821
158

COL1A2
P08123
1278
ENSG00000164692
159

COL22A1
Q8NFW1
169044
ENSG00000169436
160

COL25A1
Q9BXS0
84570
ENSG00000188517
161

COL26A1
Q96A83
136227
ENSG00000160963
162

COL2A1
P02458
1280
ENSG00000139219
163

COL3A1
P02461
1281
ENSG00000168542
164

COL4A1
P02462
1282
ENSG00000187498
165

COL4A2
P08572
1284
ENSG00000134871
166

COL4A3
Q01955
1285
ENSG00000169031
167

COL4A6
Q14031
1288
ENSG00000197565
168

COL5A1
P20908
1289
ENSG00000130635
169

COL5A2
P05997
1290
ENSG00000204262
170

COL5A3
P25940
50509
ENSG00000080573
171

COL6A1
P12109
1291
ENSG00000142156
172

COL6A2
P12110
1292
ENSG00000142173
173

COL6A3
P12111
1293
ENSG00000163359
174

COL9A2
Q14055
1298
ENSG00000049089
175

COLEC10
Q9Y6Z7
10584
ENSG00000184374
176

COMP
P49747
1311
ENSG00000105664
177

COPA
P53621
1314
ENSG00000122218
178

COTL1
Q14019
23406
ENSG00000103187
179

CP
P00450
1356
ENSG00000047457
180

CPA4
Q9UI42
51200
ENSG00000128510
181

CPE
P16870
1363
ENSG00000109472
182

CPN1
P15169
1369
ENSG00000120054
183

CPNE1
Q99829
8904
ENSG00000214078
184

CPVL
Q9H3G5
54504
ENSG00000106066
185

CPXM1
Q96SM3
56265
ENSG00000088882
186

CPXM2
Q8N436
119587
ENSG00000121898
187

CPZ
Q66K79
8532
ENSG00000109625
188

CRIM1
Q9NZV1
51232
ENSG00000150938
189

CRISPLD1
Q9H336
83690
ENSG00000121005
190

CRLF1
O75462
9244
ENSG00000006016
191

CRYL1
Q9Y2S2
51084
ENSG00000165475
192

CS
O75390
1431
ENSG00000062485
193

CSDE1
O75534
7812
ENSG00000009307
194

CSF2RA
P15509
1438
ENSG00000198223
195

CST1
P01037
1469
ENSG00000170373
196

CST3
P01034
1471
ENSG00000101439
197

CST4
P01036
1472
ENSG00000101441
198

CTGF
Q5M8T4
1490

199

CTNNA1
P35221
1495
ENSG00000044115
200

CTSD
P07339
1509
ENSG00000117984
201

CTSV
O60911
1515
ENSG00000136943
202

CUL2
Q13617
8453
ENSG00000108094
203

CUL3
Q13618
8452
ENSG00000036257
204

CUL4B
Q13620
8450
ENSG00000158290
205

CUTA
O60888
51596
ENSG00000112514
206

CXADR
P78310
1525
ENSG00000154639
207

CXCL12
P48061
6387
ENSG00000107562
208

CYR61
Q6FI18
3491

209

DAG1
Q14118
1605
ENSG00000173402
210

DARS
P14868
1615
ENSG00000115866
211

DBNL
Q9UJU6
28988
ENSG00000136279
212

DCD
P81605
117159
ENSG00000161634
213

DDOST
P39656
1650
ENSG00000244038
214

DDR1
Q08345
780
ENSG00000137332
215

DDX17
Q92841
10521
ENSG00000100201
216

DDX39B
Q13838
7919
ENSG00000215425
217

DENND5A
Q6IQ26
23258
ENSG00000184014
218

DHFR
P00374
1719
ENSG00000228716
219

DHX29
Q7Z478
54505
ENSG00000067248
220

DKK1
O94907
22943
ENSG00000107984
221

DKK3
Q9UBP4
27122
ENSG00000050165
222

DKK4
Q9UBT3
27121
ENSG00000104371
223

DLG3
Q92796
1741
ENSG00000082458
224

DMBT1
Q9UGM3
1755
ENSG00000187908
225

DNAAF5
Q86Y56
54919
ENSG00000164818
226

DNAJB11
Q9UBS4
51726
ENSG00000090520
227

DNAJC3
Q13217
5611
ENSG00000102580
228

DNMT1
P26358
1786
ENSG00000130816
229

DRAXIN
Q8NBI3
374946
ENSG00000162490
230

DRG1
Q9Y295
4733
ENSG00000185721
231

DSG2
Q14126
1829
ENSG00000046604
232

ECM1
Q16610
1893
ENSG00000143369
233

EDA
Q92838
1896
ENSG00000158813
234

EDIL3
O43854
10085
ENSG00000164176
235

EEF1G
P26641
1937
ENSG00000254772
236

EFEMP1
Q12805
2202
ENSG00000115380
237

EFTUD2
Q15029
9343
ENSG00000108883
238

EGFLAM
Q63HQ2
133584
ENSG00000164318
239

EIF1AY
O14602
9086
ENSG00000198692
240

EIF2B4
Q9UI10
8890
ENSG00000115211
241

EIF2S1
P05198
1965
ENSG00000134001
242

EIF2S2
P20042
8894
ENSG00000125977
243

EIF3A
Q14152
8661
ENSG00000107581
244

EIF3C
Q99613
8663
ENSG00000184110
245

EIF3F
O00303
8665
ENSG00000175390
246

EIF3H
O15372
8667
ENSG00000147677
247

EIF3M
Q7L2H7
10480
ENSG00000149100
248

EIF5
P55010
1983
ENSG00000100664
249

EIF5B
O60841
9669
ENSG00000158417
250

ELAC2
Q9BQ52
60528
ENSG00000006744
251

ELP3
Q9H9T3
55140
ENSG00000134014
252

EMILIN2
Q9BXX0
84034
ENSG00000132205
253

EPHA4
P54764
2043
ENSG00000116106
254

EPHB2
P29323
2048
ENSG00000133216
255

EPHB4
P54760
2050
ENSG00000196411
256

EPRS
P07814
2058
ENSG00000136628
257

ERBB3
P21860
2065
ENSG00000065361
258

ERLIN1
O75477
10613
ENSG00000107566
259

ERVMER34-1
Q9H9K5
100288413
ENSG00000226887
260

EXTL2
Q9UBQ6
2135
ENSG00000162694
261

EZR
P15311
7430
ENSG00000092820
262

F10
P00742
2159
ENSG00000126218
263

F13A1
P00488
2162
ENSG00000124491
264

F2
P00734
2147
ENSG00000180210
265

F5
P12259
2153
ENSG00000198734
266

FAM129B
Q96TA1
64855
ENSG00000136830
267

FAP
Q12884
2191
ENSG00000078098
268

FAT1
Q14517
2195
ENSG00000083857
269

FBLN1
P23142
2192
ENSG00000077942
270

FBLN2
P98095
2199
ENSG00000163520
271

FBN1
P35555
2200

272

FBN2
P35556
2201
ENSG00000138829
273

FERMT2
Q96AC1
10979
ENSG00000073712
274

FGB
P02675
2244
ENSG00000171564
275

FGF17
O60258
8822
ENSG00000158815
276

FGF2
P09038
2247
ENSG00000138685
277

FGF8
P55075
2253
ENSG00000107831
278

FGF4
P08620
2249
ENSG00000075388
279

FGF6
P10767
2251
ENSG00000111241
280

FGFBP3
Q8TAT2
143282
ENSG00000174721
281

FGFR1
P11362
2260
ENSG00000077782
282

FGFR2
P21802
2263
ENSG00000066468
283

FGFR4
P22455
2264
ENSG00000160867
284

FGFRL1
Q8N441
53834
ENSG00000127418
285

FH
P07954
2271
ENSG00000091483
286

FLT1
P17948
2321
ENSG00000102755
287

FN1
P02751
2335
ENSG00000115414
288

FRAS1
Q86XX4
80144
ENSG00000138759
289

FRZB
Q92765
2487
ENSG00000162998
290

FST
P19883
10468
ENSG00000134363
291

FSTL1
Q12841
11167
ENSG00000163430
292

FUCA2
Q9BTY2
2519
ENSG00000001036
293

FXR1
P51114
8087
ENSG00000114416
294

GALNT1
Q10472
2589
ENSG00000141429
295

GALNT16
Q8N428
57452
ENSG00000100626
296

GALNT2
Q10471
2590
ENSG00000143641
297

GALNT7
Q86SF2
51809
ENSG00000109586
298

GANAB
Q14697
23193
ENSG00000089597
299

GARS
P41250
2617
ENSG00000106105
300

GBA
P04062
2629
ENSG00000177628
301

GC
P02774
2638
ENSG00000145321
302

GCNT1
Q02742
2650
ENSG00000187210
303

GDF11
O95390
10220
ENSG00000135414
304

GDF15
Q99988
9518
ENSG00000130513
305

GDF6
Q6KF10
392255
ENSG00000156466
306

GEMIN5
Q8TEQ6
25929
ENSG00000082516
307

GFAP
P14136
2670
ENSG00000131095
308

GGH
Q92820
8836
ENSG00000137563
309

GLB1
P16278
2720
ENSG00000170266
310

GLG1
Q92896
2734
ENSG00000090863
311

GM2A
P17900
2760
ENSG00000196743
312

GNAS
O95467
2778
ENSG00000087460
313

GOLM1
Q8NBJ4
51280
ENSG00000135052
314

GOT2
P00505
2806
ENSG00000125166
315

GPC1
P35052
2817
ENSG00000063660
316

GPC3
P51654
2719
ENSG00000147257
317

GPC4
O75487
2239
ENSG00000076716
318

GPI
P06744
2821
ENSG00000105220
319

GPRC5B
Q9NZH0
51704
ENSG00000167191
320

GPX4
P36969
2879
ENSG00000167468
321

GREM1
O60565
26585
ENSG00000166923
322

GRN
P28799
2896
ENSG00000030582
323

GRSF1
Q12849
2926
ENSG00000132463
324

GSN
P06396
2934
ENSG00000148180
325

GSPT1
P15170
2935
ENSG00000103342
326

GTF3C3
Q9Y5Q9
9330
ENSG00000119041
327

HABP2
Q14520
3026
ENSG00000148702
328

HADHB
P55084
3032
ENSG00000138029
329

HAPLN1
P10915
1404
ENSG00000145681
330

HAPLN3
Q96S86
145864

331

HAPLN4
Q86UW8
404037

332

HARS
P12081
3035
ENSG00000170445
333

HBB
P68871
3043
ENSG00000244734
334

HBS1L
Q9Y450
10767
ENSG00000112339
335

HDGF
P51858
3068
ENSG00000143321
336

HDGFL2
Q7Z4V5
84717
ENSG00000167674
337

HDLBP
Q00341
3069
ENSG00000115677
338

HGF
P14210
3082
ENSG00000019991
339

HGFAC
Q04756
3083
ENSG00000109758
340

HIST1H1C
P16403
3006
ENSG00000187837
341

HIST1H1E
P10412
3008
ENSG00000168298
342

HLA-C
P04222

ENSG00000225691
343

HMCN1
Q96RW7
83872
ENSG00000143341
344

HMCN2
Q8NDA2

ENSG00000148357
345

HMGB1
P09429
3146
ENSG00000189403
346

HMGB2
P26583
3148
ENSG00000164104
347

HMGB3
O15347
3149
ENSG00000029993
348

HMGN1
P05114
3150
ENSG00000205581
349

HMGN5
P82970
79366
ENSG00000198157
350

HNRNPA2B1
P22626
3181
ENSG00000122566
351

HNRNPDL
O14979
9987
ENSG00000152795
352

HP
P00738
3240
ENSG00000257017
353

HP1BP3
Q5SSJ5
50809
ENSG00000127483
354

HPR
P00739
3250
ENSG00000261701
355

HPX
P02790
3263
ENSG00000110169
356

HS3ST3A1
Q9Y663
9955
ENSG00000153976
357

HS6ST1
O60243
9394
ENSG00000136720
358

HS6ST2
Q96MM7
90161
ENSG00000171004
359

HSD17B10
Q99714
3028
ENSG00000072506
360

HSD17B4
P51659
3295
ENSG00000133835
361

HSP90AA1
P07900
3320
ENSG00000080824
362

HSP90AB1
P08238
3326
ENSG00000096384
363

HSP90B1
P14625
7184
ENSG00000166598
364

HSPA5
P11021
3309
ENSG00000044574
365

HSPG2
P98160
3339
ENSG00000142798
366

HTRA1
Q92743
5654
ENSG00000166033
367

HYOU1
Q9Y4L1
10525
ENSG00000149428
368

IARS
P41252
3376
ENSG00000196305
369

ICAM2
P13598
3384
ENSG00000108622
370

IDE
P14735
3416
ENSG00000119912
371

IDH1
O75874
3417
ENSG00000138413
372

IDH2
P48735
3418
ENSG00000182054
373

IGF1
P05019
3479
ENSG00000017427
374

IGF2
P01344
3481
ENSG00000167244
375

IGFBP2
P18065
3485
ENSG00000115457
376

IGFBP3
P17936
3486
ENSG00000146674
377

IGFBP4
P22692
3487
ENSG00000141753
378

IGFBP5
P24593
3488
ENSG00000115461
379

IGFBP6
P24592
3489
ENSG00000167779
380

IGFBP7
Q16270
3490
ENSG00000163453
381

IGFBPL1
Q8WX77
347252
ENSG00000137142
382

IGHA1
P01876

ENSG00000211895
383

IGHA2
P01877

ENSG00000211890
384

IGHG1
P01857

ENSG00000211896
385

IGHG2
P01859

ENSG00000211893
386

IGHG4
P01861

ENSG00000211892
387

IGHM
P01871

ENSG00000211899
388

IGKC
P01834

389

IGKV2-28
A0A075B6P5

ENSG00000244116
390

IGKV2D-40
P01614

ENSG00000251039
391

IGKV3D-20
A0A0C4DH25

ENSG00000211625
392

IGLC2
P0DOY2

ENSG00000211677
393

IGLC3
P0DOY3

ENSG00000211679
394

IGLV2-11
P01706

ENSG00000211668
395

IGSF1
Q8N6C5
3547
ENSG00000147255
396

IGSF10
Q6WRI0
285313
ENSG00000152580
397

ILF2
Q12905
3608
ENSG00000143621
398

INHBA
P08476
3624
ENSG00000122641
399

INS
P01308
3630
ENSG00000254647
400

INS-IGF2
F8WCM5
723961
ENSG00000129965
401

IPO11
Q9UI26
51194
ENSG00000086200
402

IPO5
O00410
3843
ENSG00000065150
403

IPO8
O15397
10526
ENSG00000133704
404

IQGAP1
P46940
8826
ENSG00000140575
405

ISOC1
Q96CN7
51015
ENSG00000066583
406

ITGAL
P20701
3683
ENSG00000005844
407

ITIH1
P19827
3697
ENSG00000055957
408

ITIH2
P19823
3698
ENSG00000151655
409

ITIH3
Q06033
3699
ENSG00000162267
410

ITIH4
Q14624
3700
ENSG00000055955
411

ITIH5
Q86UX2
80760
ENSG00000123243
412

ITLN2
Q8WWU7
142683
ENSG00000158764
413

JCHAIN
P01591
3512
ENSG00000132465
414

KARS
Q15046
3735
ENSG00000065427
415

KDMIA
O60341
23028
ENSG00000004487
416

KMT2A
Q03164
4297
ENSG00000118058
417

KNG1
P01042
3827
ENSG00000113889
418

KRT10
P13645
3858
ENSG00000186395
419

KRT14
P02533
3861
ENSG00000186847
420

KRT17
Q04695
3872
ENSG00000128422
421

KRT18
P05783
3875
ENSG00000111057
422

KRT8
P05787
3856
ENSG00000170421
423

LACRT
Q9GZZ8
90070
ENSG00000135413
424

LAG3
P18627
3902
ENSG00000089692
425

LAMA1
P25391
284217
ENSG00000101680
426

LAMA2
P24043
3908
ENSG00000196569
427

LAMA5
O15230
3911
ENSG00000130702
428

LAMB1
P07942
3912
ENSG00000091136
429

LAMB2
P55268
3913
ENSG00000172037
430

LAMC1
P11047
3915
ENSG00000135862
431

LARS
Q9P2J5
51520
ENSG00000133706
432

LCAT
P04180
3931
ENSG00000213398
433

LCN1
P31025
3933
ENSG00000160349
434

LDHA
P00338
3939
ENSG00000134333
435

LECT2
O14960
3950
ENSG00000145826
436

LEFTY1
O75610
10637
ENSG00000243709
437

LEFTY2
O00292
7044
ENSG00000143768
438

LEFTYA

439

LFNG
Q8NES3
3955
ENSG00000106003
440

LGALS3BP
Q08380
3959
ENSG00000108679
441

LGALS7
M0R281

ENSG00000205076
442

LIG3
P49916
3980
ENSG00000005156
443

LINGO1
Q96FE5
84894
ENSG00000169783
444

LIPG
Q9Y5X9
9388
ENSG00000101670
445

LMAN2
Q12907
10960
ENSG00000169223
446

LMNA
P02545
4000
ENSG00000160789
447

LOXL1
Q08397
4016
ENSG00000129038
448

LOXL2
Q9Y4K0
4017
ENSG00000134013
449

LOXL3
P58215
84695
ENSG00000115318
450

LPL
P06858
4023
ENSG00000175445
451

LRG1
P02750
116844
ENSG00000171236
452

LRP1
Q07954
4035
ENSG00000123384
453

LRPAP1
P30533
4043
ENSG00000163956
454

LRRC59
Q96AG4
55379
ENSG00000108829
455

LRRTM4
Q86VH4
80059
ENSG00000176204
456

LSR
Q86X29
51599
ENSG00000105699
457

LTBP1
Q14766
4052
ENSG00000049323
458

LTBP4
Q8N2S1
8425
ENSG00000090006
459

LTF
P02788
4057
ENSG00000012223
460

LUM
P51884
4060
ENSG00000139329
461

LYAR
Q9NX58
55646
ENSG00000145220
462

LYZ
P61626
4069
ENSG00000090382
463

MANF
P55145
7873
ENSG00000145050
464

MAP2K2
P36507
5605
ENSG00000126934
465

MAP4
P27816
4134
ENSG00000047849
466

MAPK1
P28482
5594
ENSG00000100030
467

MASP1
P48740
5648
ENSG00000127241
468

MATN2
O00339
4147
ENSG00000132561
469

MATN3
O15232
4148
ENSG00000132031
470

MATR3
P43243
9782
ENSG00000015479
471

MAZ
P56270
4150
ENSG00000103495
472

MBNL1
Q9NR56
4154
ENSG00000152601
473

MCM5
P33992
4174
ENSG00000100297
474

MDH2
P40926
4191
ENSG00000146701
475

MDK
P21741
4192
ENSG00000110492
476

MEGF10
Q96KG7
84466
ENSG00000145794
477

MEGF6
O75095
1953
ENSG00000162591
478

METAP2
P50579
10988
ENSG00000111142
479

METTL14
Q9HCE5
57721
ENSG00000145388
480

MFAP2
P55001
4237
ENSG00000117122
481

MFGE8
Q08431
4240
ENSG00000140545
482

MGAT1
P26572
4245
ENSG00000131446
483

MIF
P14174
4282
ENSG00000240972
484

MINPP1
Q9UNW1
9562
ENSG00000107789
485

MMP2
P08253
4313
ENSG00000087245
486

MMP9
P14780
4318
ENSG00000100985
487

MSMB
P08118
4477
ENSG00000263639
488

MSN
P26038
4478
ENSG00000147065
489

MST1
P26927
4485
ENSG00000173531
490

MST1L
Q2TV78
11223

491

MTDH
Q86UE4
92140
ENSG00000147649
492

MTHFD1
P11586
4522
ENSG00000100714
493

MTHFD2
P13995
10797
ENSG00000065911
494

MXRA5
Q9NR99
25878
ENSG00000101825
495

MYBBP1A
Q9BQG0
10514
ENSG00000132382
496

MYL3
P08590
4634
ENSG00000160808
497

MYL4
P12829
4635
ENSG00000198336
498

NAA15
Q9BXJ9
80155
ENSG00000164134
499

NAMPT
P43490
10135
ENSG00000105835
500

NASP
P49321
4678
ENSG00000132780
501

NCAM1
P13591
4684
ENSG00000149294
502

NCAN
O14594
1463
ENSG00000130287
503

NDNF
Q8TB73
79625
ENSG00000173376
504

NDST1
P52848
3340
ENSG00000070614
505

NECTIN1
Q15223
5818
ENSG00000110400
506

NECTIN3
Q9NQS3
25945
ENSG00000177707
507

NELL2
Q99435
4753
ENSG00000184613
508

NID1
P14543
4811
ENSG00000116962
509

NID2
Q14112
22795
ENSG00000087303
510

NIPBL
Q6KC79
25836
ENSG00000164190
511

NLGN3
Q9NZ94
54413
ENSG00000196338
512

NLGN4Y
Q8NFZ3
22829
ENSG00000165246
513

NME1-NME2
J3KPD9

ENSG00000011052
514

NMT1
P30419
4836
ENSG00000136448
515

NOLC1
Q14978
9221
ENSG00000166197
516

NOV
A0A024R9J4
4856

517

NPC2
P61916
10577
ENSG00000119655
518

NPM3
O75607
10360
ENSG00000107833
519

NPTX1
Q15818
4884

520

NPTX2
P47972
4885
ENSG00000106236
521

NPTXR
O95502
23467
ENSG00000221890
522

NRG1
Q02297
3084
ENSG00000157168
523

NRG2
O14511
9542
ENSG00000158458
524

NRP1
O14786
8829
ENSG00000099250
525

NRP2
O60462
8828
ENSG00000118257
526

NSUN5
Q96P11
55695
ENSG00000130305
527

NTS
P30990
4922
ENSG00000133636
528

NUBP2
Q9Y5Y2
10101
ENSG00000095906
529

NUCB1
Q02818
4924
ENSG00000104805
530

NUMA1
Q14980
4926
ENSG00000137497
531

NUP155
O75694
9631
ENSG00000113569
532

OAF
Q86UD1
220323
ENSG00000184232
533

OLA1
Q9NTK5
29789
ENSG00000138430
534

OLFM2
O95897
93145

535

OLFML2A
Q68BL7
169611
ENSG00000185585
536

OLFML3
Q9NRN5
56944
ENSG00000116774
537

ORM1
P02763
5004
ENSG00000229314
538

ORM2
P19652
5005
ENSG00000228278
539

P4HB
P07237
5034
ENSG00000185624
540

PACSIN2
Q9UNF0
11252
ENSG00000100266
541

PAFAHIB1
P43034
5048
ENSG00000007168
542

PAIP1
Q9H074
10605
ENSG00000172239
543

PAM
P19021
5066
ENSG00000145730
544

PAMR1
Q6UXH9
25891
ENSG00000149090
545

PAPLN
O95428
89932
ENSG00000100767
546

PAPPA
Q13219
5069
ENSG00000182752
547

PARP1
P09874
142
ENSG00000143799
548

PC
P11498
5091
ENSG00000173599
549

PCDH1
Q08174
5097
ENSG00000156453
550

PCLO
Q9Y6V0
27445
ENSG00000186472
551

PCOLCE
Q15113
5118
ENSG00000106333
552

PCOLCE2
Q9UKZ9
26577
ENSG00000163710
553

PCSK5
Q92824
5125
ENSG00000099139
554

PCSK9
Q8NBP7
255738
ENSG00000169174
555

PDCD6IP
Q8WUM4
10015
ENSG00000170248
556

PDGFD
Q9GZP0
80310
ENSG00000170962
557

PDGFRL
Q15198
5157
ENSG00000104213
558

PDIA3
P30101
2923
ENSG00000167004
559

PDIA4
P13667
9601
ENSG00000155660
560

PDIA5
Q14554
10954
ENSG00000065485
561

PDIA6
Q15084
10130
ENSG00000143870
562

PFAS
O15067
5198
ENSG00000178921
563

PFKP
Q01813
5214
ENSG00000067057
564

PFN1
P07737
5216
ENSG00000108518
565

PGD
P52209
5226
ENSG00000142657
566

PGLYRP2
Q96PD5
114770
ENSG00000161031
567

PHGDH
O43175
26227
ENSG00000092621
568

PI16
Q6UXB8
221476
ENSG00000164530
569

PIGR
P01833
5284
ENSG00000162896
570

PIP
P12273
5304
ENSG00000159763
571

PKDCC
Q504Y2
91461
ENSG00000162878
572

PKM
P14618
5315
ENSG00000067225
573

PLAT
P00750
5327
ENSG00000104368
574

PLAU
P00749
5328
ENSG00000122861
575

PLCB3
Q01970
5331
ENSG00000149782
576

PLEC
Q15149
5339
ENSG00000178209
577

PLG
P00747
5340
ENSG00000122194
578

PLIN4
Q96Q06
729359
ENSG00000167676
579

PLOD1
Q02809
5351
ENSG00000083444
580

PLOD2
O00469
5352
ENSG00000152952
581

PLOD3
O60568
8985
ENSG00000106397
582

PLTP
P55058
5360
ENSG00000100979
583

POLL
Q9UGP5
27343
ENSG00000166169
584

POMC
P01189
5443
ENSG00000115138
585

POSTN
Q15063
10631
ENSG00000133110
586

PPIA
P62937
5478
ENSG00000196262
587

PPIB
P23284
5479
ENSG00000166794
588

PPP1CA
P62136
5499
ENSG00000172531
589

PPP1CC
P36873
5501
ENSG00000186298
590

PPP2R1A
P30153
5518
ENSG00000105568
591

PPT1
P50897
5538
ENSG00000131238
592

PRB3
Q04118

ENSG00000197870
593

PRB4
P10163

594

PRCP
P42785
5547
ENSG00000137509
595

PRDX2
P32119
7001
ENSG00000167815
596

PRDX4
Q13162
10549
ENSG00000123131
597

PRDX5
P30044
25824
ENSG00000126432
598

PRG4
Q92954
10216
ENSG00000116690
599

PRKDC
P78527
5591
ENSG00000253729
600

PRMT1
Q99873
3276
ENSG00000126457
601

PRMT5
O14744
10419
ENSG00000100462
602

PROM1
O43490
8842
ENSG00000007062
603

PRPF19
Q9UMS4
27339
ENSG00000110107
604

PRPF40A
O75400
55660
ENSG00000196504
605

PRPF4B
Q13523
8899
ENSG00000112739
606

PRPF6
O94906
24148
ENSG00000101161
607

PRPF8
Q6P2Q9
10594
ENSG00000174231
608

PRPSAP2
O60256
5636
ENSG00000141127
609

PRR4
Q16378
11272
ENSG00000111215
610

PRSS2
P07478
5645
ENSG00000275896
611

PRSS23
O95084
11098
ENSG00000150687
612

PRSS3
P35030
5646
ENSG00000010438
613

PRTG
Q2VWP7
283659
ENSG00000166450
614

PSIP1
O75475
11168
ENSG00000164985
615

PSMB6
P28072
5694
ENSG00000142507
616

PSMD 1
Q99460
5707
ENSG00000173692
617

PSMD2
Q13200
5708
ENSG00000175166
618

PSMD5
Q16401
5711
ENSG00000095261
619

PSMD6
Q15008
9861
ENSG00000163636
620

PSMD8
P48556
5714
ENSG00000099341
621

PSME3
P61289
10197
ENSG00000131467
622

PTK2
Q05397
5747
ENSG00000169398
623

PTK7
Q13308
5754
ENSG00000112655
624

PTN
P21246
5764
ENSG00000105894
625

PTPRC
P08575
5788
ENSG00000081237
626

PTPRD
P23468
5789
ENSG00000153707
627

PTPRF
P10586
5792
ENSG00000142949
628

PTPRS
Q13332
5802
ENSG00000105426
629

PTPRZ1
P23471
5803
ENSG00000106278
630

PUF60
Q9UHX1
22827
ENSG00000179950
631

PXDN
Q92626
7837
ENSG00000130508
632

PZP
P20742

ENSG00000126838
633

QPRT
Q15274
23475
ENSG00000103485
634

QSOX1
O00391
5768
ENSG00000116260
635

RAB7A
P51149
7879
ENSG00000075785
636

RACK1
P63244
10399
ENSG00000204628
637

RARRES2
Q99969
5919
ENSG00000106538
638

RBMX
P38159
27316
ENSG00000147274
639

RBP4
P02753
5950
ENSG00000138207
640

RCC1
P18754
1104
ENSG00000180198
641

RCOR1
Q9UKL0
23186
ENSG00000089902
642

RECQL
P46063
5965
ENSG00000004700
643

RELN
P78509
5649
ENSG00000189056
644

RNASE1
P07998
6035
ENSG00000129538
645

RNASE4
P34096
6038
ENSG00000258818
646

ROBO1
Q9Y6N7
6091
ENSG00000169855
647

RPL14
P50914
9045
ENSG00000188846
648

RPL18
Q07020
6141
ENSG00000063177
649

RPL19
P84098
6143
ENSG00000108298
650

RPL23A
P62750
6147
ENSG00000198242
651

RPL26
P61254
6154
ENSG00000161970
652

RPL29
P47914
6159
ENSG00000162244
653

RPL3
P39023
6122
ENSG00000100316
654

RPL35
P42766
11224
ENSG00000136942
655

RPL4
P36578
6124
ENSG00000174444
656

RPL9
A0A2R8Y5Y7

ENSG00000163682
657

RPLP0
P05388
6175
ENSG00000089157
658

RPLP1
P05386
6176
ENSG00000137818
659

RPLP2
P05387
6181
ENSG00000177600
660

RPN2
P04844
6185
ENSG00000118705
661

RPS13
P62277
6207
ENSG00000110700
662

RPS20
P60866
6224
ENSG00000008988
663

RPS23
P62266
6228
ENSG00000186468
664

RPS27A
P62979
6233
ENSG00000143947
665

RPS27L
Q71UM5
51065
ENSG00000185088
666

RPS3
P23396
6188
ENSG00000149273
667

RRBP1
Q9P2E9
6238
ENSG00000125844
668

RSF1
Q96T23
51773
ENSG00000048649
669

RSL1D1
O76021
26156
ENSG00000171490
670

RTF1
Q92541
23168
ENSG00000137815
671

RTN4
Q9NQC3
57142
ENSG00000115310
672

RTN4RL2
Q86UN3
349667
ENSG00000186907
673

RUVBL2
Q9Y230
10856
ENSG00000183207
674

S100A12
P80511
6283
ENSG00000163221
675

S100A13
Q99584
6284
ENSG00000189171
676

S100A7
P31151
6278
ENSG00000143556
677

S100A8
P05109
6279
ENSG00000143546
678

S100A9
P06702
6280
ENSG00000163220
679

SAP30
O75446
8819
ENSG00000164105
680

SARS
P49591
6301
ENSG00000031698
681

SBSN
Q6UWP8
374897
ENSG00000189001
682

SCG3
Q8WXD2
29106
ENSG00000104112
683

SCGB2A2
Q13296
4250
ENSG00000110484
684

SCUBE1
Q8IWY4
80274
ENSG00000159307
685

SCUBE3
Q8IX30
222663
ENSG00000146197
686

SDC1
P18827
6382
ENSG00000115884
687

SDC4
P31431
6385
ENSG00000124145
688

SDCBP
O00560
6386
ENSG00000137575
689

SDF4
Q9BRK5
51150
ENSG00000078808
690

SEC13
P55735
6396
ENSG00000157020
691

SELENOP
P49908
6414
ENSG00000250722
692

SEMA3A
Q14563
10371
ENSG00000075213
693

SEMA3F
Q13275
6405
ENSG00000001617
694

SEMA4B
Q9NPR2
10509
ENSG00000185033
695

SEMA4D
Q92854
10507
ENSG00000187764
696

SEMA5A
Q13591
9037
ENSG00000112902
697

SEMA6A
Q9H2E6
57556
ENSG00000092421
698

SEMA6D
Q8NFY4
80031
ENSG00000137872
699

SEMG1
P04279
6406
ENSG00000124233
700

SEPT9
Q9UHD8
10801
ENSG00000184640
701

SERBP1
Q8NC51
26135
ENSG00000142864
702

SERPINA1
P01009
5265
ENSG00000197249
703

SERPINA3
P01011
12
ENSG00000196136
704

SERPINA5
P05154
5104
ENSG00000188488
705

SERPINA7
P05543
6906
ENSG00000123561
706

SERPINB12
Q96P63
89777
ENSG00000166634
707

SERPINB3
P29508
6317
ENSG00000057149
708

SERPINB9
P50453
5272
ENSG00000170542
709

SERPINC1
P01008
462
ENSG00000117601
710

SERPIND1
P05546
3053
ENSG00000099937
711

SERPINE1
P05121
5054
ENSG00000106366
712

SERPINE2
P07093
5270
ENSG00000135919
713

SERPINF1
P36955
5176
ENSG00000132386
714

SERPINF2
P08697
5345
ENSG00000167711
715

SERPING1
P05155
710
ENSG00000149131
716

SERPINH1
P50454
871
ENSG00000149257
717

SERPINI1
Q99574
5274
ENSG00000163536
718

SF3B1
O75533
23451
ENSG00000115524
719

SF3B2
Q13435
10992
ENSG00000087365
720

SF3B3
Q15393
23450
ENSG00000189091
721

SFPQ
P23246
6421
ENSG00000116560
722

SFRP1
Q8N474
6422
ENSG00000104332
723

SFRP2
Q96HF1
6423
ENSG00000145423
724

SH2B1
Q9NRF2
25970
ENSG00000178188
725

SHBG
P04278
6462
ENSG00000129214
726

SHMT1
P34896
6470
ENSG00000176974
727

SKIV2L2
L8E9T8

728

SLC1A5
Q15758
6510
ENSG00000105281
729

SLC2A14
Q8TDB8
144195
ENSG00000173262
730

SLC39A10
Q9ULF5
57181
ENSG00000196950
731

SLIT2
O94813
9353

732

SLIT3
O75094
6586
ENSG00000184347
733

SLPI
P03973
6590
ENSG00000124107
734

SLTM
Q9NWH9
79811
ENSG00000137776
735

SLURP1
P55000
57152
ENSG00000126233
736

SMARCC1
Q92922
6599
ENSG00000173473
737

SMARCD1
Q96GM5
6602
ENSG00000066117
738

SMARCD2
Q92925
6603
ENSG00000108604
739

SMC1A
Q14683
8243
ENSG00000072501
740

SMC3
Q9UQE7
9126
ENSG00000108055
741

SMOC1
Q9H4F8
64093
ENSG00000198732
742

SMOC2
Q9H3U7
64094
ENSG00000112562
743

SMPDL3B
Q92485
27293
ENSG00000130768
744

SMR3B
P02814
10879
ENSG00000171201
745

SNRPB
P14678
6628
ENSG00000125835
746

SNRPD1
P62314
6632
ENSG00000167088
747

SNRPD3
P62318
6634
ENSG00000100028
748

SOD3
P08294
6649
ENSG00000109610
749

SPARC
P09486
6678
ENSG00000113140
750

SPINT1
O43278
6692
ENSG00000166145
751

SPINT2
O43291
10653
ENSG00000167642
752

SPOCK1
Q08629
6695
ENSG00000152377
753

SPON1
Q9HCB6
10418
ENSG00000262655
754

SPP1
P10451
6696
ENSG00000118785
755

SRP14
P37108
6727
ENSG00000140319
756

SRPX
P78539
8406
ENSG00000101955
757

SRPX2
O60687
27286
ENSG00000102359
758

SRSF1
Q07955
6426
ENSG00000136450
759

SSB
P05455
6741
ENSG00000138385
760

SSC5D
A1L4H1
284297
ENSG00000179954
761

ST6GAL1
P15907
6480
ENSG00000073849
762

ST6GAL2
Q96JF0
84620
ENSG00000144057
763

STAG1
Q8WVM7
10274
ENSG00000118007
764

STC1
P52823
6781
ENSG00000159167
765

STC2
O76061
8614
ENSG00000113739
766

SUB1
P53999
10923
ENSG00000113387
767

SULF2
Q8IWU5
55959
ENSG00000196562
768

SUMF2
Q8NBJ7
25870
ENSG00000129103
769

SUPT16H
Q9Y5B9
11198
ENSG00000092201
770

SUPT6H
Q7KZ85
6830
ENSG00000109111
771

SVEP1
Q4LDE5
79987
ENSG00000165124
772

SYNCRIP
O60506
10492
ENSG00000135316
773

TAGLN2
P37802
8407
ENSG00000158710
774

TBL1XR1
Q9BZK7
79718
ENSG00000177565
775

TCN2
P20062
6948
ENSG00000185339
776

TCOF1
Q13428
6949
ENSG00000070814
777

TF
P02787
7018
ENSG00000091513
778

TFAM
Q00059
7019
ENSG00000108064
779

TFPI
P10646
7035
ENSG00000003436
780

TFRC
P02786
7037
ENSG00000072274
781

TGFB2
P61812
7042
ENSG00000092969
782

TGFBI
Q15582
7045
ENSG00000120708
783

THBS1
P07996
7057
ENSG00000137801
784

THBS2
P35442
7058
ENSG00000186340
785

THBS3
P49746
7059
ENSG00000169231
786

THBS4
P35443
7060
ENSG00000113296
787

THOC3
Q96J01
84321
ENSG00000051596
788

THSD7A
Q9UPZ6
221981
ENSG00000005108
789

TIMP1
P01033
7076
ENSG00000102265
790

TIMP2
P16035
7077
ENSG00000035862
791

TIMP3
P35625
7078
ENSG00000100234
792

TINAGL1
Q9GZM7
64129
ENSG00000142910
793

TJP1
Q07157
7082
ENSG00000104067
794

TNC
P24821
3371
ENSG00000041982
795

TNN
Q9UQP3
63923

796

TNXB
P22105
7148
ENSG00000168477
797

TOP1
P11387
7150
ENSG00000198900
798

TPM4
P67936
7171
ENSG00000167460
799

TPP2
P29144
7174
ENSG00000134900
800

TRIM28
Q13263
10155
ENSG00000130726
801

TRIP10
Q15642
9322
ENSG00000125733
802

TRMT1
Q9NXH9
55621
ENSG00000104907
803

TSKU
Q8WUA8
25987
ENSG00000182704
804

TTR
P02766
7276
ENSG00000118271
805

TUBB4A
P04350
10382
ENSG00000104833
806

TUFM
P49411
7284
ENSG00000178952
807

TWSG1
Q9GZX9
57045
ENSG00000128791
808

TXN
P10599
7295
ENSG00000136810
809

TXNDC16
Q9P2K2
57544
ENSG00000087301
810

TXNDC5
Q8NBS9
81567
ENSG00000239264
811

U2AF2
P26368
11338
ENSG00000063244
812

UBE2O
Q9C0C9
63893
ENSG00000175931
813

UBR4
Q5T4S7
23352
ENSG00000127481
814

UCHL1
P09936
7345
ENSG00000154277
815

UCHL3
P15374
7347
ENSG00000118939
816

UFL1
O94874
23376
ENSG00000014123
817

UGP2
Q16851
7360
ENSG00000169764
818

USP11
P51784
8237
ENSG00000102226
819

USP14
P54578
9097
ENSG00000101557
820

USP43
Q70EL4
124739
ENSG00000154914
821

UTP4
Q969X6
84916
ENSG00000141076
822

VARS
P26640
7407
ENSG00000096171
823

VASN
Q6EMK4
114990
ENSG00000168140
824

VCAN
P13611
1462
ENSG00000038427
825

VCP
P55072
7415
ENSG00000165280
826

VEGFA
P15692
7422
ENSG00000112715
827

VIT
Q6UXI7
5212
ENSG00000205221
828

VNN1
O95497
8876
ENSG00000112299
829

VPS35
Q96QK1
55737
ENSG00000069329
830

VTN
P04004
7448
ENSG00000109072
831

VWF
P04275
7450
ENSG00000110799
832

WDR3
Q9UNX4
10885
ENSG00000065183
833

WDR36
Q8NI36
134430
ENSG00000134987
834

WDR4
P57081
10785
ENSG00000160193
835

WDR43
Q15061
23160
ENSG00000163811
836

WFIKKN1
Q96NZ8
117166
ENSG00000127578
837

WFIKKN2
Q8TEU8
124857
ENSG00000173714
838

XRCC5
P13010
7520
ENSG00000079246
839

XYLT1
Q86Y38
64131
ENSG00000103489
840

XYLT2
Q9H1B5
64132
ENSG00000015532
841

YBX1
P67809
4904
ENSG00000065978
842

YBX3
P16989
8531
ENSG00000060138
843

ZG16B
Q96DA0
124220
ENSG00000162078
844

ZNF207
O43670
7756
ENSG00000010244
845

ZNF326
Q5BKZ1
284695
ENSG00000162664
846

ZNF706
Q9Y5V0
51123
ENSG00000120963
847

APLP1
P51693
333
ENSG00000105290
848

APP
P05067
351
ENSG00000142192
849

NPNT
Q6UXI9
255743
ENSG00000168743
850

RPL22
Q6UXI9
6146
ENSG00000116251
851

FGF19
O95750
9965
ENSG00000162344
852

BTC
P35070
685
ENSG00000174808
853

IL13RA2
Q14627
3598
ENSG00000123496
854

CD170
O15389

ENSG00000105501
855

IL15
P40933
3600
ENSG00000164136
856

WAP
Q8TEU8

ENSG00000173714
857

MFRP
Q9BY79
83552
ENSG00000235718
858

IL10Ra
Q13651
3587
ENSG00000110324
859

ChemR23
Q99788
1240
ENSG00000174600
860

HBEGF
Q99075
1839
ENSG00000113070
861

IL16
Q14005
3603
ENSG00000172349
862

IL7Ra
P16871
3575
ENSG00000168685
863

TNFSF10C
O14798
8794
ENSG00000173535
864

BMP6
P22004
654
ENSG00000153162
865

IL36g
P14778
56300
ENSG00000136688
866

IL1RA
P18510
3557
ENSG00000136689
867

KREMEN2
Q8NCW0
79412

868

TNFSF10D
Q9UBN6
8793
ENSG00000173530
869

CXCCR1
P49238
1524
ENSG00000168329
870

CCL23
P55773
6368
ENSG00000276114
871

Catenin
P35222
1499
ENSG00000168036
872

TNFSF10
P50591
8743
ENSG00000121858
873

CCL14
Q16627
6358
ENSG00000276409
874

IL2
P60568
3558
ENSG00000109471
875

FGF1
P05230
2246
ENSG00000113578
876

In certain embodiments, the heparin-associated polypeptide comprises one or more of the polypeptides listed in Table 2, Table 1, or a proteoform thereof. In certain embodiments, the heparin-associated polypeptide is at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to a polypeptide listed in Table 2, Table 1, or a proteoform thereof. In certain embodiments, the heparin-associated polypeptide comprises a polypeptide at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, or RPL29, or any combination thereof. In certain embodiments, the heparin-associated polypeptide comprises a polypeptide at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to VTN, POSTN, FGF17, THBS2, THBS4, THBS1, IL-15, or IGF2, or any combination thereof. In certain embodiments, the heparin-associated polypeptide comprises THBS1. In certain embodiments, the heparin-associated polypeptide comprises THBS2. In certain embodiments, the heparin-associated polypeptide comprises THBS4. In certain embodiments, the heparin-associated polypeptide comprises FGF17. In certain embodiments, the heparin-associated polypeptide comprises VTN. In certain embodiments, the heparin-associated polypeptide comprises POSTN. In certain embodiments, the heparin-associated polypeptide comprises IGF2. In certain embodiments, the heparin-associated polypeptide comprises IL-15. In certain embodiments, described herein, is a composition comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to a polypeptide Table 2, Table 1, ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, RPL29, a proteoform thereof, or a combination thereof; and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, the composition comprises a plurality of peptides from Table 2; and optionally a pharmaceutically acceptable excipient, carrier, or diluent. In some cases the plurality comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides of Table 2. In some cases, one or more of the plurality of polypeptides is at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to a polypeptide of Table 2. In certain embodiments, the composition comprises a plurality of peptides from Table 1; and optionally a pharmaceutically acceptable excipient, carrier, or diluent. In some cases the plurality comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides of Table 1. In some cases, one or more of the plurality of polypeptides is at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to a polypeptide of Table 1. In certain embodiments, the composition comprises THBS1. In certain embodiments, the composition comprises THBS2. In certain embodiments, the composition comprises THBS4. In certain embodiments, the composition comprises FGF17. In certain embodiments, the composition comprises VTN. In certain embodiments, the composition comprises POSTN. In certain embodiments, the composition comprises IGF2. In certain embodiments, the composition comprises IL-15. In certain embodiments, the composition comprises IGF2, THBS2, and THBS4. In certain embodiments, the composition comprises IL-15, THBS2, and THBS4. In certain embodiments, the composition comprises THBS2 and THBS4. In certain embodiments, the composition comprises THBS2, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, THBS4, and ANOS1. In certain embodiments, the composition comprises THBS2, THBS4, and IL-15. In certain embodiments, the composition comprises THBS2, THBS4, and IGF2. In certain embodiments, the composition comprises THBS1 and FGF17. In certain embodiments, the composition comprises THBS2 and VTN. In certain embodiments, the composition comprises THBS1 and VTN. In certain embodiments, the composition comprises THBS1 and THBS2. In certain embodiments, the composition comprises THBS2 and FGF17. In certain embodiments, the composition comprises THBS1 and THBS4. In certain embodiments, the composition comprises VTN and FGF17. In certain embodiments, the composition comprises THBS4 and VTN. In certain embodiments, the composition comprises THBS4 and FGF17. In certain embodiments, described herein, is a composition comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to CTGF, THBS1, THBS2, THBS3, HGFAC, IGFBP3, IGFBP5, IGFBP7, IGFBP4, SFRP1, STC1, STC2, IGFBP2; and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, described herein, is a composition comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides, wherein one or more the polypeptides are at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4; and a pharmaceutically acceptable excipient, carrier, or diluent.

In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 40, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 40. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 41, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 41. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 42, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 42. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 43, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 43. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 44, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 44. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 58, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 58. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 59, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 59. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 60, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 60. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 61, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 61. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 62, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 62. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 63, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 63. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 64, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 64. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 65, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 65. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 66, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 66. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 67, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 67. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 68, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 68. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 69, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 69. In certain embodiments, described herein is a composition comprising a polypeptide comprising at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology or identity to SEQ ID NO: 70, and a pharmaceutically acceptable excipient, carrier, or diluent. In some cases, the polypeptide does not comprise a signal sequence of SEQ ID NO: 70.

In certain embodiments, described herein, is a composition comprising a plurality of polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, RPL29, and combinations thereof; and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, described herein, is a composition comprising a plurality of polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to CTGF, THBS1, THBS2, THBS3, HGFAC, IGFBP3, IGFBP5, IGFBP7, IGFBP4, SFRP1, STC1, STC2, IGFBP2; and a pharmaceutically acceptable excipient, carrier, or diluent.

In certain embodiments, described herein, is a composition consisting essentially of a plurality of polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, RPL29, and combinations thereof; and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, described herein, is a composition consisting essentially of a plurality of polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to CTGF, THBS1, THBS2, THBS3, HGFAC, IGFBP3, IGFBP5, IGFBP7, IGFBP4, SFRP1, STC1, STC2, IGFBP2; and a pharmaceutically acceptable excipient, carrier, or diluent.

In certain embodiments, described herein, is a composition consisting essentially of any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, and RPL29; and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, described herein, is a composition consisting essentially of any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to CTGF, THBS1, THBS2, THBS3, HGFAC, IGFBP3, IGFBP5, IGFBP7, IGFBP4, SFRP1, STC1, STC2, IGFBP2; and a pharmaceutically acceptable excipient, carrier, or diluent.

In certain embodiments, described herein, is a composition consisting of any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to ADAMTS12, INS-IGF2, AOC1, SOD3, CLU, ITIH1, APLP1, THBS1, COCH, ITIH2, APLP2, THBS3, COL11A1, LAMA1, APOB, TNXB, COL12A1, LAMA2, APOE, VEGFA, COL14A1, LAMA5, APOH, VTN, COL18A1, LAMB1, APP, ZNF207, COL1A1, LAMB2, CCDC80, COL1A2, LTF, CFH, COL2A1, MATN2, CLEC3B, COL3A1, MDK, COL25A1, COL5A1, MST1, COL5A3, COL5A2, NID1, CYR61, COL6A1, NPNT, F2, COL6A2, OLFML3, FGF2, COL6A3, PCOLCE, FGFBP3, CTGF, POSTN, FSTL1, DCD, PTN, HDGF, DRAXIN, RARRES2, KNG1, ECM1, RELN, NDNF, FBLN1, SFRP1, NRP1, FBN1, SLIT3, PAFAH1B1, FBN2, SPON1, PCOLCE2, FN1, STC1, PTPRF, FST, STC2, PTPRS, HGFAC, SVEP1, RPL22, IGFBP2, THBS2, and RPL29; and a pharmaceutically acceptable excipient, carrier, or diluent. In certain embodiments, described herein, is a composition consisting of any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptides at least about 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to CTGF, THBS1, THBS2, THBS3, HGFAC, IGFBP3, IGFBP5, IGFBP7, IGFBP4, SFRP1, STC1, STC2, IGFBP2; and a pharmaceutically acceptable excipient, carrier, or diluent.

In certain embodiments, compositions comprising heparin-associated polypeptides do not comprise fibroblast growth factors (FGF). In certain embodiments, compositions comprising heparin-associated polypeptides do not comprise fibroblast growth factor 2 (FGF2). In certain embodiments, compositions comprising heparin-associated polypeptides do not comprise FGF19, Angiogenin, BTC, IL-13 R alpha 2, Siglec-5/CD170, IL-15, APJ, IGFBP-2, Chordin-Like 1, GASP-1/WFIKKNRP, MFRP, IL-10 R alpha, Chem R23, HB-EGF, FGF-6, HGF, IL-16, IL-7 R alpha, TRAIL R3/TNFRSF10C, BMP-6, IL-1 F9/IL-1 H1, IL-1 beta, Kremen-2, TRAIL R4/TNFRSF10D, CXCR1/IL-8 RA, Ck beta 8-1/CCL23, Beta-catenin, FGF-13 1B, TRAIL/TNFSF10, CCL14/HCC-1/HCC-3, or FGF-4, or a combination thereof.

In certain aspects, heparin-associated binding polypeptides and compositions of heparin-associated binding polypeptides herein comprise polypeptides that increase the proliferation of muscle cell precursors, and/or increase their differentiation into muscle cells. In certain embodiments, the heparin-associated polypeptides increase proliferation of a muscle cell precursor by at least about 20%, 30%, 40%, 50%, or 100% compared to a muscle cell precursor not treated with the heparin-associated binding polypeptide. In certain embodiments, the heparin-associated polypeptides increase proliferation of a myoblast by at least about 20%, 30%, 40%, 50%, 100%, 200%, or 500% compared to a myoblast not treated with the heparin-associated binding polypeptide. In certain embodiments, the myoblast is a human myoblast cell line. In certain embodiments, the myoblast is a mouse myoblast cell line (e.g., C2C12). Proliferation can be measured by BrdU or EdU incorporation, which can be quantified using suitable methods such as, by way of non-limiting embodiment, microscopy, flow cytometry, or ELISA.

In certain embodiments, the heparin-associated polypeptides increase differentiation and/or fusion of a muscle cell precursor by at least about 50%, 75%, 100%, 200%, or 500% compared to a muscle cell precursor not treated with the heparin-associated binding polypeptide. In certain embodiments, the heparin-associated polypeptides increase differentiation of a myoblast by at least about 50%, 75%, or 100% compared to a myoblast not treated with the heparin-associated binding polypeptide. In certain embodiments, the myoblast is a human myoblast cell line. In certain embodiments, the myoblast is a mouse myoblast cell line (e.g., C2C12). Differentiation can be measured and/or quantified by eMyHC staining, which detects fusion of a myoblast or muscle cell precursor. This staining can be quantified, for example, by microscopy or flow cytometry.

Heparin-associated polypeptides that increase muscle or connective tissue cell precursor proliferation and/or differentiation are useful in methods of treating muscle or connective tissue disorders. These disorders can arise from the normal aging process, injury related to trauma or physical exertion, genetic predispositions, or incident to other disease states.

Heparin-associated binding polypeptides that are useful for increasing muscle cell precursor differentiation or proliferation are described herein, and in certain embodiments comprise Vitronectin (VTN), Stanniocalcin-2 (STC2), Periostin (POSTN), Agrin (AGRN), Fibroblast growth factor (FGF17, also known as Fibroblast growth factor 13 or FGF13), Thrombospondin 2 (THBS2), follistatin (FST), Thrombospondin 4 (THBS4), Thrombospondin 1 (THBS1), Insulin-like growth factor 2 (IGF2), or Interleukin 15 (IL-15), or any combination thereof. In certain embodiments, any one, two, three, four, or five of VTN, STC2, AGRN, THBS2, or FST are present in a composition useful for increasing muscle cell precursor proliferation or muscle cell differentiation. In certain embodiments, any one, two, three, four, five, six, seven, or eight of VTN, POSTN, FGF17, THBS2, THBS1, IL-15, IGF2, and THBS4 are present in a composition useful for increasing muscle cell precursor proliferation or muscle cell differentiation.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Vitronectin (VTN). VTN may be further included in the composition with any one, two, three, four, five, six, seven, eight, nine, or all polypeptides selected from STC2, AGRN, POSTN, FGF17, THBS2, FST, THBS1, IL-15, IGF2, and THBS4. In certain embodiments, the composition comprises VTN and STC2. In certain embodiments, the composition comprises VTN and AGRN. In certain embodiments, the composition comprises VTN and THBS2. In certain embodiments, the composition comprises VTN and FST. In certain embodiments, the composition comprises VTN and POSTN. In certain embodiments, the composition comprises VTN and FGF17. In certain embodiments, the composition comprises VTN and THBS4. In certain embodiments, the composition comprises VTN and THBS1. In certain embodiments, the composition comprises VTN and IGF2. In certain embodiments, the composition comprises VTN and IL-15. Human VTN is disclosed in SEQ ID NO: 1. In certain embodiments, the VTN of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1 or amino acids 20-478 of SEQ ID NO: 1. In certain embodiments, the VTN polypeptide lacks a secretory leader sequence, e.g., amino acids 1-19 of SEQ ID NO: 1. In certain embodiments, the VTN polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the VTN polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the VTN polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the VTN polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the VTN polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from STC2, AGRN, THBS2, THBS1, THBS4, FGF17, POSTN, IGF2, IL-15 and FST. In certain embodiments, the VTN polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, the VTN polypeptide is present in a concatemer with one, two, three, four, or more distinct VTN polypeptides. In certain embodiments, the VTN polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the VTN polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the VTN polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Periostin (POSTN). POSTN may be further included in the composition with any one, two, three, four, five, six, or all polypeptides selected from VTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, the composition comprises POSTN and VTN. In certain embodiments, the composition comprises POSTN and FGF17. In certain embodiments, the composition comprises POSTN and THBS2. In certain embodiments, the composition comprises POSTN and THBS4. In certain embodiments, the composition comprises POSTN and THBS1. In certain embodiments, the composition comprises POSTN and IGF2. In certain embodiments, the composition comprises POSTN and IL-15. Human POSTN is disclosed in SEQ ID NO: 6. In certain embodiments, the POSTN of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 6 or amino acids 22-836 of SEQ ID NO: 6. In certain embodiments, the POSTN polypeptide lacks a secretory leader sequence, e.g., amino acids 1-21 of SEQ ID NO: 6. In certain embodiments, the POSTN polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the POSTN polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the POSTN polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the POSTN polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the POSTN polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, FGF17, THBS2, THBS1, IGF2, IL-15 and THBS4. In certain embodiments, the POSTN polypeptide is present in a concatemer with one, two, three, four, or more distinct POSTN polypeptides. In certain embodiments, the POSTN polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the POSTN polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the POSTN polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Fibroblast growth factor (FGF17). FGF17 may be further included in the composition with any one, two, three, four, five, six or all polypeptides selected from VTN, POSTN, THBS2, THBS1, IL-15, IGF2, and THBS4. In certain embodiments, the composition comprises FGF17 and VTN. In certain embodiments, the composition comprises FGF17 and POSTN. In certain embodiments, the composition comprises FGF17 and THBS2. In certain embodiments, the composition comprises FGF17 and THBS4. In certain embodiments, the composition comprises FGF17 and THBS1. In certain embodiments, the composition comprises FGF17 and IGF2. In certain embodiments, the composition comprises FGF17 and IL-15. Human FGF17 is disclosed in SEQ ID NO: 7. In certain embodiments, the FGF17 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 7, or amino acids 23-216 of SEQ ID NO: 7. In certain embodiments, the FGF17 polypeptide lacks a secretory leader sequence, e.g., amino acids 1-22 of SEQ ID NO: 7. In certain embodiments, the FGF17 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the FGF17 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the FGF17 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the FGF17 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the FGF17 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, POSTN, THBS2, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, the FGF17 polypeptide is present in a concatemer with one, two, three, four, or more distinct FGF17 polypeptides. In certain embodiments, the FGF17 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the FGF17 polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the FGF17 polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Stanniocalcin-2 (STC2). STC-2 may be further included in the composition with any one, two, three, four or more polypeptides selected from VTN, AGRN, THBS2, THBS1, THBS4, POSTN, FGF17, IGF2, IL-15, and FST. In certain embodiments, the composition comprises STC2 and VTN. In certain embodiments, the composition comprises STC2 and AGRN. In certain embodiments, the composition comprises STC2 and THBS2. In certain embodiments, the composition comprises STC2 and FST. Human STC2 is disclosed in SEQ ID NO: 2. In certain embodiments, the STC2 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2. In certain embodiments, the STC2 polypeptide lacks a secretory leader sequence. In certain embodiments, the STC2 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the STC2 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the STC2 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the STC2 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the STC2 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, AGRN, THBS2, THBS1, THBS4, FGF17, POSTN, IGF2, IL_15, and FST. In certain embodiments, the STC2 polypeptide is present in a concatemer with one, two, three, four, or more distinct STC2 polypeptides. In certain embodiments, the STC2 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, a heparin-associated binding polypeptide composition comprises Agrin (AGRN). AGRN may be further included in the composition with any one, two, three, four or more polypeptides selected from VTN, STC2, THBS2, THBS1, THBS4, FGF17, POSTN, IGF2, IL-15, and FST. In certain embodiments, the composition comprises AGRN and VTN. In certain embodiments, the composition comprises AGRN and STC2. In certain embodiments, the composition comprises AGRN and THBS2. In certain embodiments, the composition comprises AGRN and FST. Human AGRN is disclosed in SEQ ID NO: 3. In certain embodiments, the AGRN of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 3. In certain embodiments, the AGRN polypeptide lacks a secretory leader sequence. In certain embodiments, the AGRN polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the AGRN polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the AGRN polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the AGRN polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the AGRN polypeptide is present in a concatemer with one, two, three, or four other distinct polypeptides selected from VTN, STC2, THBS2, THBS1, THBS4, FGF17, POSTN, IGF2, IL-15, and FST. In certain embodiments, the AGRN polypeptide is present in a concatemer with one, two, three, four, or more distinct AGRN polypeptides. In certain embodiments, the AGRN polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, a heparin-associated binding polypeptide composition comprises Thrombospondin 2 (THBS2). THBS2 may be further included in the composition with any one, two, three, four, five, six or all polypeptides selected from VTN, STC2, AGRN, THBS1, IL-15, IGF2, and FST. In certain embodiments, the composition comprises THBS2 and VTN. In certain embodiments, the composition comprises THBS2 and STC2. In certain embodiments, the composition comprises THBS2 and AGRN. In certain embodiments, the composition comprises THBS2 and FST. In certain embodiments, the composition comprises AGRN and FST. In certain embodiments, the composition comprises THBS2 and THBS1. In certain embodiments, the composition comprises THBS2 and IGF2. In certain embodiments, the composition comprises THBS2 and IL-15. THBS2 may be further included in the composition with any one, two, three, four, five, six, or all polypeptides selected from VTN, POSTN, FGF17, THBS1, IL-15, IGF2, and THBS4. In certain embodiments, the composition comprises THBS2 and VTN. In certain embodiments, the composition comprises THBS2 and POSTN. In certain embodiments, the composition comprises THBS2 and FGF17. In certain embodiments, the composition comprises THBS2 and THBS4. In certain embodiments, the composition comprises FGF17 and THBS4. Human THBS2 is disclosed in SEQ ID NO: 4. In certain embodiments, the THBS2 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 4 or amino acids 19-1,172 of SEQ ID NO: 4. In certain embodiments, the THBS2 polypeptide lacks a secretory leader sequence, e.g., amino acids 1-18 of SEQ ID NO: 4. In certain embodiments, the THBS2 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the THBS2 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the THBS2 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the THBS2 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the THBS2 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, FGF17, POSTN, IGF2, IL-15, and FST. In certain embodiments, the THBS2 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, POSTN, THBS1, IGF2, IL-15, FGF17, and THBS4. In certain embodiments, the THBS2 polypeptide is present in a concatemer with one, two, three, four, or more distinct THBS2 polypeptides. In certain embodiments, the THBS2 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the THBS2 polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the THBS2 polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Thrombospondin 4 (THBS4). THBS4 may be further included in the composition with any one, two, three, four, five, six or all polypeptides selected from VTN, POSTN, FGF17, THBS1, IL-15, IGF2, and THBS2. In certain embodiments, the composition comprises THBS4 and VTN. In certain embodiments, the composition comprises THBS4 and POSTN. In certain embodiments, the composition comprises THBS4 and FGF17. In certain embodiments, the composition comprises THBS4 and THBS2. In certain embodiments, the composition comprises THBS4 and THBS1. In certain embodiments, the composition comprises THBS4 and IL-15. In certain embodiments, the composition comprises THBS4 and IGF2. Human THBS4 is disclosed in SEQ ID NO: 8. In certain embodiments, the THBS4 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8 or amino acids 27-961 of SEQ ID NO: 8. In certain embodiments, the THBS4 polypeptide lacks a secretory leader sequence, e.g., amino acids 1-26 of SEQ ID NO: 8. In certain embodiments, the THBS4 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the THBS4 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the THBS4 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the THBS4 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the THBS4 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, POSTN, FGF17, THBS1, IGF2, IL-15, and THBS2. In certain embodiments, the THBS4 polypeptide is present in a concatemer with one, two, three, four, or more distinct THBS4 polypeptides. In certain embodiments, the THBS4 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the THBS4 polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the THBS2 polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises follistatin (FST). FST may be further included in the composition with any one, two, three, four or more polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, FGF17, POSTN, IGF2, IL-15, and THBS2. In certain embodiments, the composition comprises FST and VTN. In certain embodiments, the composition comprises FST and STC2. In certain embodiments, the composition comprises FST and AGRN. In certain embodiments, the composition comprises FST and THBS2. Human FST is disclosed in SEQ ID NO: 5. In certain embodiments, the FST of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 5. In certain embodiments, the FST polypeptide lacks a secretory leader sequence. In certain embodiments, the FST polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the FST polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the FST polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the FST polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the FST polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, FGF17, POSTN, IGF2, IL-15, and THBS2. In certain embodiments, the FST polypeptide is present in a concatemer with one, two, three, four, or more distinct FST polypeptides. In certain embodiments, the FST polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, a heparin-associated binding polypeptide composition comprises Thrombospondin 1 (THBS1). THSB1 may be further included in the composition with any one, two, three, four, five, six, seven, eight or all polypeptides selected from VTN, STC2, AGRN, THBS4, FGF17, POSTN, IGF2, IL-15, and THBS2. In certain embodiments, the composition comprises THSB1 and VTN. In certain embodiments, the composition comprises THSB1 and STC2. In certain embodiments, the composition comprises THSB1 and AGRN. In certain embodiments, the composition comprises THSB1 and THBS2. In certain embodiments, the composition comprises THSB1 and THBS4. In certain embodiments, the composition comprises THSB1 and FGF17. In certain embodiments, the composition comprises THSB1 and POSTN. In certain embodiments, the composition comprises THSB1 and IGF2. In certain embodiments, the composition comprises THSB1 and IL-15. Human THSB1 is disclosed in SEQ ID NO: 9. In certain embodiments, the THSB1 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 9 or amino acids 19-1170 of SEQ ID NO: 9. In certain embodiments, the THSB1 polypeptide lacks a secretory leader sequence. In certain embodiments, the THSB1 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the THSB1 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the THSB1 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the THSB1 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the THSB1 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, STC2, AGRN, THBS4, FGF17, POSTN, IGF2, IL-15 and THBS2. In certain embodiments, the THSB1 polypeptide is present in a concatemer with one, two, three, four, or more distinct THSB1 polypeptides. In certain embodiments, the THSB1 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the THBS1 polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the THBS1 polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Interleukin-15 (IL-15). IL-15 may be further included in the composition with any one, two, three, four or more polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, IGF2, POSTN, FGF17, and THBS2. In certain embodiments, the composition comprises IL-15 and VTN. In certain embodiments, the composition comprises IL-15 and STC2. In certain embodiments, the composition comprises IL-15 and AGRN. In certain embodiments, the composition comprises IL-15 and THBS2. In certain embodiments, the composition comprises IL-15 and THBS1. In certain embodiments, the composition comprises IL-15 and THBS4. In certain embodiments, the composition comprises IL-15 and IGF2. In certain embodiments, the composition comprises IL-15 and POSTN. In certain embodiments, the composition comprises IL-15 and FGF17. In certain embodiments, the composition comprises IL-15 and THBS1. Human IL-15 is disclosed in SEQ ID NO: 10. In certain embodiments, the IL-15 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 10 or amino acids 49-162 of SEQ ID NO: 10. In certain embodiments, the IL-15 polypeptide lacks a secretory leader sequence. In certain embodiments, the IL-15 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the IL-15 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the IL-15 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the IL-15 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the IL-15 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, FGF17, POSTN, IGF2, and THBS2. In certain embodiments, the IL-15 polypeptide is present in a concatemer with one, two, three, four, or more distinct IL-15 polypeptides. In certain embodiments, the IL-15 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the IL-15 polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the THBS1 polypeptide is prepared by chemical synthesis.

In certain embodiments, a heparin-associated binding polypeptide composition comprises Insulin-like growth factor 2 (IGF2). IGF2 may be further included in the composition with any one, two, three, four or more polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, POSTN, FGF17, IL-15 and THBS2. In certain embodiments, the composition comprises IGF2 and VTN. In certain embodiments, the composition comprises IGF2 and STC2. In certain embodiments, the composition comprises IGF2 and AGRN. In certain embodiments, the composition comprises IGF2 and THBS2. In certain embodiments, the composition comprises IGF2 and THBS1. In certain embodiments, the composition comprises IGF2 and THBS4. In certain embodiments, the composition comprises IGF2 and IL-15. In certain embodiments, the composition comprises IGF2 and POSTN. In certain embodiments, the composition comprises IGF2 and FGF17. Human IGF2 is disclosed in SEQ ID NO: 11. In certain embodiments, the IGF2 of the heparin-associated binding polypeptide composition comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 10 or amino acids 25-91 of SEQ ID NO: 11. In certain embodiments, the IGF2 polypeptide lacks a secretory leader sequence. In certain embodiments, the IGF2 polypeptide is modified by a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids from the N-terminal or C-terminal end of the polypeptide, including increments therein. In certain embodiments, the IGF2 polypeptide comprises one or more additional modifications to increase stability. In certain embodiments, the IGF2 polypeptide is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, the IGF2 polypeptide is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, the IGF2 polypeptide is present in a concatemer with one, two, three, four or more distinct polypeptides selected from VTN, STC2, AGRN, THBS1, THBS4, FGF17, POSTN, IL-15, and THBS2. In certain embodiments, the IGF2 polypeptide is present in a concatemer with one, two, three, four, or more distinct IGF2 polypeptides. In certain embodiments, the IGF2 polypeptide is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In some cases, the IGF2 polypeptide is prepared recombinantly in an expression system (e.g., bacteria, yeast, mammalian, insect). In some cases, the THBS1 polypeptide is prepared by chemical synthesis.

In certain embodiments, the heparin-associated binding polypeptide composition comprises any two polypeptides selected from VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, the composition comprises THBS1. In certain embodiments, the composition comprises THBS2. In certain embodiments, the composition comprises THBS4. In certain embodiments, the composition comprises FGF17. In certain embodiments, the composition comprises VTN. In certain embodiments, the composition comprises POSTN. In certain embodiments, the composition comprises IGF2. In certain embodiments, the composition comprises IL-15. In certain embodiments, the composition comprises VTN and POSTN. In certain embodiments, the composition comprises VTN and FGF17. In certain embodiments, the composition comprises VTN and THBS2. In certain embodiments, the composition comprises VTN and THBS1. In certain embodiments, the composition comprises VTN and IGF2. In certain embodiments, the composition comprises VTN and IL-15. In certain embodiments, the composition comprises VTN and THBS4. In certain embodiments, the composition comprises POSTN and FGF17. In certain embodiments, the composition comprises POSTN and THBS2. In certain embodiments, the composition comprises POSTN and THBS1. In certain embodiments, the composition comprises POSTN and IGF2. In certain embodiments, the composition comprises POSTN and IL-15. In certain embodiments, the composition comprises POSTN and THBS4. In certain embodiments, the composition comprises FGF17 and THBS2. In certain embodiments, the composition comprises FGF17 and THBS1. In certain embodiments, the composition comprises FGF17 and IGF2. In certain embodiments, the composition comprises FGF17 and IL-15. In certain embodiments, the composition comprises FGF17 and THBS4. In certain embodiments, the composition comprises THBS2 and THBS1. In certain embodiments, the composition comprises THBS2 and IGF2. In certain embodiments, the composition comprises THBS2 and IL-15. In certain embodiments, the composition comprises THBS2 and THBS4. In certain embodiments, the composition comprises THBS1 and IGF2. In certain embodiments, the composition comprises THBS1 and IL-15. In certain embodiments, the composition comprises THBS1 and THBS4. In certain embodiments, the composition comprises IGF2 and IL-15. In certain embodiments, the composition comprises IGF2 and THBS4. In certain embodiments, the composition comprises IL-15 and THBS4.

In certain embodiments, the heparin-associated binding polypeptide composition comprising any two polypeptides selected from VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4, comprises one or more additional modifications to increase stability. In certain embodiments, one or more of the heparin-associated polypeptides is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, one or more of the heparin-associated polypeptides is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, one or more of the heparin-associated polypeptides is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, or four other distinct polypeptides selected from THBS2, VTN, POSTN, FGF17, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four, or more distinct polypeptides. In certain embodiments, one or more of the heparin-associated polypeptides is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, the heparin-associated binding polypeptide composition comprises any three polypeptides selected from VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, the composition comprises THBS1. In certain embodiments, the composition comprises THBS2. In certain embodiments, the composition comprises THBS4. In certain embodiments, the composition comprises FGF17. In certain embodiments, the composition comprises VTN. In certain embodiments, the composition comprises POSTN. In certain embodiments, the composition comprises IGF2. In certain embodiments, the composition comprises IL-15. In certain embodiments, the composition comprises IGF2, THBS2, and THBS4. In certain embodiments, the composition comprises IL-15, THBS2, and THBS4. In certain embodiments, the composition comprises THBS2 and THBS4. In certain embodiments, the composition comprises THBS2, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, THBS4, and ANOS1. In certain embodiments, the composition comprises THBS2, THBS4, and IL-15. In certain embodiments, the composition comprises THBS2, THBS4, and IGF2. In certain embodiments, the composition comprises THBS1 and FGF17. In certain embodiments, the composition comprises THBS2 and VTN. In certain embodiments, the composition comprises THBS1 and VTN. In certain embodiments, the composition comprises THBS1 and THBS2. In certain embodiments, the composition comprises THBS2 and FGF17. In certain embodiments, the composition comprises THBS1 and THBS4. In certain embodiments, the composition comprises VTN and FGF17. In certain embodiments, the composition comprises THBS4 and VTN. In certain embodiments, the composition comprises THBS4 and FGF17.

In certain embodiments, the composition comprises VTN, FGF17, and THBS2. In certain embodiments, the composition comprises VTN, FGF17, and POSTN. In certain embodiments, the composition comprises VTN, FGF17, and THBS2. In certain embodiments, the composition comprises VTN, FGF17, and THBS1. In certain embodiments, the composition comprises VTN, FGF17, and IGF2. In certain embodiments, the composition comprises VTN, FGF17, and IL-15. In certain embodiments, the composition comprises VTN, FGF17, and THBS4.

In certain embodiments, the composition comprises VTN, THBS2, and POSTN. In certain embodiments, the composition comprises VTN, THBS2, and FGF17. In certain embodiments, the composition comprises VTN, THBS2, and THBS1. In certain embodiments, the composition comprises VTN, THBS2, and IGF2. In certain embodiments, the composition comprises VTN, THBS2, and IL-15. In certain embodiments, the composition comprises VTN, THBS2, and THBS4.

In certain embodiments, the composition comprises VTN, THBS1, and POSTN. In certain embodiments, the composition comprises VTN, THBS1, and FGF17. In certain embodiments, the composition comprises VTN, THBS1, and THBS2. In certain embodiments, the composition comprises VTN, THBS1, and IGF2. In certain embodiments, the composition comprises VTN, THBS1, and IL-15. In certain embodiments, the composition comprises VTN, THBS1, and THBS4.

In certain embodiments, the composition comprises VTN, IGF2, and POSTN. In certain embodiments, the composition comprises VTN, IGF2, and FGF17. In certain embodiments, the composition comprises VTN, IGF2, and THBS2. In certain embodiments, the composition comprises VTN, IGF2, and THBS1. In certain embodiments, the composition comprises VTN, IGF2, and IL-15. In certain embodiments, the composition comprises VTN, IGF2, and THBS4.

In certain embodiments, the composition comprises VTN, IL-15, and POSTN. In certain embodiments, the composition comprises VTN, IL-15, and FGF17. In certain embodiments, the composition comprises VTN, IL-15, and THBS2. In certain embodiments, the composition comprises VTN, IL-15, and THBS1. In certain embodiments, the composition comprises VTN, IL-15, and IGF2. In certain embodiments, the composition comprises VTN, IL-15, and THBS4.

In certain embodiments, the composition comprises VTN, TBHS4, and POSTN. In certain embodiments, the composition comprises VTN, TBHS4, and FGF17. In certain embodiments, the composition comprises VTN, TBHS4, and THBS2. In certain embodiments, the composition comprises VTN, TBHS4, and THBS1. In certain embodiments, the composition comprises VTN, TBHS4, and IGF2. In certain embodiments, the composition comprises VTN, TBHS4, and IL-15.

In certain embodiments, the composition comprises POSTN, FGF17, and VTN. In certain embodiments, the composition comprises POSTN, FGF17, and TBHS2. In certain embodiments, the composition comprises POSTN, FGF17, and THBS1. In certain embodiments, the composition comprises POSTN, FGF17, and IGF2. In certain embodiments, the composition comprises POSTN, FGF17, and IL-15. In certain embodiments, the composition comprises POSTN, FGF17, and THBS4.

In certain embodiments, the composition comprises POSTN, THBS2, and VTN. In certain embodiments, the composition comprises POSTN, THBS2, and FGF17. In certain embodiments, the composition comprises POSTN, THBS2, and THBS1. In certain embodiments, the composition comprises POSTN, THBS2, and IGF2. In certain embodiments, the composition comprises POSTN, THBS2, and IL-15. In certain embodiments, the composition comprises POSTN, THBS2, and THBS4.

In certain embodiments, the composition comprises POSTN, THBS1, and VTN. In certain embodiments, the composition comprises POSTN, THBS1, and FGF17. In certain embodiments, the composition comprises POSTN, THBS1, and THBS2. In certain embodiments, the composition comprises POSTN, THBS1, and IGF2. In certain embodiments, the composition comprises POSTN, THBS1, and IL-15. In certain embodiments, the composition comprises POSTN, THBS1, and THBS4.

In certain embodiments, the composition comprises POSTN, IGF2, and VTN. In certain embodiments, the composition comprises POSTN, IGF2, and FGF17. In certain embodiments, the composition comprises POSTN, IGF2, and THBS2. In certain embodiments, the composition comprises POSTN, IGF2, and THBS1. In certain embodiments, the composition comprises POSTN, IGF2, and IL-15. In certain embodiments, the composition comprises POSTN, IGF2, and THBS4.

In certain embodiments, the composition comprises POSTN, IL-15, and VTN. In certain embodiments, the composition comprises POSTN, IL-15, and FGF17. In certain embodiments, the composition comprises POSTN, IL-15, and THBS2. In certain embodiments, the composition comprises POSTN, IL-15, and THBS1. In certain embodiments, the composition comprises POSTN, IL-15, and IGF2. In certain embodiments, the composition comprises POSTN, IL-15, and THBS4.

In certain embodiments, the composition comprises POSTN, THBS4, and VTN. In certain embodiments, the composition comprises POSTN, THBS4, and FGF17. In certain embodiments, the composition comprises POSTN, THBS4, and THBS2. In certain embodiments, the composition comprises POSTN, THBS4, and THBS1. In certain embodiments, the composition comprises POSTN, THBS4, and IGF2. In certain embodiments, the composition comprises POSTN, THBS4, and IL-15.

In certain embodiments, the composition comprises FGF17, THBS2, and VTN. In certain embodiments, the composition comprises FGF17, THBS2, and POSTN. In certain embodiments, the composition comprises FGF17, THBS2, and THBS1. In certain embodiments, the composition comprises FGF17, THBS2, and IGF2. In certain embodiments, the composition comprises FGF17, THBS2, and IL-15. In certain embodiments, the composition comprises FGF17, THBS2, and THBS4.

In certain embodiments, the composition comprises FGF17, THBS1, and VTN. In certain embodiments, the composition comprises FGF17, THBS1, and POSTN. In certain embodiments, the composition comprises FGF17, THBS1, and THBS2. In certain embodiments, the composition comprises FGF17, THBS1, and IGF2. In certain embodiments, the composition comprises FGF17, THBS1, and IL-15. In certain embodiments, the composition comprises FGF17, THBS1, and THBS4.

In certain embodiments, the composition comprises FGF17, IGF2, and VTN. In certain embodiments, the composition comprises FGF17, IGF2, and POSTN. In certain embodiments, the composition comprises FGF17, IGF2, and THBS2. In certain embodiments, the composition comprises FGF17, IGF2, and THBS1. In certain embodiments, the composition comprises FGF17, IGF2, and IL-15. In certain embodiments, the composition comprises FGF17, IGF2, and THBS4.

In certain embodiments, the composition comprises FGF17, IL-15, and VTN. In certain embodiments, the composition comprises FGF17, IL-15, and POSTN. In certain embodiments, the composition comprises FGF17, IL-15, and THBS2. In certain embodiments, the composition comprises FGF17, IL-15, and THBS1. In certain embodiments, the composition comprises FGF17, IL-15, and IGF2. In certain embodiments, the composition comprises FGF17, IL-15, and THBS4.

In certain embodiments, the composition comprises FGF17, THBS4, and VTN. In certain embodiments, the composition comprises FGF17, THBS4, and POSTN. In certain embodiments, the composition comprises FGF17, THBS4, and THBS2. In certain embodiments, the composition comprises FGF17, THBS4, and THBS1. In certain embodiments, the composition comprises FGF17, THBS4, and IGF2. In certain embodiments, the composition comprises FGF17, THBS4, and IL-15.

In certain embodiments, the composition comprises THBS2, THBS1, and VTN. In certain embodiments, the composition comprises THBS2, THBS1, and POSTN. In certain embodiments, the composition comprises THBS2, THBS1, and FGF17. In certain embodiments, the composition comprises THBS2, THBS1, and IGF2. In certain embodiments, the composition comprises THBS2, THBS1, and IL-15. In certain embodiments, the composition comprises THBS2, THBS1, and THBS4.

In certain embodiments, the composition comprises THBS2, IGF2, and VTN. In certain embodiments, the composition comprises THBS2, IGF2, and POSTN. In certain embodiments, the composition comprises THBS2, IGF2, and FGF17. In certain embodiments, the composition comprises THBS2, IGF2, and THBS1. In certain embodiments, the composition comprises THBS2, IGF2, and IL-15. In certain embodiments, the composition comprises THBS2, IGF2, and THBS4.

In certain embodiments, the composition comprises THBS2, IL-15, and VTN. In certain embodiments, the composition comprises THBS2, IL-15, and POSTN. In certain embodiments, the composition comprises THBS2, IL-15, and FGF17. In certain embodiments, the composition comprises THBS2, IL-15, and THBS1. In certain embodiments, the composition comprises THBS2, IL-15, and IGF2. In certain embodiments, the composition comprises THBS2, IL-15, and THBS4.

In certain embodiments, the composition comprises THBS2, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, THBS4, and POSTN. In certain embodiments, the composition comprises THBS2, THBS4, and FGF17. In certain embodiments, the composition comprises THBS2, THBS4, and THBS1. In certain embodiments, the composition comprises THBS2, THBS4, and IGF2. In certain embodiments, the composition comprises THBS2, THBS4, and IL-15.

In certain embodiments, the composition comprises THBS1, IGF2, and VTN. In certain embodiments, the composition comprises THBS1, IGF2, and POSTN. In certain embodiments, the composition comprises THBS1, IGF2, and FGF17. In certain embodiments, the composition comprises THBS1, IGF2, and THBS2. In certain embodiments, the composition comprises THBS1, IGF2, and IL-15. In certain embodiments, the composition comprises THBS1, IGF2, and THBS4.

In certain embodiments, the composition comprises THBS1, IL-15, and VTN. In certain embodiments, the composition comprises THBS1, IL-15, and POSTN. In certain embodiments, the composition comprises THBS1, IL-15, and FGF17. In certain embodiments, the composition comprises THBS1, IL-15, and THBS2. In certain embodiments, the composition comprises THBS1, IL-15, and IGF2. In certain embodiments, the composition comprises THBS1, IL-15, and THBS4.

In certain embodiments, the composition comprises THBS1, and THBS4, and VTN. In certain embodiments, the composition comprises THBS1, and THBS4, and POSTN. In certain embodiments, the composition comprises THBS1, and THBS4, and FGF17. In certain embodiments, the composition comprises THBS1, and THBS4, and THBS2. In certain embodiments, the composition comprises THBS1, and THBS4, and IGF2. In certain embodiments, the composition comprises THBS1, and THBS4, and IL-15.

In certain embodiments, the composition comprises IGF2, IL-15, and VTN. In certain embodiments, the composition comprises IGF2, IL-15, and POSTN. In certain embodiments, the composition comprises IGF2, IL-15, and FGF17. In certain embodiments, the composition comprises IGF2, IL-15, and THBS2. In certain embodiments, the composition comprises IGF2, IL-15, and THBS1. In certain embodiments, the composition comprises IGF2, IL-15, and THBS4.

In certain embodiments, the composition comprises IGF2, THBS4, and VTN. In certain embodiments, the composition comprises IGF2, THBS4, and POSTN. In certain embodiments, the composition comprises IGF2, THBS4, and FGF17. In certain embodiments, the composition comprises IGF2, THBS4, and THBS2. In certain embodiments, the composition comprises IGF2, THBS4, and THBS1. In certain embodiments, the composition comprises IGF2, THBS4, and IL-15.

In certain embodiments, the composition comprises IL-15, and THBS4, and VTN. In certain embodiments, the composition comprises IL-15, and THBS4, and POSTN. In certain embodiments, the composition comprises IL-15, and THBS4, and FGF17. In certain embodiments, the composition comprises IL-15, and THBS4, and THBS2. In certain embodiments, the composition comprises IL-15, and THBS4, and THBS1. In certain embodiments, the composition comprises IL-15, and THBS4, and IGF2.

In certain embodiments, the composition comprises VTN, POSTN, and FGF17. In certain embodiments, the composition comprises VTN, POSTN, and THBS2. In certain embodiments, the composition comprises VTN, POSTN, and THBS4. In certain embodiments, the composition comprises VTN, FGF17, and POSTN. In certain embodiments, the composition comprises VTN, FGF17, and THBS2. In certain embodiments, the composition comprises VTN, FGF17, and THBS4. In certain embodiments, the composition comprises VTN, THBS2, and POSTN. In certain embodiments, the composition comprises VTN, THBS2, and FGF17. In certain embodiments, the composition comprises VTN, THBS2, and THBS4. In certain embodiments, the composition comprises VTN, THBS4, and POSTN. In certain embodiments, the composition comprises VTN, THBS4, and FGF17. In certain embodiments, the composition comprises VTN, THBS4, and THBS2. In certain embodiments, the composition comprises POSTN, VTN, and THBS4. In certain embodiments, the composition comprises POSTN, VTN, and FGF17. In certain embodiments, the composition comprises POSTN, VTN, and THBS2. In certain embodiments, the composition comprises POSTN, FGF17, and THBS4. In certain embodiments, the composition comprises POSTN, FGF17, and VTN. In certain embodiments, the composition comprises POSTN, FGF17, and THBS2. In certain embodiments, the composition comprises POSTN, THBS2, and THBS4. In certain embodiments, the composition comprises POSTN, THBS2, and VTN. In certain embodiments, the composition comprises POSTN, THBS2, and FGF17. In certain embodiments, the composition comprises POSTN, THBS4, and THBS2. In certain embodiments, the composition comprises POSTN, THBS4, and VTN. In certain embodiments, the composition comprises POSTN, THBS4, and FGF17. In certain embodiments, the composition comprises FGF17, VTN, and THBS2. In certain embodiments, the composition comprises FGF17, VTN, and THBS4. In certain embodiments, the composition comprises FGF17, VTN, and POSTN. In certain embodiments, the composition comprises FGF17, POSTN, and THBS2. In certain embodiments, the composition comprises FGF17, POSTN, and THBS4. In certain embodiments, the composition comprises FGF17, POSTN, and VTN. In certain embodiments, the composition comprises FGF17, THBS2, and POSTN. In certain embodiments, the composition comprises FGF17, THBS2, and THBS4. In certain embodiments, the composition comprises FGF17, THBS2, and VTN. In certain embodiments, the composition comprises FGF17, THBS4, and POSTN. In certain embodiments, the composition comprises FGF17, THBS4, and THBS2. In certain embodiments, the composition comprises FGF17, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, VTN, and POSTN. In certain embodiments, the composition comprises THBS2, VTN, and FGF17. In certain embodiments, the composition comprises THBS2, VTN, and THBS4. In certain embodiments, the composition comprises THBS2, POSTN, and VTN. In certain embodiments, the composition comprises THBS2, POSTN, and FGF17. In certain embodiments, the composition comprises THBS2, POSTN, and THBS4. In certain embodiments, the composition comprises THBS2, FGF17, and VTN. In certain embodiments, the composition comprises THBS2, FGF17, and POSTN. In certain embodiments, the composition comprises THBS2, FGF17, and THBS4. In certain embodiments, the composition comprises THBS2, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, THBS4, and POSTN. In certain embodiments, the composition comprises THBS2, THBS4, and FGF17. In certain embodiments, the composition comprises THBS4, VTN, and THBS2. In certain embodiments, the composition comprises THBS4, VTN, and POSTN. In certain embodiments, the composition comprises THBS4, VTN, and FGF17. In certain embodiments, the composition comprises THBS4, POSTN, and THBS2. In certain embodiments, the composition comprises THBS4, POSTN, and VTN. In certain embodiments, the composition comprises THBS4, POSTN, and FGF17. In certain embodiments, the composition comprises THBS4, FGF17, and THBS2. In certain embodiments, the composition comprises THBS4, FGF17, and VTN. In certain embodiments, the composition comprises THBS4, FGF17, and POSTN. In certain embodiments, the composition comprises THBS4, THBS2, and FGF17. In certain embodiments, the composition comprises THBS4, THBS2, and VTN. In certain embodiments, the composition comprises THBS4, THBS2, and POSTN.

In certain embodiments, the heparin-associated binding polypeptide composition comprising any three polypeptides selected from VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4, comprises one or more additional modifications to increase stability. In certain embodiments, one or more of the heparin-associated polypeptides is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, one or more of the heparin-associated polypeptides is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, one or more of the heparin-associated polypeptides is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, or four other distinct polypeptides selected from THBS2, VTN, POSTN, FGF17, THBS1, IGF2, IL-15, and THBS4. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four, or more distinct polypeptides. In certain embodiments, one or more of the heparin-associated polypeptides is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, the heparin-associated binding polypeptide composition comprises any four polypeptides selected from VTN, POSTN, FGF17, THBS1, IGF2, IL-15, THBS2, and THBS4. In certain embodiments, the composition comprises VTN, POSTN, FGF17, and THBS2. In certain embodiments, the composition comprises VTN, POSTN, FGF17, and THBS4. In certain embodiments, the composition comprises VTN, POSTN, THBS2, and FGF17. In certain embodiments, the composition comprises VTN, POSTN, THBS2, and THBS4. In certain embodiments, the composition comprises VTN, POSTN, THBS4, and FGF17. In certain embodiments, the composition comprises VTN, POSTN, THBS4, and THBS2. In certain embodiments, the composition comprises VTN, FGF17, POSTN, and THBS4. In certain embodiments, the composition comprises VTN, FGF17, POSTN, and THBS2. In certain embodiments, the composition comprises VTN, FGF17, THBS2, and THBS4. In certain embodiments, the composition comprises VTN, FGF17, THBS2, and POSTN. In certain embodiments, the composition comprises VTN, FGF17, THBS4, and THBS2. In certain embodiments, the composition comprises VTN, FGF17, THBS4, and POSTN. In certain embodiments, the composition comprises VTN, THBS2, POSTN, and FGF17. In certain embodiments, the composition comprises VTN, THBS2, POSTN, and THBS4. In certain embodiments, the composition comprises VTN, THBS2, FGF17, and POSTN. In certain embodiments, the composition comprises VTN, THBS2, FGF17, and THBS4. In certain embodiments, the composition comprises VTN, THBS2, THBS4, and POSTN. In certain embodiments, the composition comprises VTN, THBS2, THBS4, and FGF17. In certain embodiments, the composition comprises VTN, THBS4, POSTN, and THBS2. In certain embodiments, the composition comprises VTN, THBS4, POSTN, and FGF17. In certain embodiments, the composition comprises VTN, THBS4, FGF17, and THBS2. In certain embodiments, the composition comprises VTN, THBS4, FGF17, and POSTN. In certain embodiments, the composition comprises VTN, THBS4, THBS2, and FGF17. In certain embodiments, the composition comprises VTN, THBS4, THBS2, and POSTN. In certain embodiments, the composition comprises POSTN, VTN, THBS4, and FGF17. In certain embodiments, the composition comprises POSTN, VTN, THBS4, and THBS2. In certain embodiments, the composition comprises POSTN, VTN, FGF17, and THBS4. In certain embodiments, the composition comprises POSTN, VTN, FGF17, and THBS2. In certain embodiments, the composition comprises POSTN, VTN, THBS2, and THBS4. In certain embodiments, the composition comprises POSTN, VTN, THBS2, and FGF17. In certain embodiments, the composition comprises POSTN, FGF17, THBS4, and THBS2. In certain embodiments, the composition comprises POSTN, FGF17, THBS4, and VTN. In certain embodiments, the composition comprises POSTN, FGF17, VTN, and THBS2. In certain embodiments, the composition comprises POSTN, FGF17, VTN, and THBS4. In certain embodiments, the composition comprises POSTN, FGF17, THBS2, and VTN. In certain embodiments, the composition comprises POSTN, FGF17, THBS2, and THBS4. In certain embodiments, the composition comprises POSTN, THBS2, THBS4, and VTN. In certain embodiments, the composition comprises POSTN, THBS2, THBS4, and FGF17. In certain embodiments, the composition comprises POSTN, THBS2, VTN, and THBS4. In certain embodiments, the composition comprises POSTN, THBS2, VTN, and FGF17. In certain embodiments, the composition comprises POSTN, THBS2, FGF17, and THBS4. In certain embodiments, the composition comprises POSTN, THBS2, FGF17, and VTN. In certain embodiments, the composition comprises POSTN, THBS4, THBS2, and FGF17. In certain embodiments, the composition comprises POSTN, THBS4, THBS2, and VTN. In certain embodiments, the composition comprises POSTN, THBS4, VTN, and FGF17. In certain embodiments, the composition comprises POSTN, THBS4, VTN, and THBS2. In certain embodiments, the composition comprises POSTN, THBS4, FGF17, and VTN. In certain embodiments, the composition comprises POSTN, THBS4, FGF17, and THBS2. In certain embodiments, the composition comprises FGF17, VTN, THBS2, and THBS4. In certain embodiments, the composition comprises FGF17, VTN, THBS2, and POSTN. In certain embodiments, the composition comprises FGF17, VTN, THBS4, and THBS2. In certain embodiments, the composition comprises FGF17, VTN, THBS4, and POSTN. In certain embodiments, the composition comprises FGF17, VTN, POSTN, and THBS2. In certain embodiments, the composition comprises FGF17, VTN, POSTN, and THBS4. In certain embodiments, the composition comprises FGF17, POSTN, THBS2, and VTN. In certain embodiments, the composition comprises FGF17, POSTN, THBS2, and THBS4. In certain embodiments, the composition comprises FGF17, POSTN, THBS4, and VTN. In certain embodiments, the composition comprises FGF17, POSTN, THBS4, and THBS2. In certain embodiments, the composition comprises FGF17, POSTN, VTN, and THBS4. In certain embodiments, the composition comprises FGF17, POSTN, VTN, and THBS2. In certain embodiments, the composition comprises FGF17, THBS2, POSTN, and THBS4. In certain embodiments, the composition comprises FGF17, THBS2, POSTN, and VTN. In certain embodiments, the composition comprises FGF17, THBS2, THBS4, and POSTN. In certain embodiments, the composition comprises FGF17, THBS2, THBS4, and VTN. In certain embodiments, the composition comprises FGF17, THBS2, VTN, and POSTN. In certain embodiments, the composition comprises FGF17, THBS2, VTN, and THBS4. In certain embodiments, the composition comprises FGF17, THBS4, POSTN, and VTN. In certain embodiments, the composition comprises FGF17, THBS4, POSTN, and THBS2. In certain embodiments, the composition comprises FGF17, THBS4, THBS2, and VTN. In certain embodiments, the composition comprises FGF17, THBS4, THBS2, and POSTN. In certain embodiments, the composition comprises FGF17, THBS4, VTN, and THBS2. In certain embodiments, the composition comprises FGF17, THBS4, VTN, and POSTN. In certain embodiments, the composition comprises THBS2, VTN, POSTN, and FGF17. In certain embodiments, the composition comprises THBS2, VTN, POSTN, and THBS4. In certain embodiments, the composition comprises THBS2, VTN, FGF17, and POSTN. In certain embodiments, the composition comprises THBS2, VTN, FGF17, and THBS4. In certain embodiments, the composition comprises THBS2, VTN, THBS4, and POSTN. In certain embodiments, the composition comprises THBS2, VTN, THBS4, and FGF17. In certain embodiments, the composition comprises THBS2, POSTN, VTN, and THBS4. In certain embodiments, the composition comprises THBS2, POSTN, VTN, and FGF17. In certain embodiments, the composition comprises THBS2, POSTN, FGF17, and THBS4. In certain embodiments, the composition comprises THBS2, POSTN, FGF17, and VTN. In certain embodiments, the composition comprises THBS2, POSTN, THBS4, and FGF17. In certain embodiments, the composition comprises THBS2, POSTN, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, FGF17, VTN, and POSTN. In certain embodiments, the composition comprises THBS2, FGF17, VTN, and THBS4. In certain embodiments, the composition comprises THBS2, FGF17, POSTN, and VTN. In certain embodiments, the composition comprises THBS2, FGF17, POSTN, and THBS4. In certain embodiments, the composition comprises THBS2, FGF17, THBS4, and VTN. In certain embodiments, the composition comprises THBS2, FGF17, THBS4, and POSTN. In certain embodiments, the composition comprises THBS2, THBS4, VTN, and FGF17. In certain embodiments, the composition comprises THBS2, THBS4, VTN, and POSTN. In certain embodiments, the composition comprises THBS2, THBS4, POSTN, and FGF17. In certain embodiments, the composition comprises THBS2, THBS4, POSTN, and VTN. In certain embodiments, the composition comprises THBS2, THBS4, FGF17, and POSTN. In certain embodiments, the composition comprises THBS2, THBS4, FGF17, and VTN. In certain embodiments, the composition comprises THBS4, VTN, THBS2, and POSTN. In certain embodiments, the composition comprises THBS4, VTN, THBS2, and FGF17. In certain embodiments, the composition comprises THBS4, VTN, POSTN, and THBS2. In certain embodiments, the composition comprises THBS4, VTN, POSTN, and FGF17. In certain embodiments, the composition comprises THBS4, VTN, FGF17, and THBS2. In certain embodiments, the composition comprises THBS4, VTN, FGF17, and POSTN. In certain embodiments, the composition comprises THBS4, POSTN, THBS2, and FGF17. In certain embodiments, the composition comprises THBS4, POSTN, THBS2, and VTN. In certain embodiments, the composition comprises THBS4, POSTN, VTN, and FGF17. In certain embodiments, the composition comprises THBS4, POSTN, VTN, and THBS2. In certain embodiments, the composition comprises THBS4, POSTN, FGF17, and VTN. In certain embodiments, the composition comprises THBS4, POSTN, FGF17, and THBS2. In certain embodiments, the composition comprises THBS4, FGF17, THBS2, and VTN. In certain embodiments, the composition comprises THBS4, FGF17, THBS2, and POSTN. In certain embodiments, the composition comprises THBS4, FGF17, VTN, and THBS2. In certain embodiments, the composition comprises THBS4, FGF17, VTN, and POSTN. In certain embodiments, the composition comprises THBS4, FGF17, POSTN, and THBS2. In certain embodiments, the composition comprises THBS4, FGF17, POSTN, and VTN. In certain embodiments, the composition comprises THBS4, THBS2, FGF17, and POSTN. In certain embodiments, the composition comprises THBS4, THBS2, FGF17, and VTN. In certain embodiments, the composition comprises THBS4, THBS2, VTN, and POSTN. In certain embodiments, the composition comprises THBS4, THBS2, VTN, and FGF17. In certain embodiments, the composition comprises THBS4, THBS2, POSTN, and VTN. In certain embodiments, the composition comprises THBS4, THBS2, POSTN, and FGF17.

In certain embodiments, the composition comprises VTN, POSTN, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, POSTN, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises VTN, FGF17, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, FGF17, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, FGF17, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, FGF17, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, FGF17, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, FGF17, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, FGF17, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises VTN, THBS2, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS2, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS2, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises VTN, THBS1, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS1, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS1, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS1, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS1, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, THBS1, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises VTN, IGF2, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IGF2, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IGF2, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IGF2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IGF2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IGF2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises VTN, IL-15, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IL-15, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IL-15, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IL-15, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IL-15, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, IL-15, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises VTN, TBHS4, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, TBHS4, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, TBHS4, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, TBHS4, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, TBHS4, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises VTN, TBHS4, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises POSTN, FGF17, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, FGF17, TBHS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, FGF17, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, FGF17, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, FGF17, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, FGF17, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises POSTN, THBS2, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS2, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS2, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises POSTN, THBS1, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS1, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS1, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS1, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS1, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS1, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises POSTN, IGF2, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IGF2, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IGF2, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IGF2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IGF2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IGF2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises POSTN, IL-15, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IL-15, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IL-15, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IL-15, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IL-15, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, IL-15, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises POSTN, THBS4, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS4, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS4, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS4, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS4, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises POSTN, THBS4, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises FGF17, THBS2, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS2, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS2, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises FGF17, THBS1, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS1, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS1, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS1, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS1, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS1, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises FGF17, IGF2, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IGF2, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IGF2, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IGF2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IGF2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IGF2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises FGF17, IL-15, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IL-15, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IL-15, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IL-15, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IL-15, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, IL-15, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises FGF17, THBS4, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS4, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS4, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS4, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS4, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises FGF17, THBS4, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS2, THBS1, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS1, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS1, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS1, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS1, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS1, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS2, IGF2, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IGF2, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IGF2, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IGF2, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IGF2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IGF2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS2, IL-15, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IL-15, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IL-15, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IL-15, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IL-15, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, IL-15, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS2, THBS4, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS4, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS4, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS4, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2,

THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS4, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS2, THBS4, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS1, IGF2, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IGF2, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IGF2, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IGF2, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IGF2, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IGF2, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS1, IL-15, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IL-15, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IL-15, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IL-15, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IL-15, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, IL-15, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises THBS1, and THBS4, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, THBS4, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, THBS4, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, THBS4, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, THBS4, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises THBS1, THBS4, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises IGF2, IL-15, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, IL-15, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, IL-15, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, IL-15, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, IL-15, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, IL-15, THBS4, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises IGF2, THBS4, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, THBS4, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, THBS4, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, THBS4, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, THBS4, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IGF2, THBS4, IL-15, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the composition comprises IL-15, THBS4, VTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IL-15, THBS4, POSTN, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IL-15, THBS4, FGF17, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IL-15, THBS4, THBS2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IL-15, THBS4, THBS1, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4. In certain embodiments, the composition comprises IL-15, THBS4, IGF2, and a polypeptide comprising VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, or THBS4.

In certain embodiments, the heparin-associated binding polypeptide composition comprising any four polypeptides selected from VTN, POSTN, FGF17, THBS2, THBS1, IGF2, IL-15, and THBS4, comprises one or more additional modifications to increase stability. In certain embodiments, one or more of the heparin-associated polypeptides is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, one or more of the heparin-associated polypeptides is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, one or more of the heparin-associated polypeptides is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four or more distinct polypeptides selected from THBS2, VTN, POSTN, FGF17, THBS1, IL-15, IGF2, and THBS4. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four, or more distinct polypeptides. In certain embodiments, one or more of the heparin-associated polypeptides is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, the heparin-associated binding polypeptide composition comprises any three polypeptides selected from VTN, STC2, AGRN, THBS2, and FST. In certain embodiments, the composition comprises VTN, STC2, and AGRN. In certain embodiments, the composition comprises VTN, STC2, and THBS2. In certain embodiments, the composition comprises VTN, STC2, and FST. In certain embodiments, the composition comprises VTN, AGRN, and STC2. In certain embodiments, the composition comprises VTN, AGRN, and THBS2. In certain embodiments, the composition comprises VTN, AGRN, and FST. In certain embodiments, the composition comprises VTN, THBS2, and STC2. In certain embodiments, the composition comprises VTN, THBS2, and AGRN. In certain embodiments, the composition comprises VTN, THBS2, and FST. In certain embodiments, the composition comprises VTN, FST, and STC2. In certain embodiments, the composition comprises VTN, FST, and AGRN. In certain embodiments, the composition comprises VTN, FST, and THBS2. In certain embodiments, the composition comprises STC2, VTN, and FST. In certain embodiments, the composition comprises STC2, VTN, and AGRN. In certain embodiments, the composition comprises STC2, VTN, and THBS2. In certain embodiments, the composition comprises STC2, AGRN, and FST. In certain embodiments, the composition comprises STC2, AGRN, and VTN. In certain embodiments, the composition comprises STC2, AGRN, and THBS2. In certain embodiments, the composition comprises STC2, THBS2, and FST. In certain embodiments, the composition comprises STC2, THBS2, and VTN. In certain embodiments, the composition comprises STC2, THBS2, and AGRN. In certain embodiments, the composition comprises STC2, FST, and THBS2. In certain embodiments, the composition comprises STC2, FST, and VTN. In certain embodiments, the composition comprises STC2, FST, and AGRN. In certain embodiments, the composition comprises AGRN, VTN, and THBS2. In certain embodiments, the composition comprises AGRN, VTN, and FST. In certain embodiments, the composition comprises AGRN, VTN, and STC2. In certain embodiments, the composition comprises AGRN, STC2, and THBS2. In certain embodiments, the composition comprises AGRN, STC2, and FST. In certain embodiments, the composition comprises AGRN, STC2, and VTN. In certain embodiments, the composition comprises AGRN, THBS2, and STC2. In certain embodiments, the composition comprises AGRN, THBS2, and FST. In certain embodiments, the composition comprises AGRN, THBS2, and VTN. In certain embodiments, the composition comprises AGRN, FST, and STC2. In certain embodiments, the composition comprises AGRN, FST, and THBS2. In certain embodiments, the composition comprises AGRN, FST, and VTN. In certain embodiments, the composition comprises THBS2, VTN, and STC2. In certain embodiments, the composition comprises THBS2, VTN, and AGRN. In certain embodiments, the composition comprises THBS2, VTN, and FST. In certain embodiments, the composition comprises THBS2, STC2, and VTN. In certain embodiments, the composition comprises THBS2, STC2, and AGRN. In certain embodiments, the composition comprises THBS2, STC2, and FST. In certain embodiments, the composition comprises THBS2, AGRN, and VTN. In certain embodiments, the composition comprises THBS2, AGRN, and STC2. In certain embodiments, the composition comprises THBS2, AGRN, and FST. In certain embodiments, the composition comprises THBS2, FST, and VTN. In certain embodiments, the composition comprises THBS2, FST, and STC2. In certain embodiments, the composition comprises THBS2, FST, and AGRN. In certain embodiments, the composition comprises FST, VTN, and THBS2. In certain embodiments, the composition comprises FST, VTN, and STC2. In certain embodiments, the composition comprises FST, VTN, and AGRN. In certain embodiments, the composition comprises FST, STC2, and THBS2. In certain embodiments, the composition comprises FST, STC2, and VTN. In certain embodiments, the composition comprises FST, STC2, and AGRN. In certain embodiments, the composition comprises FST, AGRN, and THBS2. In certain embodiments, the composition comprises FST, AGRN, and VTN. In certain embodiments, the composition comprises FST, AGRN, and STC2. In certain embodiments, the composition comprises FST, THBS2, and AGRN. In certain embodiments, the composition comprises FST, THBS2, and VTN. In certain embodiments, the composition comprises FST, THBS2, and STC2. In certain embodiments, one or more of the heparin-associated polypeptides comprise one or more additional modifications to increase stability. In certain embodiments, one or more of the heparin-associated polypeptides is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, one or more of the heparin-associated polypeptide is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, one or more of the heparin-associated polypeptides is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four or more distinct polypeptides selected from THBS2, VTN, STC2, AGRN, or FST. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four, or more distinct polypeptides. In certain embodiments, one or more of the heparin-associated polypeptides is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the heparin-associated binding polypeptide composition comprises any four polypeptides selected from VTN, STC2, AGRN, THBS2, and FST. In certain embodiments, the composition comprises VTN, STC2, AGRN, and THBS2. In certain embodiments, the composition comprises VTN, STC2, AGRN, and FST. In certain embodiments, the composition comprises VTN, STC2, THBS2, and AGRN. In certain embodiments, the composition comprises VTN, STC2, THBS2, and FST. In certain embodiments, the composition comprises VTN, STC2, FST, and AGRN. In certain embodiments, the composition comprises VTN, STC2, FST, and THBS2. In certain embodiments, the composition comprises VTN, AGRN, STC2, and FST. In certain embodiments, the composition comprises VTN, AGRN, STC2, and THBS2. In certain embodiments, the composition comprises VTN, AGRN, THBS2, and FST. In certain embodiments, the composition comprises VTN, AGRN, THBS2, and STC2. In certain embodiments, the composition comprises VTN, AGRN, FST, and THBS2. In certain embodiments, the composition comprises VTN, AGRN, FST, and STC2. In certain embodiments, the composition comprises VTN, THBS2, STC2, and AGRN. In certain embodiments, the composition comprises VTN, THBS2, STC2, and FST. In certain embodiments, the composition comprises VTN, THBS2, AGRN, and STC2. In certain embodiments, the composition comprises VTN, THBS2, AGRN, and FST. In certain embodiments, the composition comprises VTN, THBS2, FST, and STC2. In certain embodiments, the composition comprises VTN, THBS2, FST, and AGRN. In certain embodiments, the composition comprises VTN, FST, STC2, and THBS2. In certain embodiments, the composition comprises VTN, FST, STC2, and AGRN. In certain embodiments, the composition comprises VTN, FST, AGRN, and THBS2. In certain embodiments, the composition comprises VTN, FST, AGRN, and STC2. In certain embodiments, the composition comprises VTN, FST, THBS2, and AGRN. In certain embodiments, the composition comprises VTN, FST, THBS2, and STC2. In certain embodiments, the composition comprises STC2, VTN, FST, and AGRN. In certain embodiments, the composition comprises STC2, VTN, FST, and THBS2. In certain embodiments, the composition comprises STC2, VTN, AGRN, and FST. In certain embodiments, the composition comprises STC2, VTN, AGRN, and THBS2. In certain embodiments, the composition comprises STC2, VTN, THBS2, and FST. In certain embodiments, the composition comprises STC2, VTN, THBS2, and AGRN. In certain embodiments, the composition comprises STC2, AGRN, FST, and THBS2. In certain embodiments, the composition comprises STC2, AGRN, FST, and VTN. In certain embodiments, the composition comprises STC2, AGRN, VTN, and THBS2. In certain embodiments, the composition comprises STC2, AGRN, VTN, and FST. In certain embodiments, the composition comprises STC2, AGRN, THBS2, and VTN. In certain embodiments, the composition comprises STC2, AGRN, THBS2, and FST. In certain embodiments, the composition comprises STC2, THBS2, FST, and VTN. In certain embodiments, the composition comprises STC2, THBS2, FST, and AGRN. In certain embodiments, the composition comprises STC2, THBS2, VTN, and FST. In certain embodiments, the composition comprises STC2, THBS2, VTN, and AGRN. In certain embodiments, the composition comprises STC2, THBS2, AGRN, and FST. In certain embodiments, the composition comprises STC2, THBS2, AGRN, and VTN. In certain embodiments, the composition comprises STC2, FST, THBS2, and AGRN. In certain embodiments, the composition comprises STC2, FST, THBS2, and VTN. In certain embodiments, the composition comprises STC2, FST, VTN, and AGRN. In certain embodiments, the composition comprises STC2, FST, VTN, and THBS2. In certain embodiments, the composition comprises STC2, FST, AGRN, and VTN. In certain embodiments, the composition comprises STC2, FST, AGRN, and THBS2. In certain embodiments, the composition comprises AGRN, VTN, THBS2, and FST. In certain embodiments, the composition comprises AGRN, VTN, THBS2, and STC2. In certain embodiments, the composition comprises AGRN, VTN, FST, and THBS2. In certain embodiments, the composition comprises AGRN, VTN, FST, and STC2. In certain embodiments, the composition comprises AGRN, VTN, STC2, and THBS2. In certain embodiments, the composition comprises AGRN, VTN, STC2, and FST. In certain embodiments, the composition comprises AGRN, STC2, THBS2, and VTN. In certain embodiments, the composition comprises AGRN, STC2, THBS2, and FST. In certain embodiments, the composition comprises AGRN, STC2, FST, and VTN. In certain embodiments, the composition comprises AGRN, STC2, FST, and THBS2. In certain embodiments, the composition comprises AGRN, STC2, VTN, and FST. In certain embodiments, the composition comprises AGRN, STC2, VTN, and THBS2. In certain embodiments, the composition comprises AGRN, THBS2, STC2, and FST. In certain embodiments, the composition comprises AGRN, THBS2, STC2, and VTN. In certain embodiments, the composition comprises AGRN, THBS2, FST, and STC2. In certain embodiments, the composition comprises AGRN, THBS2, FST, and VTN. In certain embodiments, the composition comprises AGRN, THBS2, VTN, and STC2. In certain embodiments, the composition comprises AGRN, THBS2, VTN, and FST. In certain embodiments, the composition comprises AGRN, FST, STC2, and VTN. In certain embodiments, the composition comprises AGRN, FST, STC2, and THBS2. In certain embodiments, the composition comprises AGRN, FST, THBS2, and VTN. In certain embodiments, the composition comprises AGRN, FST, THBS2, and STC2. In certain embodiments, the composition comprises AGRN, FST, VTN, and THBS2. In certain embodiments, the composition comprises AGRN, FST, VTN, and STC2. In certain embodiments, the composition comprises THBS2, VTN, STC2, and AGRN. In certain embodiments, the composition comprises THBS2, VTN, STC2, and FST. In certain embodiments, the composition comprises THBS2, VTN, AGRN, and STC2. In certain embodiments, the composition comprises THBS2, VTN, AGRN, and FST. In certain embodiments, the composition comprises THBS2, VTN, FST, and STC2. In certain embodiments, the composition comprises THBS2, VTN, FST, and AGRN. In certain embodiments, the composition comprises THBS2, STC2, VTN, and FST. In certain embodiments, the composition comprises THBS2, STC2, VTN, and AGRN. In certain embodiments, the composition comprises THBS2, STC2, AGRN, and FST. In certain embodiments, the composition comprises THBS2, STC2, AGRN, and VTN. In certain embodiments, the composition comprises THBS2, STC2, FST, and AGRN. In certain embodiments, the composition comprises THBS2, STC2, FST, and VTN. In certain embodiments, the composition comprises THBS2, AGRN, VTN, and STC2. In certain embodiments, the composition comprises THBS2, AGRN, VTN, and FST. In certain embodiments, the composition comprises THBS2, AGRN, STC2, and VTN. In certain embodiments, the composition comprises THBS2, AGRN, STC2, and FST. In certain embodiments, the composition comprises THBS2, AGRN, FST, and VTN. In certain embodiments, the composition comprises THBS2, AGRN, FST, and STC2. In certain embodiments, the composition comprises THBS2, FST, VTN, and AGRN. In certain embodiments, the composition comprises THBS2, FST, VTN, and STC2. In certain embodiments, the composition comprises THBS2, FST, STC2, and AGRN. In certain embodiments, the composition comprises THBS2, FST, STC2, and VTN. In certain embodiments, the composition comprises THBS2, FST, AGRN, and STC2. In certain embodiments, the composition comprises THBS2, FST, AGRN, and VTN. In certain embodiments, the composition comprises FST, VTN, THBS2, and STC2. In certain embodiments, the composition comprises FST, VTN, THBS2, and AGRN. In certain embodiments, the composition comprises FST, VTN, STC2, and THBS2. In certain embodiments, the composition comprises FST, VTN, STC2, and AGRN. In certain embodiments, the composition comprises FST, VTN, AGRN, and THBS2. In certain embodiments, the composition comprises FST, VTN, AGRN, and STC2. In certain embodiments, the composition comprises FST, STC2, THBS2, and AGRN. In certain embodiments, the composition comprises FST, STC2, THBS2, and VTN. In certain embodiments, the composition comprises FST, STC2, VTN, and AGRN. In certain embodiments, the composition comprises FST, STC2, VTN, and THBS2. In certain embodiments, the composition comprises FST, STC2, AGRN, and VTN. In certain embodiments, the composition comprises FST, STC2, AGRN, and THBS2. In certain embodiments, the composition comprises FST, AGRN, THBS2, and VTN. In certain embodiments, the composition comprises FST, AGRN, THBS2, and STC2. In certain embodiments, the composition comprises FST, AGRN, VTN, and THBS2. In certain embodiments, the composition comprises FST, AGRN, VTN, and STC2. In certain embodiments, the composition comprises FST, AGRN, STC2, and THBS2. In certain embodiments, the composition comprises FST, AGRN, STC2, and VTN. In certain embodiments, the composition comprises FST, THBS2, AGRN, and STC2. In certain embodiments, the composition comprises FST, THBS2, AGRN, and VTN. In certain embodiments, the composition comprises FST, THBS2, VTN, and STC2. In certain embodiments, the composition comprises FST, THBS2, VTN, and AGRN. In certain embodiments, the composition comprises FST, THBS2, STC2, and VTN. In certain embodiments, the composition comprises FST, THBS2, STC2, and AGRN. In certain embodiments, one or more of the heparin-associated polypeptides comprise one or more additional modifications to increase stability. In certain embodiments, one or more of the heparin-associated polypeptides is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, one or more of the heparin-associated polypeptides is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, one or more of the heparin-associated polypeptides is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, or four other distinct polypeptides selected from THBS2, VTN, STC2, AGRN, or FST. In certain embodiments, one or more of the heparin-associated polypeptides is present in a concatemer with one, two, three, four, or more distinct polypeptides. In certain embodiments, one or more of the heparin-associated polypeptides is included in a composition comprising a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In some embodiments, a composition herein comprises polypeptide 1 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 2 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 3 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 4 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 5 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 6 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 7 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 8 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 9 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 10 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 11 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 12 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 13 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 14 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 15 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 16 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 17 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 18 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 19 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 21 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 22 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 23 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 24 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 25 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 26 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 27 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 28 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 29 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 30 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 31 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 32 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 33 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 34 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 35 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 36 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 37 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 38 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 39 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 40 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 41 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 42 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 43 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 44 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 45 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 46 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 47 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 48 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 49 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 50 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 51 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 52 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 53 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 54 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 55 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 56 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 57 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 58 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 59 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 60 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 61 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 62 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 63 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 64 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 65 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 66 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 67 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 68 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 69 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 70 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 71 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 72 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 73 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 74 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 75 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 76 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 77 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 78 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 79 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 80 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 81 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 82 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 83 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 84 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 85 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 86 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 87 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 88 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 89 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 90 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 91 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 92 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 93 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 94 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 95 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 96 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 97 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 98 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 99 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 100 and one or more polypeptides from Table 2.

In some embodiments, a composition herein comprises polypeptide 101 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 102 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 103 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 104 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 105 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 106 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 107 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 108 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 109 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 110 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 111 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 112 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 113 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 114 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 115 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 116 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 117 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 118 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 119 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 121 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 122 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 123 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 124 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 125 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 126 and one or more poly peptides from Table 2. In some embodiments, a composition herein comprises polypeptide 127 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 128 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 129 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 130 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 131 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 132 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 133 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 134 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 135 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 136 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 137 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 138 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 139 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 140 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 141 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 142 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 143 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 144 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 145 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 146 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 147 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 148 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 149 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 150 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 151 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 152 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 153 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 154 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 155 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 156 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 157 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 158 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 159 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 160 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 161 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 162 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 163 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 164 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 165 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 166 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 167 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 168 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 169 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 170 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 171 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 172 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 173 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 174 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 175 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 176 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 177 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 178 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 179 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 180 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 181 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 182 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 183 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 184 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 185 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 186 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 187 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 188 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 189 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 190 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 191 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 192 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 193 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 194 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 195 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 196 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 197 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 198 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 199 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 200 and one or more polypeptides from Table 2.

In some embodiments, a composition herein comprises polypeptide 201 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 202 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 203 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 204 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 205 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 206 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 207 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 208 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 209 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 210 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 211 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 212 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 213 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 214 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 215 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 216 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 217 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 218 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 219 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 221 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 222 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 223 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 224 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 225 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 226 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 227 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 228 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 229 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 230 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 231 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 232 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 233 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 234 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 235 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 236 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 237 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 238 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 239 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 240 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 241 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 242 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 243 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 244 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 245 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 246 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 247 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 248 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 249 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 250 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 251 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 252 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 253 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 254 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 255 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 256 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 257 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 258 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 259 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 260 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 261 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 262 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 263 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 264 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 265 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 266 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 267 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 268 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 269 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 270 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 271 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 272 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 273 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 274 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 275 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 276 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 277 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 278 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 279 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 280 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 281 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 282 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 283 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 284 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 285 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 286 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 287 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 288 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 289 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 290 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 291 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 292 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 293 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 294 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 295 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 296 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 297 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 298 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 299 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 300 and one or more polypeptides from Table 2.

In some embodiments, a composition herein comprises polypeptide 401 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 402 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 403 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 404 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 405 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 406 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 407 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 408 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 409 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 410 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 411 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 412 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 413 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 414 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 415 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 416 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 417 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 418 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 419 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 421 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 422 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 423 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 424 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 425 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 426 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 427 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 428 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 429 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 430 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 431 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 432 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 433 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 434 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 435 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 436 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 437 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 438 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 439 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 440 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 441 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 442 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 443 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 444 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 445 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 446 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 447 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 448 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 449 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 450 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 451 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises poly peptide 452 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 453 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 454 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 455 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 456 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 457 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 458 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 459 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 460 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 461 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 462 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 463 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 464 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 465 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 466 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 467 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 468 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 469 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 470 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 471 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 472 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 473 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 474 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 475 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 476 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 477 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 478 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 479 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 480 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 481 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 482 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 483 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 484 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 485 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 486 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 487 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 488 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 489 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 490 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 491 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 492 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 493 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 494 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 495 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 496 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 497 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 498 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 499 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 500 and one or more polypeptides from Table 2.

In some embodiments, a composition herein comprises polypeptide 501 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 502 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 503 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 504 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 505 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 506 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 507 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 508 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 509 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 510 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 511 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 512 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 513 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 514 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 515 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 516 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 517 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 518 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 519 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 521 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 522 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 523 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 524 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 525 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 526 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 527 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 528 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 529 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 530 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 531 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 532 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 533 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 534 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 535 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 536 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 537 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 538 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 539 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 540 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 541 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 542 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 543 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 544 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 545 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 546 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 547 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 548 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 549 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 550 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 551 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 552 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 553 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 554 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 555 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 556 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 557 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 558 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 559 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 560 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 561 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 562 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 563 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 564 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 565 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 566 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 567 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 568 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 569 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 570 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 571 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 572 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 573 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 574 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 575 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 576 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 577 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 578 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 579 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 580 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 581 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 582 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 583 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 584 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 585 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 586 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 587 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 588 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 589 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 590 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 591 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 592 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 593 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 594 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 595 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 596 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 597 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 598 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 599 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 600 and one or more polypeptides from Table 2.

In some embodiments, a composition herein comprises polypeptide 701 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 702 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 703 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 704 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 705 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 706 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 707 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 708 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 709 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 710 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 711 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 712 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 713 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 714 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 715 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 716 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 717 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 718 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 719 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 721 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 722 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 723 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 724 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 725 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 726 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 727 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 728 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 729 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 730 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 731 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 732 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 733 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 734 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 735 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 736 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 737 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 738 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 739 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 740 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 741 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 742 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 743 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 744 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 745 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 746 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 747 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 748 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 749 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 750 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 751 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 752 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 753 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 754 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 755 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 756 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 757 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 758 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 759 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 760 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 761 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 762 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 763 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 764 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 765 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 766 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 767 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 768 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 769 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 770 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 771 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 772 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 773 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 774 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 775 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 776 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 777 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 778 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 779 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 780 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 781 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 782 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 783 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 784 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 785 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 786 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 787 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 788 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 789 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 790 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 791 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 792 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 793 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 794 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 795 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 796 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 797 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 798 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 799 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 800 and one or more polypeptides from Table 2.

In some embodiments, a composition herein comprises polypeptide 801 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 802 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 803 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 804 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 805 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 806 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 807 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 808 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 809 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 810 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 811 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 812 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 813 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 814 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 815 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 816 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 817 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 818 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 819 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 821 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 822 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 823 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 824 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 825 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 826 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 827 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 828 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 829 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 830 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 831 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 832 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 833 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 834 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 835 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 836 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 837 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 838 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 839 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 840 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 841 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 842 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 843 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 844 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 845 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 846 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 847 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 848 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 849 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 850 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 851 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 852 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 853 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 854 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 855 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 856 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 857 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 858 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 859 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 860 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 861 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 862 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 863 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 864 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 865 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 866 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 867 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 868 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 869 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 870 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 871 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 872 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 873 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 874 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 875 and one or more polypeptides from Table 2. In some embodiments, a composition herein comprises polypeptide 876 and one or more polypeptides from Table 2.

In some cases, the one or more polypeptides from Table 2 comprises IL-15. In some cases, the one or more polypeptides from Table 2 comprises THBS4. In some cases, the one or more polypeptides from Table 2 comprises POSTN. In some cases, the one or more polypeptides from Table 2 comprises THBS1. In some cases, the one or more polypeptides from Table 2 comprises THBS2. In some cases, the one or more polypeptides from Table 2 comprises VTN. In some cases, the one or more polypeptides from Table 2 comprises FGF17. In some cases, the one or more polypeptides from Table 2 comprises IGF2. In some cases, the one or more polypeptides from Table 2 comprises polypeptide 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, or 876. In some cases, one or a plurality of the polypeptides of the composition are heparin-associated prolylpeptides. In some cases, one or a plurality of the polypeptides of the composition are mitogenic and/or fusion promoting prolylpeptides. In certain embodiments, one or more of the polypeptides of the composition comprise one or more additional modifications to increase stability. In certain embodiments, one or more of the polypeptides is covalently conjugated to polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol, polysialic acid, glycolic acid, or polypropylene glycol. In certain embodiments, one or more of the polypeptides is fused or conjugated to another protein to increase stability and or bioavailability. In certain embodiments, one or more of the polypeptides is fused with an Fc region of an immunoglobulin or with serum albumin. In certain embodiments, one or more of the polypeptides is present in a concatemer with one, two, three, four or more distinct polypeptides selected from Table 2 and/or Table 1. In certain embodiments, one or more of the polypeptides is present in a concatemer with one, two, three, four, or more distinct polypeptides. In certain embodiments, one or more of the polypeptides is included in the composition with a biodegradable or bioabsorbable carrier that promotes polypeptide stability. In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA), polyglycolic acid (PGA), or Poly(D,L-lactic-coglycolic-acid) (PLGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polylactic acid (PLA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises polyglycolic acid (PGA). In certain embodiments, the biodegradable or bioabsorbable carrier comprises Poly(D,L-lactic-coglycolic-acid) (PLGA).

In certain embodiments, the heparin-associated polypeptides increase the mitogenic (e.g., proliferative capacity) of a somatic cell that is a tissue cell or a tissue precursor, such as: a muscle cell, a muscle precursor cell, a tenocyte, a tenocyte precursor cell, a chondrocyte, a chondrocyte precursor, a mesenchymal stem cell, or a fibroblast. The cell can be a precursor cell derived from any mammal, such as, monkeys, apes, dogs, cats, horses, rats, mice, or humans. In certain embodiments, the precursor cell is a human precursor cell. In certain embodiments, the heparin-associated polypeptides increase the proliferative capacity of a mouse myoblast by at least about 1.5-fold, about 2-fold, about 3-fold, or about 4-fold as measured by BrdU or EdU incorporation.

Therapeutic Indications

In certain aspects, heparin-associated polypeptides and compositions comprising heparin-associated polypeptides, described herein, are useful for treating diseases and disorders that involve soft-tissue injury, degradation, or destruction. Aging disorders that result in the deterioration and loss of muscle tissue are such soft-tissue disorders. Sarcopenia, for example, is the degenerative loss of skeletal muscle mass quality, and strength associated with aging. Injuries that result in acute muscle damage are other such disorders. The disorders include muscle ruptures, strains, and contusions. A rupture is a separating of the muscle tissues. Muscle strains are contraction-induced injuries in which muscle fibers tear due to extensive mechanical stress, and can be classified as a grade I, II, or III. Muscle contusions are muscle hematomas. Muscle injury can also be caused by non-mechanical stresses such as cachexia. Cachexia may be caused by malnutrition, cancer, AIDS, coeliac disease, chronic obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, congestive heart failure, tuberculosis, familial amyloid polyneuropathy, mercury poisoning (acrodynia), Crohn's disease, untreated/severe type 1 diabetes mellitus, anorexia nervosa, chemotherapy, muscular dystrophy or other genetic diseases which cause immobility, and hormonal deficiencies. Certain disorders that are weaknesses of specific muscles such as dysphagia or facioscapulohumeral muscular dystrophy may also be treated by the polypeptides described herein. Additional soft-tissues disorders that may be treated using the heparin-associated polypeptides described herein are those that inflict injury to the tendons, ligaments or cartilage. In certain embodiments, the muscle wasting disease is a muscular dystrophy. In certain embodiments, the muscular dystrophy comprises myotonic muscular dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, Limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital, muscular dystrophy, oculopharyngeal muscular dystrophy, or distal muscular dystrophy. In certain embodiments, the muscular dystrophy is Becker muscular dystrophy. In certain embodiments, the heparin-associated polypeptides useful for treating a soft-tissue disorder comprise any one, two, three, four, or five heparin-associated polypeptides selected from Vitronectin (VTN), Periostin (POSTN), Fibroblast growth factor (FGF17), Thrombospondin 2 (THBS2), Thrombospondin 4 (THBS4), Thrombospondin 1 (THBS1), Insulin-like growth factor 2 (IGF2), and Interleukin 15 (IL-15). In certain embodiments, the heparin-associated polypeptides useful for treating a soft-tissue disorder comprise any one, two, three, four, or five heparin-associated polypeptides selected from Vitronectin (VTN), Stanniocalcin-2 (STC2), Agrin (AGRN), Thrombospondin 2 (THBS2), follistatin (FST), Periostin (POSTN), Fibroblast growth factor (FGF17), Thrombospondin 4 (THBS4), Thrombospondin 1 (THBS1), Insulin-like growth factor 2 (IGF2), and Interleukin 15 (IL-15).

In certain embodiments, the heparin-associated polypeptides and compositions comprising heparin-associated polypeptides, described herein, are for use in treating an individual with an aging disorder, a muscle wasting disorder, a muscle injury, an injury to a connective tissue, or an injury to a non-muscle soft-tissue, or any combination thereof. In certain embodiments, the aging disorder is sarcopenia. In certain embodiments, the muscle wasting disorder is cachexia. In certain embodiments, the cachexia is a result of a cancer. In certain embodiments, the cachexia is a result of AIDS. In certain embodiments, the injury is a muscle injury. In certain embodiments, the muscle wasting is atrophy do to limb immobilization or disuse. In certain embodiments, the muscle injury is a strain or a tear. In certain embodiments, the muscle injury is a Grade III strain. In certain embodiments, sarcopenia contributes to the incidence of the muscle injury. In certain embodiments, the injury is ligament damage. In certain embodiments, the ligament damage is a rupture or a tear. In certain embodiments, the injury is tendon damage. In certain embodiments, the tendon damage is a rupture or a tear. In certain embodiments, the injury is cartilage damage. In certain embodiments, the heparin-associated polypeptides comprise any one, two, three, four, five or more heparin-associated polypeptides selected from Vitronectin (VTN), Periostin (POSTN), Fibroblast growth factor (FGF17), Thrombospondin 2 (THBS2), Thrombospondin 4 (THBS4), Thrombospondin 1 (THBS1), Insulin-like growth factor 2 (IGF2), and Interleukin 15 (IL-15). In certain embodiments, the heparin-associated polypeptides comprise any one, two, three, four, five or more heparin-associated polypeptides selected from Vitronectin (VTN), Stanniocalcin-2 (STC2), Agrin (AGRN), Thrombospondin 2 (THBS2), and follistatin (FST).

In certain embodiments, the heparin-associated polypeptides and compositions comprising heparin-associated polypeptides, described herein, are for use in a method of treating myositis. In certain embodiments, the myositis comprises dermatomyositis, polymyositis, necrotizing myopathy (also called necrotizing autoimmune myopathy or immune-mediated necrotizing myopathy), juvenile myositis, or sporadic inclusion-body myositis. In certain embodiments, the heparin-associated polypeptides comprise any one, two, three, four, five or more heparin-associated polypeptides selected from Vitronectin (VTN), Periostin (POSTN), Fibroblast growth factor (FGF17), Thrombospondin 2 (THBS2), Thrombospondin 4 (THBS4), Thrombospondin 1 (THBS1), Insulin-like growth factor 2 (IGF2), and Interleukin 15 (IL-15). In certain embodiments, the heparin-associated polypeptides comprise any one, two, three, four, or five heparin-associated polypeptides selected from Vitronectin (VTN), Stanniocalcin-2 (STC2), Agrin (AGRN), Thrombospondin 2 (THBS2), and follistatin (FST).

In certain embodiments, the heparin-associated polypeptides and compositions comprising heparin-associated polypeptides, described herein, are for use in a method of increasing proliferation or promoting survival of a cell associated with soft-tissue damage. In certain embodiments, the heparin-associated polypeptides described herein are useful in a method of increasing proliferation or promoting survival of any one or more of a muscle cell, a muscle precursor cell, a tenocyte, a tenocyte precursor cell, a chondrocyte, a chondrocyte precursor cell, a mesenchymal stem cell, or a fibroblast. In certain embodiments, the heparin-associated polypeptides comprise any one, two, three, four, five or more heparin-associated polypeptides selected from Vitronectin (VTN), Periostin (POSTN), Fibroblast growth factor (FGF17), Thrombospondin 2 (THBS2), Thrombospondin 4 (THBS4), Thrombospondin 1 (THBS1), Insulin-like growth factor 2 (IGF2), and Interleukin 15 (IL-15). In certain embodiments, the heparin-associated polypeptides comprise any one, two, three, four, or five heparin-associated polypeptides selected from Vitronectin (VTN), Stanniocalcin-2 (STC2), Agrin (AGRN), Thrombospondin 2 (THBS2), and follistatin (FST).

The heparin-associated polypeptides compositions described herein can be administered separately or as a mixture of 2, 3, 4, 5, 6, 7, 8, 9, 10 or more heparin-binding or heparin-associated polypeptides for the treatment of any disorder associated with muscle or soft-tissue.

In certain aspects, a method of treating a disease or condition, such as those described herein, in a subject in need thereof comprises administering to the subject a composition comprising a polypeptide of Table 2. In some embodiments, the polypeptide of Table 2 is a polypeptide of Table 1. In some embodiments, the composition comprises a pharmaceutically acceptable excipient, such as described herein. In some embodiments, the disease or condition comprises an aging disorder, muscle wasting disorder, muscle injury, or injury to connective tissue, or a combination thereof. In some embodiments, the aging disorder comprises sarcopenia. In some embodiments, the muscle wasting disorder comprises muscular dystrophy. In some embodiments, the muscle wasting is a result of obesity. In certain embodiments, the muscle wasting is the result of a metabolic disorder. In some cases the metabolic disorder is diabetes. In some cases the diabetes is Type 2 Diabetes. In some embodiments, muscle wasting is a result of disease progression. In some embodiments, muscle wasting is a result of therapeutic treatment. In some embodiments, the muscle wasting is cachexia. In some embodiments, the therapeutic polypeptide promotes fusion of myocytes.

In some embodiments, the polypeptide is a heparin-associated binding polypeptide as described herein. In some embodiments, the polypeptide is a mitogenic and/or fusion promoting polypeptide as described herein. In some embodiments, a composition comprising a plurality of heparin-associated binding polypeptides as described herein is administered. In some embodiments, a composition comprising a plurality of mitogenic and/or fusion promoting polypeptides as described herein is administered.

In some embodiments, the polypeptide has been recombinantly produced. In some embodiments, the polypeptide has been produced in a mammalian cell culture. In certain embodiments, the polypeptide has been produced in a mammalian cell and the mammalian cell is a human cell. In some cases the human cell is a human embryonic kidney-derived epithelial cell (e.g., HEK293 cells). In some embodiments, the mammalian cell culture is a mouse myeloma cell culture. In some embodiments, the mammalian cell culture is a Chinese Hamster Ovary (CHO) cell culture. In some embodiments, the polypeptide has been produced in a non-mammalian cell culture, e.g., in bacteria, yeast, or insect cells. In certain embodiments, the polypeptide has been purified from a human biological sample. In some cases, the human biological sample is human plasma. In some embodiments, the composition is formulated for administration by injection to the subject. In some embodiments, the composition comprises one or more polypeptides having at least about 90% homology to a sequence selected from SEQ ID NOS: 1-44, 55, 56, and 58-70. In some embodiments, the composition comprises polypeptide 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, or 876, or any combination thereof.

In some embodiments, the polypeptide comprises VTN. In some cases, the VTN comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 1. In some cases, the VTN comprises a polypeptide comprising at least about 90% homology or identity to amino acids 20-478 of SEQ ID NO: 1. In some cases, the VTN is purified from human plasma.

In some embodiments, the polypeptide comprises POSTN. In some cases, the POSTN comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 6. In some cases, the POSTN comprises a polypeptide comprising at least about 90% homology or identity to amino acids 22-836 of SEQ ID NO: 6. In some cases, the POSTN is expressed in a mouse myeloma cell line.

In some embodiments, the polypeptide comprises FGF17. In some cases, the FGF17 comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 7. In some cases, the FGF17 comprises a polypeptide comprising at least about 90% homology or identity to amino acids 23-216 of SEQ ID NO: 7. In some cases, the FGF17 is expressed in a bacterial cell. In some embodiments, the bacterial cell is E. coli.

In some embodiments, the polypeptide comprises THBS2. In some cases, the THBS2 comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 4. In some cases, the THBS2 comprises a polypeptide comprising at least about 90% homology or identity to amino acids 19-1172 of SEQ ID NO: 4. In some cases, the THBS2 is expressed in a mouse myeloma cell line.

In some embodiments, the polypeptide comprises THBS4. In some cases, the THBS4 comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 8. In some cases, the THBS4 comprises a polypeptide comprising at least about 90% homology or identity to amino acids 27-961 of SEQ ID NO: 8. In some cases, the THBS4 is expressed in Chinese hamster ovary cell.

In some embodiments, the polypeptide comprises IGF2. In some cases, the IGF2 comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 11. In some cases, the IGF2 comprises a polypeptide comprising at least about 90% homology or identity to amino acids 25-91 of SEQ ID NO: 11. In some cases, the IGF2 is expressed in a bacterial cell. In some embodiments, the bacterial cell is E. coli.

In some embodiments, the polypeptide comprises IL-15. In some cases, the IL-15 comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 10. In some cases, the IL-15 comprises a polypeptide comprising at least about 90% homology or identity to amino acids 49-162 of SEQ ID NO: 10. In some cases, the IL-15 is expressed in a bacterial cell. In some embodiments, the bacterial cell is E. coli.

In some embodiments, the polypeptide comprises THBS1. In some cases, the THBS1 comprises a polypeptide comprising at least about 90% homology or identity to SEQ ID NO: 9. In some cases, the THBS1 comprises a polypeptide comprising at least about 90% homology or identity to amino acids 19-1170 of SEQ ID NO: 9. In some cases, the THBS1 is expressed in a mouse myeloma cell line.

In some embodiments, the polypeptide comprises IL-15, and the composition further comprises THBS2. In some embodiments, the polypeptide comprises IL-15, and the composition further comprises THBS4. In some embodiments, the polypeptide comprises THBS4, and the composition further comprises THBS2. In some embodiments, the polypeptide comprises IL-15, and the composition further comprises THBS2 and THBS4.

In some embodiments, the polypeptide comprises IGF2, and the composition further comprises THBS2. In some embodiments, the polypeptide comprises IGF2, and the composition further comprises THBS4. In some embodiments, the polypeptide comprises THBS4, and the composition further comprises THBS2. In some embodiments, the polypeptide comprises IGF2, and the composition further comprises THBS2 and THBS4.

Schedules Routes of Administration and Amounts

In certain embodiments, the heparin-associated polypeptides can be administered by any suitable route such as, for example, subcutaneous, intravenous, or intramuscular. In certain embodiments, the heparin-associated polypeptides are administered on a suitable dosage schedule, for example, weekly, twice weekly, monthly, twice monthly, once every three weeks, or once every four weeks. The heparin-associated polypeptides can be administered in any therapeutically effective amount. In certain embodiments, the therapeutically acceptable amount is about 0.001 mg/kg to about 1 mg/kg. In certain embodiments, the therapeutically acceptable amount is about 0.001 mg/kg to about 0.002 mg/kg, about 0.001 mg/kg to about 0.005 mg/kg, about 0.001 mg/kg to about 0.01 mg/kg, about 0.001 mg/kg to about 0.02 mg/kg, about 0.001 mg/kg to about 0.05 mg/kg, about 0.001 mg/kg to about 0.1 mg/kg, about 0.001 mg/kg to about 0.2 mg/kg, about 0.001 mg/kg to about 0.5 mg/kg, about 0.001 mg/kg to about 1 mg/kg, about 0.002 mg/kg to about 0.005 mg/kg, about 0.002 mg/kg to about 0.01 mg/kg, about 0.002 mg/kg to about 0.02 mg/kg, about 0.002 mg/kg to about 0.05 mg/kg, about 0.002 mg/kg to about 0.1 mg/kg, about 0.002 mg/kg to about 0.2 mg/kg, about 0.002 mg/kg to about 0.5 mg/kg, about 0.002 mg/kg to about 1 mg/kg, about 0.005 mg/kg to about 0.01 mg/kg, about 0.005 mg/kg to about 0.02 mg/kg, about 0.005 mg/kg to about 0.05 mg/kg, about 0.005 mg/kg to about 0.1 mg/kg, about 0.005 mg/kg to about 0.2 mg/kg, about 0.005 mg/kg to about 0.5 mg/kg, about 0.005 mg/kg to about 1 mg/kg, about 0.01 mg/kg to about 0.02 mg/kg, about 0.01 mg/kg to about 0.05 mg/kg, about 0.01 mg/kg to about 0.1 mg/kg, about 0.01 mg/kg to about 0.2 mg/kg, about 0.01 mg/kg to about 0.5 mg/kg, about 0.01 mg/kg to about 1 mg/kg, about 0.02 mg/kg to about 0.05 mg/kg, about 0.02 mg/kg to about 0.1 mg/kg, about 0.02 mg/kg to about 0.2 mg/kg, about 0.02 mg/kg to about 0.5 mg/kg, about 0.02 mg/kg to about 1 mg/kg, about 0.05 mg/kg to about 0.1 mg/kg, about 0.05 mg/kg to about 0.2 mg/kg, about 0.05 mg/kg to about 0.5 mg/kg, about 0.05 mg/kg to about 1 mg/kg, about 0.1 mg/kg to about 0.2 mg/kg, about 0.1 mg/kg to about 0.5 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.2 mg/kg to about 0.5 mg/kg, about 0.2 mg/kg to about 1 mg/kg, or about 0.5 mg/kg to about 1 mg/kg. In certain embodiments, the therapeutically acceptable amount is about 0.001 mg/kg, about 0.002 mg/kg, about 0.005 mg/kg, about 0.01 mg/kg, about 0.02 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.2 mg/kg, about 0.5 mg/kg, or about 1 mg/kg. In certain embodiments, the therapeutically acceptable amount is at least about 0.001 mg/kg, about 0.002 mg/kg, about 0.005 mg/kg, about 0.01 mg/kg, about 0.02 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.2 mg/kg, or about 0.5 mg/kg. In certain embodiments, the therapeutically acceptable amount is at most about 0.002 mg/kg, about 0.005 mg/kg, about 0.01 mg/kg, about 0.02 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.2 mg/kg, about 0.5 mg/kg, or about 1 mg/kg. In certain embodiments, the therapeutically acceptable amount is about 0.1 mg/kg to about 50 mg/kg. In certain embodiments, the therapeutically acceptable amount is about 0.1 mg/kg to about 0.2 mg/kg, about 0.1 mg/kg to about 0.5 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 0.1 mg/kg to about 2 mg/kg, about 0.1 mg/kg to about 5 mg/kg, about 0.1 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 20 mg/kg, about 0.1 mg/kg to about 50 mg/kg, about 0.2 mg/kg to about 0.5 mg/kg, about 0.2 mg/kg to about 1 mg/kg, about 0.2 mg/kg to about 2 mg/kg, about 0.2 mg/kg to about 5 mg/kg, about 0.2 mg/kg to about 10 mg/kg, about 0.2 mg/kg to about 20 mg/kg, about 0.2 mg/kg to about 50 mg/kg, about 0.5 mg/kg to about 1 mg/kg, about 0.5 mg/kg to about 2 mg/kg, about 0.5 mg/kg to about 5 mg/kg, about 0.5 mg/kg to about 10 mg/kg, about 0.5 mg/kg to about 20 mg/kg, about 0.5 mg/kg to about 50 mg/kg, about 1 mg/kg to about 2 mg/kg, about 1 mg/kg to about 5 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 50 mg/kg, about 2 mg/kg to about 5 mg/kg, about 2 mg/kg to about 10 mg/kg, about 2 mg/kg to about 20 mg/kg, about 2 mg/kg to about 50 mg/kg, about 5 mg/kg to about 10 mg/kg, about 5 mg/kg to about 20 mg/kg, about 5 mg/kg to about 50 mg/kg, about 10 mg/kg to about 20 mg/kg, about 10 mg/kg to about 50 mg/kg, or about 20 mg/kg to about 50 mg/kg. In certain embodiments, the therapeutically acceptable amount is about 0.1 mg/kg, about 0.2 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10 mg/kg, about 20 mg/kg, or about 50 mg/kg. In certain embodiments, the therapeutically acceptable amount is at least about 0.1 mg/kg, about 0.2 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10 mg/kg, or about 20 mg/kg. In certain embodiments, the therapeutically acceptable amount is at most about 0.2 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10 mg/kg, about 20 mg/kg, or about 50 mg/kg.

Nucleic Acids

TABLE 3

Nucleic acid sequences.

Protein

Protein
mRNA

Name
Size (AA)
UniProtKB
accession#
accession#
Gene ID
SEQ ID

FGF17
216
O60258.1
NP_003858.1
NM_003867.4
8822
45

TIBS1
1170
P07996.2
NP_003237.2
NM_003246.4
7057
46

TIBS2
1172
P35442.2
NP_003238.2
NM_003247.3
7058
47

TIBS4
961
P35443.2
NP_003239.2
NM_003248.6
7060
48

IGF2
180
P01344.1
NP_000603.1
NM_000612.6
3481
49

IL15
162
P40933.1
NP_000576.1
NM_000585.5
3600
50

IGFBP7
282
Q16270.1
NP_001544.1
NM_001553.3
3490
51

VTN
478
P04004
NP_000629.3
NM_000638.4
7448
52

POSTN
836
Q15063.2
NP_006466.2
NM_006475.3
10631
53

PDGFRL
375
Q15198.1
NP_006198.1
NM_006207.2
5157
54

ANOS1
3730
P23352
NP_000207.2
NM_000216.4
3730
57

In certain embodiments, described herein, are nucleic acids that encode the heparin-associated polypeptides described herein. In certain embodiments, the nucleic acids are exogenous. In certain embodiments, the nucleic acid is a plasmid. In certain embodiments, the nucleic acid is a viral vector. In certain embodiments, the viral vector is an adenovirus, lentivirus, retrovirus, adeno-associated virus, or vaccinia virus. In certain embodiments, the nucleic acid comprises RNA. In certain embodiments, the nucleic acid encodes any of the polypeptides listed in Table 1 or Table 2, or VTN, STC2, AGRN, POSTN, FGF17, THBS2, FST, THBS1, IL-15, IGF2, or THBS4. In certain embodiments, the nucleic acid encodes any one or more polypeptide embodiments described herein. Nucleic acids according to this description can comprise additional nucleic acid sequences sufficient to propagate the vector or express a polypeptide encoded by the vector. In certain embodiments, the nucleic acid comprises a universal promoter, such as the CMV promoter, or an inducible promoter system such as a TETON, TETOFF or GAL4. In certain embodiments, the nucleic acid is expressed via a tissue specific promoter or one compatible with a eukaryotic or prokaryotic cellular expression system. The nucleic acid can further comprise a sequence encoding a suitable purification tag (e.g., HIS-tag, V5, FLAG, MYC).

Production of Heparin-Associated or Heparin-Binding Polypeptides

Once a polypeptide is determined as a heparin-associated or heparin-binding polypeptide it can be purified or synthesized in any suitable manner. A nucleic acid encoding the polypeptide can be cloned into a suitable vector and expressed in a suitable cellular system. In certain embodiments, the cellular system is a prokaryotic cell system. In certain embodiments, the cellular system is a eukaryotic cell system. In certain embodiments, the cellular system is a mammalian cell system. The supernatants from such an expression system can be subjected to one or more purification steps involving centrifugation, ultracentrifugation, filtration, diafiltration, tangential-flow filtration, dialysis, chromatography (e.g., cation exchange, ion exchange, hydrophobic interaction, reverse phase, affinity, or size exclusion). The polypeptides can be purified to an extent suitable for human administration. Additionally, polypeptides can be synthesized for inclusion in a formulation to be administered to a human subject. In certain embodiments, the polypeptides can be produced by a suitable peptide synthesis method, such as solid-phase synthesis.

Master Cell Bank and Transgenic Cells

In a certain embodiment, described herein is a master cell bank comprising a cell that comprises a nucleic acid encoding one or more heparin-associated polypeptides integrated into its genome creating a transgenic cell-line. In some embodiments, the master cell bank comprises a plurality of cells that each comprise a nucleic acid encoding a heparin-associated polypeptide. In certain embodiments, the nucleic acid is maintained extrachromosomally on a plasmid or yeast artificial chromosome. In certain embodiments, the nucleic acid is integrated into a chromosomal location. In certain embodiments, the cell is a yeast cell. In certain embodiments, the yeast is Pichia pastoris or Saccharomyces cerevisiae. In certain embodiments, the cell is a mammalian cell. In certain embodiments, the mammalian cell is a 293T cell or derivative thereof (e.g., 293T-Rex). In certain embodiments, the cell is a bacterial cell.

In certain embodiments, the transgenic mammalian, yeast, or bacterial cell is a master cell bank that comprises a cryopreservative suitable for freezing to at least about −80° or below. In certain embodiments, the master cell bank comprises glycerol at between about 10 and about 30%, and is suitable for long-term storage at about −80° or below. In certain embodiments, the master cell bank can preserve a transgenic mammalian, yeast, or bacterial strain for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more years.

Pharmaceutically Acceptable Excipients, Carriers, and Diluents

The heparin-associated polypeptide(s) described herein can be administered in a pharmaceutical composition that comprises one or more pharmaceutically acceptable excipients, carriers, or diluents. The exact components can differ based upon the preferred route of administration. The excipients used in a pharmaceutical composition can provide additional function to the polypeptide by making the polypeptide suitable for a particular route of administration (e.g., intravenous, topical, subcutaneous, or intramuscular), increasing polypeptide stability, increasing penetration of a desired tissue (e.g., muscle or skin), increasing residence time at particular site, increasing solubility, enhancing the efficacy of the polypeptide, and/or reducing inflammatory reactions coincident with administration.

In certain embodiments, the heparin-associated polypeptide(s) described herein are included in a pharmaceutical composition with a solubilizing emulsifying, or dispersing agent. In certain embodiments, the solubilizing agent can allow high-concentration solutions of heparin-associated polypeptides that exceed at least about 2 mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL, or 20 mg/mL. Carbomers in an aqueous pharmaceutical composition serve as emulsifying agents and viscosity modifying agents. In certain embodiments, the pharmaceutically acceptable excipient comprises or consists of a carbomer. In certain embodiments, the carbomer comprises or consists of carbomer 910, carbomer 934, carbomer 934P, carbomer 940, carbomer 941, carbomer 1342, or combinations thereof. Cyclodextrins in an aqueous pharmaceutical composition serve as solubilizing and stabilizing agents. In certain embodiments, the pharmaceutically acceptable excipient comprises or consists of a cyclodextrin. In certain embodiments, the cyclodextrin comprises or consists of alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin, or combinations thereof. Lecithin in a pharmaceutical composition may serve as a solubilizing agent. In certain embodiments, the solubilizing agent comprises or consists of lecithin. Poloxamers in a pharmaceutical composition serve as emulsifying agents, solubilizing agents, and dispersing agents. In certain embodiments, the pharmaceutically acceptable excipient comprises or consists of a poloxamer. In certain embodiments, the poloxamer comprises or consists of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, or combinations thereof. Polyoxyethylene sorbitan fatty acid esters in a pharmaceutical composition serve as emulsifying agents, solubilizing agents, surfactants, and dispersing agents. In certain embodiments, the pharmaceutically acceptable excipient comprises or consists of a polyoxyethylene sorbitan fatty acid ester. In certain embodiments, the polyoxyethylene sorbitan fatty acid ester comprises or consists of polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85, polysorbate 120, or combinations thereof. Polyoxyethylene stearates in a pharmaceutical composition serve as emulsifying agents, solubilizing agents, surfactants, and dispersing agents. In certain embodiments, the pharmaceutically acceptable excipient comprises or consists of a polyoxyethylene stearate. In certain embodiments, the polyoxyethylene stearate comprises or consists of polyoxyl 2 stearate, polyoxyl 4 stearate, polyoxyl 6 stearate, polyoxyl 8 stearate, polyoxyl 12 stearate, polyoxyl 20 stearate, polyoxyl 30 stearate, polyoxyl 40 stearate, polyoxyl 50 stearate, polyoxyl 100 stearate, polyoxyl 150 stearate, polyoxyl 4 distearate, polyoxyl 8 distearate, polyoxyl 12 distearate, polyoxyl 32 distearate, polyoxyl 150 distearate, or combinations thereof. Sorbitan esters in a pharmaceutical composition serve as emulsifying agents, solubilizing agents, and non-ionic surfactants, and dispersing agents. In certain embodiments, the pharmaceutically acceptable excipient comprises or consists of a sorbitan ester. In certain embodiments, the sorbitan ester comprises or consists of sorbitan laurate, sorbitan oleate, sorbitan palmitate, sorbitan stearate, sorbitan trioleate, sorbitan sesquioleate, or combinations thereof. In certain embodiments, solubility can be achieved with a protein carrier. In certain embodiments the protein carrier comprises recombinant human albumin.

In certain embodiments, the heparin-associated polypeptide(s) of the current disclosure are formulated to increase stability. Polypeptides in aqueous formulations may require stabilization to prevent degradation. In certain embodiments, the stabilizer comprises pH buffers, salts, amino acids, polyols/disaccharides/polysaccharides, liposomes, surfactants, antioxidants, reducing agents, or chelating agents. In certain embodiments, the stabilizer comprises or consists of a polyol/non-reducing sugar. In certain embodiments, the non-reducing sugar comprises or consists of sucrose, mannitol, trehalose, raffinose, stachyose, xylitol, starch, verbascose, or combinations thereof. Polypeptides can be encapsulated in liposomes to increase stability. In certain embodiments, the stabilizer comprises or consists of liposomes. In certain embodiments, the liposomes comprise or consists of ipalmitoylphosphatidylcholine (DPPC) liposomes, phosphatidylcholine: cholesterol (PC:Chol) (70:30) liposomes, or dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylserine (DPPC:DPPS) liposomes (70:30). Non-ionic surfactants can increase the stability of a polypeptide. In certain embodiments, the stabilizer comprises or consists of a non-ionic surfactant. In certain embodiments, the non-ionic surfactant comprises or consists of polysorbates (e.g., poly sorbate 80, poly sorbate 20), alkylsaccharides alkyl ethers and alkyl glyceryl ethers, polyoxyethelene (4) lauryl ether; polyoxyethylene cetyl ethers, polyoxyethylene stearyl ethers, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, or combinations thereof. In certain embodiments, the polypeptide is formulated with a protein surfactant, such as recombinant human serum albumin as a stabilizer. Antioxidants or reducing agents can increase the stability of a polypeptide. In certain embodiments, the stabilizer comprises or consists of an antioxidant or reducing agent. In certain embodiments, the reducing agent comprises or consists of dithiothreitol, ethylenediaminetetraacetic acid, 2-Mercaptoethanol, Tris(2-carboxyethyl)phosphine hydrochloride, Tris(hydroxypropyl)phosphine, or combinations thereof. In certain embodiments, the antioxidant comprises or consists of methionine, ascorbic acid, citric acid, alpha tocopherol, sodium bisulfite, ascorbyl palmitate, erythorbic acid, or combinations thereof. Chelating agents can stabilize polypeptides by reducing the activity of proteases. In certain embodiments, the stabilizer comprises or consists of a chelating agent. In certain embodiments, the chelating agent comprises or consists of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), metal complexes (e.g. Zn-protein complexes), or combinations thereof. Buffer agents can stabilize polypeptides by reducing the acid hydrolysis of polypeptides. In certain embodiments, the stabilizer comprises or consists of a buffer agent. In certain embodiments, the buffer agent comprises or consists of sucrose octa-sulfate, ammonium carbonate, ammonium phosphate, boric acid, sodium citrate, potassium citrate, lactic acid, 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), hydroxymethylaminomethane (Tris), calcium carbonate, calcium phosphate or combinations thereof.

The heparin-associated polypeptide(s) also may be entrapped in or associated with microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively), in colloidal delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980).

The heparin-associated polypeptide(s) of the current disclosure may be formulated or delivered with an anti-inflammatory agent. In certain embodiments, the anti-inflammatory agent comprises or consists of a corticosteroid. In certain embodiments, the corticosteroid comprises or consists of hydrocortisone, cortisone, ethamethasoneb (Celestone), prednisone (Prednisone Intensol), prednisolone (Orapred, Prelone), triamcinolone (Aristospan Intra-Articular, Aristospan Intralesional, Kenalog), methylprednisolone (Medrol, Depo-Medrol, Solu-Medrol), or dexamethasone (Dexamethasone Intensol). In certain embodiments, the anti-inflammatory comprises or consists of a non-steroidal anti-inflammatory (NSAID). In certain embodiments, the NSAID comprises or consists of aspirin, celecoxib, diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, or tolmetin.

In certain embodiments, the heparin-associated polypeptide(s) of the current disclosure are included in a pharmaceutical composition suitable for intravenous administration comprising one or more pharmaceutically acceptable excipients, carriers, and diluents. In certain embodiments, the polypeptides of the current disclosure are administered suspended in a sterile solution. In certain embodiments, the solution is one commonly used for administration of biological formulations, and comprises, for example, about 0.9% NaCl or about 5% dextrose. In certain embodiments, the solution further comprises one or more of: buffers, for example, acetate, citrate, histidine, succinate, phosphate, potassium phosphate, bicarbonate and hydroxymethylaminomethane (Tris); surfactants, for example, polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), and poloxamer 188; polyol/disaccharide/polysaccharides, for example, glucose, dextrose, mannose, mannitol, sorbitol, sucrose, trehalose, and dextran 40; amino acids, for example, glycine, histidine, leucine, or arginine; antioxidants, for example, ascorbic acid, methionine; or chelating agents, for example, EDTA, or EGTA.

In certain embodiments, the heparin-associated polypeptide(s) of the current disclosure are included in a pharmaceutical composition suitable for intramuscular or subcutaneous administration comprising one or more pharmaceutically acceptable excipients, carriers, and diluents. Formulations suitable for intramuscular or subcutaneous injection can include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include ethanol, polyols (inositol, propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like) and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity is maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Formulations suitable for subcutaneous injection also contain optional additives such as preserving, wetting, emulsifying, and dispensing agents.

In certain embodiments, the heparin-associated polypeptide(s) of the current disclosure are formulated for topical administration as a cream, gel, paste, ointment, or emulsion. Excipients in a cream, gel, paste, ointment, or emulsion can comprise gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecyl sulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, sugars, and starches.

The excipient used with the heparin-associated polypeptide(s) described herein will allow for storage, formulation, or administration of highly concentrated formulations. In certain embodiments, a highly concentrated heparin-associated polypeptide(s) comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 20, 25, 40, 45, 50 or more milligrams per milliliter.

In certain embodiments, the polypeptides of the current disclosure are shipped/stored lyophilized and reconstituted before administration. In certain embodiments, lyophilized heparin-associated polypeptide formulations comprise a bulking agent such as, mannitol, sorbitol, sucrose, trehalose, and dextran 40. The lyophilized formulation can be contained in a vial comprised of glass. The heparin-associated polypeptides when formulated, whether reconstituted or not, can be buffered at a certain pH, generally less than 7.0. In certain embodiments, the pH can be between 4.5 and 6.5, 4.5 and 6.0, 4.5 and 5.5, 4.5 and 5.0, or 5.0 and 6.0.

Further Embodiments

1. A composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the polypeptide is a heparin-associated polypeptide secreted from a stem cell or a transformed cell line, wherein the heparin-associated polypeptide possesses mitogenic and/or fusion promoting activity. 2. The composition of embodiment 1, comprising a plurality of mitogenic and/or fusion promoting polypeptides. 3. The composition of embodiment 2, wherein the plurality comprises three, four, five, six, seven, eight, nine, ten or more mitogenic and/or fusion promoting polypeptides. 4. The composition of embodiment 1 to 3, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. 5. The composition of embodiment 1 to 3, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly produced. 6. The composition of embodiment 1 to 3, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. 7. The composition of embodiment 1 to 3, wherein the stem cell is a pluripotent stem cell. 8. The composition of embodiment 1 to 3, wherein the stem cell is an induced pluripotent stem cell. 9. The composition of embodiment 1 to 3, wherein the mitogenic activity comprises the ability to increase proliferation in a somatic cell or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. 10. The composition of embodiment 1 to 3, wherein the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. 11. The composition of embodiment 10, wherein the somatic cell is a muscle, muscle progenitor cell, tenocyte, or tenocyte precursor. 12. The composition of embodiment 11, wherein the somatic cell is a mammalian cell. 13. The composition of embodiment 11, wherein the somatic cell is a human cell. 14. The composition of any one of embodiments 1 to 13, wherein any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are produced in a heterologous cellular production system. 15. The composition of any one of embodiments 1 to 13, wherein any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are synthetically produced. 16. The composition of any one of embodiments 1 to 15, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprise one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. 17. The composition of embodiment 16, wherein the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic polypeptide. 18. A nucleic acid encoding at least one mitogenic and/or fusion promoting polypeptide of any one of embodiments 1 to 17. 19. A cell line comprising the nucleic acid of embodiment 18. 20. The cell line of embodiment 19, wherein the cell line is a eukaryotic cell line. 21. The composition comprising the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 1 to 17, and a pharmaceutically acceptable excipient, carrier, or diluent. 22. The composition of any one of embodiments 1 to 17 or 21, formulated in injectable form. 23. Use of the composition of any one of embodiments 1 to 17, 21, or 22 in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue. 24. The use of embodiment 23, wherein the aging disorder is sarcopenia. 25. The use of embodiment 23, wherein the muscle wasting disorder is a muscular dystrophy. 26. A method of treating an individual with aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising administering to the individual the composition of any one of embodiments 1 to 17, 21, or 22. 27. The method of embodiment 26, wherein the muscle wasting disorder is sarcopenia. 28. The method of embodiment 26, wherein the aging disorder is a muscular dystrophy. 29. A method of producing a composition suitable for the treatment of an aging disorder comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 1 to 17. 30. A method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing the cell line of embodiment 19 under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

31. A composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide is identified by: a) identifying at least one polypeptide in a mixture of a plurality of polypeptides secreted from a stem cell or a transformed cell line that binds heparin; and b) determining the mitogenic and/or fusion promoting activity of the at least one polypeptide for a somatic cell, wherein the at least one polypeptide is identified as a mitogenic and/or fusion promoting polypeptide if the at least one polypeptide exhibits mitogenic and/or fusion promoting activity. 32. The composition of embodiment 31, wherein the composition comprises a mixture of a plurality of mitogenic and/or fusion promoting polypeptides. 33. The composition of embodiment 32, wherein the plurality of mitogenic and/or fusion promoting polypeptides comprises three, four, five, six, seven, eight, nine, ten or more polypeptides. 34. The composition of any one of embodiments 31 to 33, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. 35. The composition of any one of embodiments 31 to 33, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly produced. 36. The composition of any one of embodiments 31 to 33, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. 37. The composition of any one of embodiments 31 to 33, wherein the stem cell is a pluripotent stem cell. 38. The composition of any one of embodiments 31 to 33, wherein the stem cell is an induced pluripotent stem cell. 39. The composition of any one of embodiments 31 to 33, wherein the mitogenic activity comprises the ability to increase proliferation in a somatic cell or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. 40. The composition of any one of embodiments 31 to 33, wherein the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. 41. The composition of embodiment 40, wherein the somatic cell is a muscle, muscle progenitor cell, tenocyte, or tenocyte precursor. 42. The composition of embodiment 41, wherein the somatic cell is a mammalian cell. 43. The composition of embodiment 41, wherein the somatic cell is a human cell. 44. The composition of any one of embodiments 31 to 43, wherein any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are produced in a heterologous cellular production system. 45. The composition of any one of embodiments 31 to 43, wherein any one of the mitogenic and/or fusion promoting polypeptides or plurality of mitogenic and/or fusion promoting polypeptides are synthetically produced. 46. The composition of any one of embodiments 31 to 43, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprise one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. 47. The composition of embodiment 46, wherein the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. 48. A nucleic acid encoding at least one mitogenic and/or fusion promoting polypeptide of any one of embodiments 31 to 47. 49. A cell line comprising the nucleic acid of embodiment 48. 50. The cell line of embodiment 49, wherein the cell line is a eukaryotic cell line. 51. The composition comprising the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 31 to 47, and a pharmaceutically acceptable excipient, carrier, or diluent. 52. The composition of any one of embodiments 31 to 47 or 51, formulated in injectable form. 53. Use of the composition of any one of embodiments 31 to 47, 51, or 52 in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue. 54. The use of embodiment 53, wherein the aging disorder is sarcopenia. 55. The use of embodiment 53, wherein the muscle wasting disorder is muscular dystrophy. 56. A method of treating an individual with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising administering to the individual the composition of any one of embodiments 31 to 47, 51, or 52. 57. The method of embodiment 56, wherein the aging disorder is sarcopenia. 58. The method of embodiment 56, wherein the muscle wasting disorder is a muscular dystrophy. 59. A method of producing a composition suitable for the treatment of an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 31 to 47. 60. A method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing the cell line of embodiment 59 under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

61. A composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide comprises a protein listed in Table 2, and combinations thereof 62. The composition of embodiment 61, wherein the mitogenic and/or fusion promoting polypeptide comprises VTN, POSTN, FGF17, THBS2, or THBS4. 63. The composition of embodiment 61, wherein the mitogenic and/or fusion promoting polypeptide comprises VTN. 64. The composition of embodiment 61, wherein the mitogenic and/or fusion promoting polypeptide comprises POSTN. 65. The composition of embodiment 61, wherein the mitogenic and/or fusion promoting polypeptide comprises FGF17. 66. The composition of embodiment 61, wherein the mitogenic and/or fusion promoting polypeptide comprises THBS2. 67. The composition of embodiment 61, wherein the mitogenic and/or fusion promoting polypeptide comprises THBS4. 68. The composition of any one of embodiments 61 to 67, wherein the composition comprises a mixture of a plurality of mitogenic and/or fusion promoting polypeptides. 69. The composition of embodiment 68, wherein the plurality of mitogenic and/or fusion promoting polypeptides comprises three, four, five, six, seven, eight, nine, ten or more mitogenic and/or fusion promoting polypeptides. 70. The composition of any one of embodiments 61 to 69, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. 71. The composition of any one of embodiments 61 to 69, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly produced. 72. The composition of any one of embodiments 61 to 69, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. 73. The composition of any one of embodiments 61 to 69, wherein the stem cell is a pluripotent stem cell. 74. The composition of any one of embodiments 61 to 69, wherein the stem cell is an induced pluripotent stem cell. 75. The composition of any one of embodiments 61 to 69, wherein the mitogenic activity comprises the ability to increase proliferation in a somatic cell or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. 76. The composition of any one of embodiments 61 to 69, wherein the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. 77. The composition of embodiment 76, wherein the somatic cell is a muscle, muscle progenitor cell, tenocyte, or tenocyte precursor. 78. The composition of embodiment 77, wherein the somatic cell is a mammalian cell. 79. The composition of embodiment 77, wherein the somatic cell is a human cell. 80. The composition of any one of embodiments 61 to 79, wherein any one of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are produced in a heterologous cellular production system. 81. The composition of any one of embodiments 61 to 79, wherein any one of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are synthetically produced. 82. The composition of any one of embodiments 61 to 79, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprise one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. 83. The composition of embodiment 82, wherein the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. 84. A nucleic acid encoding at least one mitogenic and/or fusion promoting polypeptide of any one of embodiments 61 to 83. 85. A cell line comprising the nucleic acid of embodiment 84. 86. The cell line of embodiment 85, wherein the cell line is a eukaryotic cell line. 87. The composition comprising the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 61 to 83, and a pharmaceutically acceptable excipient, carrier, or diluent. 88. The composition of any one of embodiments 61 to 83, formulated in injectable form. 89. Use of the composition of any one of embodiments 61 to 83 in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue. 90. The use of embodiment 89, wherein the aging disorder is sarcopenia. 91. The use of embodiment 89, wherein the muscle wasting disorder is muscular dystrophy. 92. A method of treating an individual with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising administering to the individual the composition of any one of embodiments 61 to 83. 93. The method of embodiment 92, wherein the aging disorder is sarcopenia. 94. The method of embodiment 92, wherein the muscle wasting disorder is a muscular dystrophy. 95. A method of producing a composition suitable for the treatment of an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 61 to 83. 96. A method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing the cell line of embodiment 95 under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

97. A composition comprising a mitogenic and/or fusion promoting polypeptide, wherein the mitogenic and/or fusion promoting polypeptide comprises VTN, POSTN, FGF17, THBS2, or THBS4. 98. The composition of embodiment 97, wherein the mitogenic and/or fusion promoting polypeptide comprises VTN. 99. The composition of embodiment 97, wherein the mitogenic and/or fusion promoting polypeptide comprises POSTN. 100. The composition of embodiment 97, wherein the mitogenic and/or fusion promoting polypeptide comprises FGF17. 101. The composition of embodiment 97, wherein the mitogenic and/or fusion promoting polypeptide comprises THBS2. 102. The composition of embodiment 97, wherein the mitogenic and/or fusion promoting polypeptide comprises THBS4. 103. The composition of any one of embodiments 97 to 102, wherein the composition comprises a mixture of a plurality of different mitogenic and/or fusion promoting polypeptides. 104. The composition of embodiment 103, wherein the plurality of different mitogenic and/or fusion promoting polypeptides comprise three, four, or five different mitogenic and/or fusion promoting polypeptides. 105. The composition of any one of embodiments 97 to 104, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are isolated and purified. 106. The composition of any one of embodiments 97 to 105, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are recombinantly or synthetically produced. 107. The composition of any one of embodiments 97 to 105, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are secreted from a stem cell. 108. The composition embodiment 107, wherein the stem cell is a pluripotent stem cell. 109. The composition of embodiment 108, wherein the stem cell is an induced pluripotent stem cell. 110. The composition of any one of embodiments 97 to 109, wherein the mitogenic activity comprises the ability to increase proliferation in a somatic cell or increase the ability of another heparin-associated polypeptide to increase proliferation in a somatic cell. 111. The composition of any one of embodiments 97 to 109, wherein the fusion promoting activity comprises the ability to increase fusion of a plurality of somatic cells or increase the ability of another heparin-associated polypeptide to increase fusion in a plurality of somatic cells. 112. The composition of embodiment 111, wherein the muscle cell precursor is a myoblast. 113. The composition of embodiment 112, wherein the somatic cell is a mammalian cell. 114. The composition of embodiment 112, wherein the somatic cell is a human cell. 115. The composition of any one of embodiments 97 to 114, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides comprise one or more modifications to improve activity, stability, or increase polypeptide yield from a heterologous cellular production system. 116. The composition of embodiment 115, wherein the modification is an alteration of one or more amino acids in the polypeptide sequence of the mitogenic and/or fusion promoting polypeptide compared to the wildtype polypeptide sequence of the mitogenic and/or fusion promoting polypeptide. 117. The composition of embodiment 115, wherein the modification is a fusion of a mitogenic and/or fusion promoting polypeptide to a non-mitogenic and/or fusion promoting polypeptide. 118. The composition of embodiment 117, wherein the non-mitogenic and/or fusion promoting polypeptide comprises an immunoglobulin Fc region or serum albumin. 119. The composition of embodiment 117 or 108, wherein the non-mitogenic or fusion promoting polypeptide is a human polypeptide. 120. The composition of any one of embodiments 97 to 114, wherein the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides are concatemerized. 121. The composition of embodiment 120, wherein the concatemerized polypeptides are separated by a polypeptide linker. 122. The composition of embodiment 120 or 121, wherein the concatemerized polypeptides are the same polypeptide. 123. The composition of embodiment 120 or 121, wherein the concatemerized polypeptides are different polypeptides. 124. The composition of embodiment 120 or 123, wherein the concatemerized polypeptides are covalently concatemerized through a non-peptide linkage. 125. The composition of embodiment 120 or 123, wherein the concatemerized polypeptides are non-covalently concatemerized. 126. A nucleic acid encoding a mitogenic and/or fusion promoting polypeptide of any one of embodiments 97 to 125. 127. A cell line comprising the nucleic acid of embodiment 126. 128. The cell line of embodiment 127, wherein the cell line is a eukaryotic cell line. 129. The composition comprising the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 97 to 125, and a pharmaceutically acceptable excipient, carrier, or diluent. 130. The composition comprising the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of embodiment 129, wherein the pharmaceutically acceptable excipient, carrier, or diluent increases the function of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides. 131. The composition comprising the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of embodiment 130, wherein the function comprises increasing proliferation in a muscle cell precursor, increasing stability of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides, or increasing bioavailability of the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides. 132. The composition of any one of embodiments 97 to 131, formulated for subcutaneous, intravenous, intramuscular, or topical administration. 133. Use of the composition of any one of embodiments 97 to 132, in a method of treating an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue. 134. The use of embodiment 133, wherein the aging disorder is sarcopenia. 135. The use of embodiment 133, wherein the muscle wasting disorder is a muscular dystrophy. 136. A method of treating an individual with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising administering to the individual the composition of any one of embodiments 97 to 132. 137. A method of increasing proliferation of a muscle cell precursor or connective tissue cell precursor in an individual comprising administering to the individual the composition of any one of embodiments 97 to 132. 138. The method of embodiment 137, wherein the individual is afflicted with or suspected of being afflicted with an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue. 139. The method of embodiment 138, wherein the aging disorder is sarcopenia. 140. The method of embodiment 138, wherein the muscle wasting disorder is a muscular dystrophy. 141. A method of producing a composition suitable for the treatment of an aging disorder, a muscle wasting disorder, a muscle injury, or an injury to a connective tissue comprising admixing a pharmaceutically acceptable excipient, carrier, or diluent with the mitogenic and/or fusion promoting polypeptide or plurality of mitogenic and/or fusion promoting polypeptides of any one of embodiments 97 to 125. 142. A method of producing a mitogenic and/or fusion promoting polypeptide comprising culturing the cell line of embodiment 127, under conditions sufficient to produce the mitogenic and/or fusion promoting polypeptide.

EXAMPLES

The following illustrative examples are representative of embodiments of the compositions and methods described herein and are not meant to be limiting in any way.

Example 1—Isolation of Heparin-Associated Polypeptides

hESC secretome collection (differentiated vs undifferentiated): Human embryonic or induced pluripotent stem cells (H1, H9, H7 lines, and 2 iPSC lines derived from 1 healthy young adult female (18-25 years) and 1 aged female (greater than 65 year) donor), were cultured in triplicate on 10 cm plates on diluted Matrigel (1:30), in mTeSR-1 (Stem Cell Technologies), for a total media volume of 10 mL per plate. Another triplicate set of hPSCs/iPSCs were cultured on 10 cm plates and differentiated after plating in mTeSR-1 by changing the medium to DMEM/F12 with 10% Bovine Growth Serum (Hyclone), and culturing for an additional 7 days. hPSCs/iPSCs and differentiated hPSCs/iPSCs (6 plates in total) were washed twice with Opti-MEM (Gibco) and then cultured in Opti-MEM for 16 hours. 10 ml media was then collected per plate as hPSCs/iPSCs-secretome or differentiated hPSCs/iPSCs-secretome containing media. Media was spun for 5 min at 1000 g and transferred to new tubes to remove cell debris, aliquoted and flash frozen at 2 mL per plate as 0.5 mL aliquots and stored at −80 C; remaining 8 mL/plate was used immediately for heparin-associated protein purification.

Heparin-Associated Protein Purification

10 mL of Heparin-Agarose Type I Beads (H 6508, Sigma Aldrich) was washed with molecular grade water and preconditioned in 1 mL OptiMEM as recommended by manufacturer. 8-9 ml secretome containing media was incubated with 1 ml Heparin-Agarose Beads for 2 hours shaking at 4° C. to allow binding. Remaining heparin-depleted hPSCs/iPSCs-conditioned medium or differentiated hPSCs/iPSCs-conditioned medium was aliquoted in 15 mL tubes, flash frozen and stored at −80 C to serve as negative controls for efficacy testing. Protein bound heparin beads were washed twice via a 10 minute incubation at 4° C. in 1 mL sterile PBS+0.05% Tween. Proteins were eluted twice for 15 minutes at 4° C. in 400 μl of elution buffer A (Eluted-A) (0.01M HEPES pH 7.5+1.5M NaCl+0.1% BSA) per 10 cm plate for the first two plates, or elution buffer B (Eluted-B) lacking BSA (0.01M HEPES pH 7.5+1.5M NaCl)** for the 3rd 10 cm plate, to collect proteins in a total of 800 μl of elute per original plate. The proteins were desalted by diffusion dialysis (3500 MWCO) (by a 2 hour dialysis shaking at 4 C in 500 ml McCoy's 5 A Medium or similar tissue culture medium (Gibco) followed by overnight (not more than 16 hours) dialysis shaking at 4 C in 200 ml OptiMEM (Gibco). The collected eluate was aliquoted in appropriately capped tubes, flash frozen and stored at −80 C.

Secretome Heparin-Associated Fraction Validation Assays:

BCA assay (Pierce) was performed for total protein yield in the eluate using 2 ul per sample in triplicate according to manufacturer's instructions from each Elution A sample and Elution B.

SDS-PAGE Silver Stain/SDS-PAGE Coomassie was performed for protein integrity and rough MW analysis (loading <5-10 ug per lane for each sample).

Mouse Myoblast Proliferation Assay

Reduced regeneration from an individual's tissue progenitor cells is a hallmark of aging, therefore assays that measure mitogenic capacity in tissue progenitor cells serve as a read-out for potential success of any given heparin-associated polypeptide as a regenerative factor. Measuring the increased proliferation rate of treated mouse or human muscle progenitor cells will provide good basis for potentially therapeutic regenerative factors for treating individuals who have suffered illness, injury, or who possess genetic or developmental defects leading to premature tissue loss, wasting, or weakening. As a control, the assay will also be performed on proteins purified from differentiated cells, which result in no in myoblast proliferation, cultured in medium conditioned by differentiated cells, or purified heparin-associated fractions.

Mouse muscle progenitor cells (early passage myoblasts) were cultured and expanded in mouse growth medium: Ham's F-10 (Gibco), 20% Bovine Growth Serum (Hyclone), 5 ng/mL FGF2 and 1% penicillin-streptomycin on Matrigel coated plates (1:300 matrigel:PBS), at 37° C. and 5% CO2. For experimental conditions, cells were plated at 40,000 cells/well on Matrigel coated 8-well chamber slides in 250-500 uL medium per well (1:100 matrigel:PBS) in mouse fusion medium: DMEM (Gibco)+2% horse serum (Hyclone). One hour after plating, mouse myoblasts were treated with 50% respective medias:

TABLE 4

8-well Chamber Slide A: Eluted Heparin-associated Proteins from H9/H7

hPSCs and 2 iPSC lines - 4 slides total, 1 for each cell line tested.

50% FM! 50%

Eluted-A
50% FM! 50%
50% FM! 50%

Heparin-
Differentiated
Differentiated

Fusion Media
associated
hPSC-conditioned
hPSC-conditioned

(FM) (250 uL)
proteins
OptiMem
OptiMem

50% FM (125 ul)/
50% FM/50%
50% FM/50%
50% FM/50% Eluted-B

50% Growth
hPSC-conditioned
Heparin-depleted
Heparin-associated

Media (125 uL)
OptiMEM
hESC-conditioned
proteins (no BSA)

OptiMEM

TABLE 5

Assay for Eluted heparin- associated proteins purified from

Differentiated hPSSs/iPSCs (Control). 50% FM/50% OptiMEM

50% FM/50%
50% FM/50%
50% FM/50%

Eluted-A Heparin-
Differentiated hPSC-
Eluted-B

associated proteins
conditioned ptiMem
Heparin-

associated

proteins (no BSA)

TABLE 6

8-well Chamber Slide B: Eluted Heparin-associated Protein Serial Dilution.

50% FM/50% Eluted-
75% FM/25%
75% FM/12.5%

Fusion Media (FM)
A Heparin- associated
Eluted-A Heparin-
Eluted-A Heparin-

(250 uL)
protein
associated protein
associated protein

81.25% FM/6.25%
84.375% FM/3.125%
98.44% FM/1.56%
75% FM/25% hPSC-

Eluted-A Heparin-
Eluted-A Heparin-
Eluted-A Heparin-
conditioned OptiMEM

associated protein
associated protein
associated protein

Mouse Myoblasts were cultured for 24 hours in the above conditions, at 37° C. in 10% CO2 incubator. BrdU (300 μM) in DMSO was added for 2 hours prior to fixation with cold 70% ethanol and stored at 4° C. until staining.

Quantifying Regenerative Index

Following permeabilization in PBS+0.25% Triton X-100, antigen retrieval was performed via a 10 minute 4 N HCl treatment followed by PBS washes. Primary staining was performed overnight at 4° C. in PBS+2% FBS. Primary antibodies include: a species-specific monoclonal antibody for mouse anti-embryonic Myosin Heavy Chain (eMyHC, hybridoma clone 1.652, Developmental Studies Hybridoma Bank) and Rat-anti-BrdU (Abcam Inc. ab6326). Secondary staining with fluorophore-conjugated, species-specific antibodies (Donkey anti-Rat-488, #712-485-150; Donkey anti-Mouse-488, #715-485-150; all secondary antibodies from Jackson ImmunoResearch) was performed for 1 hour at room temperature at a 1:500 dilution in PBS+2% FBS. Nuclei are visualized by Hoechst staining. For cell quantification, 5 images per well were collected at 20× in each of the channels as well as DIC to achieve at least 2000 imaged cells per condition. Using the Hoechst stain to tally cell number, the percent of cells positive for BrdU and eMyHC were tabulated and reported.

Human muscle progenitor cells (myoblasts) were similarly activated to proliferate when conditioned with hPSC-secreted heparin-associated proteins. Proliferation assays were performed on human myoblasts to test protein candidate factors for enhanced precursor cell activity in an in vitro screening assay. Conditions for culturing human muscle cells were optimized to reflect the slower rate of growth and differentiation of human muscle cells, where early passage human myoblasts were cultured for 72 hours with daily medium changes rather 24 hours, and pulsed for 4 hours with BrdU instead of 2 hours.

Example 2—Characterization of the Protein Components of the Heparin Bead Binding hPSC Secretomes
Protein Quantification

The protein concentration in the eluted sample was determined using the bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Waltham, MA). The protocol was performed as follows: A volume containing 100 ug protein was extracted and disulfide bonds were reduced with 5 mM tris-(2-carboxyethyl)-phosphine (TCEP), at room temperature for 25 min, and alkylated with 10 mM iodoacetamide at room temperature for 30 min in the dark). Excess iodoacetamide was quenched with 15 mM dithiothreitol (room temperature, 15 min in the dark). At this point the sample were split, with 20 μg analyzed immediately via SDS-PAGE Silver Stain, 20 μg saved for SDS-PAGE Coomassie stained gel band analysis, and 60 ug proceeded to in-solution mass spectrometry sample preparation.

Quantify the Size Distribution of Proteins

Silver staining provides a sensitive, rapid, low cost way to survey the complexity and general molecular weight distribution of the proteins in a complex mixture. By running a matched sample treated to remove glycans, the presence of this PTM common secreted proteins can be determined by the resulting shift in apparent molecular weight. Additional rounds of selective glycosylation reactions can then be run to gain insight into the identity and structure of glycan modifications on proteins of interest. Five micrograms of sample can be removed and treated with Protein Deglycosylation Mix II (NEB) to remove all N-linked and simple O-linked glycans as well as some complex O-linked glycans, which can be visualized by molecular weight shifts relative to an untreated control on a silver stained SDS-PAGE gel.

A 4-12% acrylamide gel (BioRad) in 1×MOPS buffer was loaded gel with samples (>0.20 ug/lane) and ladder (as per manufacturer's instructions), run at 200V for 45 minutes or until sample front neared the bottom of the gel, and incubated in 50% methanol/50% LC grade water >1 hour. Stain solution was prepared adding a solution of 0.8 g AgNO3 in 4 mL LC grade H2O dropwise into a solution of 1 mL 0.36% NaOH+1.4 mL 14.8M ammonium hydroxide under constant stirring followed by the addition of LC grade water to a final volume of 100 mL. Gel staining proceeded by incubating gel in stain solution for 15 minutes, before washing twice with LC grade water, allowing 5-8 minutes of incubation per wash step. The silver stain was developed by incubation in a solution of 0.25 mL 1% citric acid+25 uL 37% formaldehyde in 50 mL LC grade water for 10-15 minutes in the dark (or until desired density was achieved). Developer solution was removed and the gel washed with LC grade water to slow development for an imaging series, or development was stopped by incubation in a solution of 45% methanol, 10% acetic acid.

In-Solution Mass Spectrometry Sample Preparation

Methanol-chloroform precipitation was performed prior to protease digestion (a standard trichloroacetic acid-based precipitation protocol would be substituted here if protein yield from the heparin bead eluates are below 25 ug total). In brief, four parts neat methanol was added to each sample and vortexed, one part chloroform was added to the sample and vortexed, and three parts water was added to the sample and vortexed. The sample was centrifuged at 4,000 RPM for 15 min at room temperature and subsequently washed twice with 100% methanol, prior to air-drying. Samples were resuspended in 50 mM HEPES pH 8.5 and digested at room temperature for 12 hrs with LysC protease at a 100:1 protein-to-protease ratio. Trypsin was then added at a 100:1 protein-to-protease ratio and the reaction was incubated 6 hours at 37° C. Peptide concentrations in the digests were measured using the Quantitative Colorometric Peptide assay kit (Pierce). From each sample 10 ug of peptide digestion solution was taken and enzymatic activity quenched with formic acid to a final pH of <2 before de-salting via C-18 Stagetips, using a standard formic acid/acetonitrile buffer system. Stagetips were eluted directly into autosampler vials in a buffer of 70% acetonitrile and 1% formic acid, dried in a vacuum concentrator, and stored at −80 C until being resuspended to −1 ug/μl of Buffer A (typically −0.2% formic acid, 5% acetonitrile) for mass spectrometry analysis.

SDS-PAGE Coomassie and In-Gel Band Mass Spectrometry Sample Preparation

A gel based sample preparation pipeline may be employed if the abundance distribution of the sample is heavily skewed, or where only a few species of proteins account for a substantial majority of the molecules in the sample. This size based separation method has been shown to effectively improve depth of proteomic coverage in biochemically purified protein mixtures.

Briefly, the protocol begins by running >20 ug per lane of sample out on an SDS-PAGE as in the Silver Stain method above, staining and destaining by Coomassie as per manufacturer's instructions, excising sections of the gel containing potentially interesting proteins, and cutting excised gel sections into 1 mm×1 mm squares. Ensure gel pieces are at neutral pH by adding 50-100 μl 100 mM Ammonium bicarbonate, let sit for 10 minutes and discard. Wash gel pieces with 100-150 μl 50 mM Ammonium bicarbonate/50% acetonitrile for 10 minutes, vortexing every 5 minutes to dehydrate. Depending on intensity of stain, repeat step 9 until the gel pieces are clear. Discard solution phase and dry samples in speed vac for 5-10 minutes. To digest proteins add 5 pmol sequencing grade trypsin (Promega Corp.) in 50 mM Ammonium bicarbonate and 0.02% Protease Max to each sample and incubate overnight in 37° C. on a shaking heatblock. Spin down samples at 1000G for 2 minutes, pull off all liquid, and transfer to a glass autosampler vial. Add 40-50 μl 1% formic acid, 66% acetonitrile 33% 100 mM Ammonium bicarbonate and incubate for 10 minutes at 37° C. to increase peptide release from gel. Spin at 10,000G for 2 minutes to pellet insoluble protein or detergent degradation production. Extract all solution being sure to avoid pellet areas and combine into autosampler vial. Speed vac total combined extracts to dryness and store at −80 C until being resuspended to −1 ug/μl of Buffer A (typically −0.2% formic acid, 5% acetonitrile) for mass spectrometry analysis.

nHPLC-MS2 Instrumentation and Analysis

Two, 3-hr gradients were collected per sample using an Orbitrap Fusion instrument coupled to a Waters liquid chromatography (LC) pump (Thermo Fisher Scientific). Peptides are fractionated on a 100 μm inner diameter microcapillary column packed with ˜25 cm of Accucore 150 resin (1.2 μm, 150 Å, ThermoFisher Scientific). For each analysis, 1 μg per sample was loaded onto the column. Peptides were separated using a 3 hr gradient of 6 to 46% acetonitrile in 0.2% formic acid at a flow rate of ˜400 nL/min. Instrument settings for the Orbitrap fusion were as follows: FTMS1 resolution (120,000), ITMS2 isolation window (0.4 m/z), ITMS2 max ion time (120 ms), ITMS2 AGC (2E4), ITMS2 CID energy (35%), dynamic exclusion window (90 sec). A TOP10 method was used where each FTMS1 scan was used to select up to 10 FTMS2 precursors for interrogation by HCD-MS2 with readout in the orbitrap.

Data Analysis

Resulting mass spectra were searched using commercially available analysis software (e.g., Byonic) against a human database publicly available from Uniprot which was concatenated with common contaminants and reversed sequences of the human and contaminant proteins as decoys for FDR determination. Searches restricted the precursor ion tolerance to 20 ppm, and product ion tolerance window was set to 0.5 m/z. Searches allowed up to two missed cleavages, including static carbamidomethylation of cysteine residues (+57.021 Da) and variable oxidation of methionine residues (+15.995 Da). Additional variable modifications may be included, particularly glycosylations, based on the results of the gel shift assay following de-glycosylation treatment or the preview search PTM scan. Results were filtered to a 1% FDR at the protein level per sample.

Example 3—In Vitro Screening of Stem Cell Secreted Factors

A deeper understanding of a given protein factor's contribution to the regenerative effects of the pool of heparin-associated hPSC secretome will be gained by screening against an established panel of assays for cellular age. Assays include measurements of reactive oxygen species (ROS) production or tolerance, cytoplasmically and in the mitochondria, telomerase activity, measurements of proteostasis capacity via lysosomal, autophagy, and proteasomal routes, epigenetic re-patterning, and cellular energy balance (e.g., ATP/ADP and NAD/NADH ratios). Many of these assay leverage the high-throughput automated microscopy described above to make these measurements in a variety of cell types, including fibroblast, endothelial cells, mesenchymal stem cells, and chondrocytes. Collectively these metrics can inform both the pathway and the mechanisms by which the heparin-associated hPSC secretome or its individual components enact their regenerative effects.

To begin screening and validating potential regenerative protein factors protein coding sequences will be collected from a publicly available source, such as used for the proteomics analysis (e.g., UniProt). The sequence for each of the proteins will be used to construct a DNA sequence encoding the proteins. The sequences are then each cloned into a plasmid vector system tailored for inducible or constitutive high-copy expression (in mammalian or prokaryotic settings). Alternatively such a plasmid vector system may be designed in silico. Such a plasmid can be transformed into a pool of cells where the encoded protein was transiently expressed from the plasmid. Alternatively the gene of interest could be incorporated in the genomes of a pool of cells (e.g. lentiviral transduction for mammalian cells or homologous recombination for S. cerevisiae) to create stable cell lines for recombinant protein production.

To de-bulk the target factor list and validate recombinant expression for factor production, a viable route would be to express the construct in a human cell line (like 293T-REx), which exploits: 1) that proteins of interest naturally purify themselves during the secretion process; and 2) will be processed in a natural context, potentially preserving important post translational processing steps. T-REx cells will be grown on 10 cm plates to ˜50% confluence in DMEM with 10% Bovine Growth Serum (Hyclone), 2 mM L-glutamine, and 10% Pen-Strep before initiating translation of a target protein of interest for 48 hr. The media would be collected, spun at 2,000 g to purify, and the supernatant used for heparin-associated enrichment of target factors in mouse myoblast regeneration assays.

Machine Learning Classifier

By combining and statistically comparing the information from the Regenerative index assay, the Panel of Cellular Age Makers, the Proteomics we can create deep feature vectors for each protein factor, the pool of all factors (from each repeat of the assays), and the negative control pool (from each repeat of the assays). Treating the pool of all factors (or known factors such as FGF-2) as True Positives, and the negative control pool (or known non-functional proteins such as BSA) as True Negatives a supervised clustering algorithm can be trained to classify protein factors. Using a standard 10-fold cross validation scheme to assess the relative accuracy, recall, and confusion matrix graphs of the output of various algorithms' outputs (e.g., Naive Bayes, Support Vector Machine, Linear Regression, or Random Forest) trained classifier most likely to successfully distinguish proteins with regenerative potential from the set of target factors can be selected. Target factors (or tested combinations) can then be rank ordered by the probability they derive from the regenerative set compared to the null set. A number of the top scoring target factors (or tested combinations) will then be selected for GMP-grade production for in vivo and in vitro validation.

Based on the complexity of the original heparin-associated fraction of the hPSC secretome and the limits to which individual proteins can recapitulate the activity of the whole pool, we will test combinations of factors as well. In the simplest approach, we would combine the 293T-REx secretome containing media from two or more cell lines each producing a given factor, and test their combined regenerative efficacy across a range of concentrations in an isobologram analysis using the regenerative index from the Myoblast Regeneration assay.

Example 4—In Vivo Testing of Stem Cell Secreted Factors

There are two main aspects of muscle degeneration with aging, acute loss following trauma and chronic wasting (sarcopenia), and both of them will be tested. As the therapeutic approach to each case is expected to be different two arms for the in vivo validation is envisioned to specifically test each use-case for the factors as therapeutics in humans. The following Acute Injury Model and Sarcopenia/Chronic Administration Model for the most promising proteins emerging from the machine learning classifier can be carried out.

Acute Injury Model

Animals were kept under standard animal husbandry condition. Animals were fed standard chow, and have ad libitum access to food and water. Temperature were kept at 22° C. and 12 h light/12 h dark cycles. Animals were acclimated prior to study initiation. The experimental design was: C57BL/6J male mice, N=18; Young: 12-13 week old (3-month-old) mice, n=6; Aged: 77-78 week old (18-month-old) mice, n=12. This design was used to test any single factor identified and validated in in vitro assays or complex mixtures of 2 or more factors.

TABLE 7

Experimental design of acute injury model.

Dose

Blood

No
Group
n
Test
(mg/kg)
Administration
collection
Tissue collection

1
Young,
6
vehicle
n/a
i.m, q.d; into
terminal
TA/GA muscles

Vehicle

injured muscle

into 25% sucrose;

2
Aged,
6
vehicle
n/a
site on day 0,

Brain, liver, heart,

Vehicle

and 2

and lung into 4%

3
Aged,
6
Test
0.1

PFA

Test

factor

factor

On Day 0, mice were weighed and underwent muscle injury with focal injection of barium chloride (BaCl, 10 μL, 1.2% w/v in saline, Sigma-Aldrich) in the Tibialis anterior (TA; Day 0) of both the right and left hindlegs. Injections of vehicle or factor A (0.1 mg/kg) were co-administered intramuscularly (i.m) following the BaCl into the TA injured hindleg sites, and again 48 hours later on day 2 (i.m.) into the TA injured hindleg sites. Also on day 2, BaCl (Ctx; 10 μL, 1.2% w/v in saline, Sigma-Aldrich) was injected into the Gastrocnemius (GA, Day 2, i.m.) muscles of both right and left hind legs. Injections of vehicle or a factor were sequentially administered (i.m.) following the BaCl into the TA hindleg sites post-injury, and again 48 hours later on day 4 (i.m.) into the GA injured hind leg sites. Bromodeoxyuridine (BrdU) was be administered (100 mg/kg, i.p.) once daily for 3 days, day 2-4, before sacrifice to label proliferating cells.

On day 5, animals were sacrificed and animal weight recorded followed by collecting 0.5 ml of terminal blood via cardiac puncture which was processed to plasma and stored at 80° C. We then perfused the animal with 1×PBS, carefully dissected the skin from the GA/TA muscles of each hind leg and took photos (prior to excision). After excision of exclusively the GA or TA muscle, excised tissue was photographed, weighed, then placed into 25% sucrose in PBS at 4° C. for 4 hr rinsed in 1×PBS, immersed in Tissue-TEK OCT and rapidly frozen before storing the muscles tissues frozen at 80° C. Cryosectioning and H&E were performed to ensure muscle injury site was appropriately visualized. A diagram of the time points for these experiments can be seen in FIG. 2A. Muscle tissue composition from new skeletal muscle fibers, fibrotic tissue, and adipose (fat), were measured. Muscle regeneration, as defined as the number of number of new myofibers with centrally located nuclei per millimeter, fibrosis as defined as the area of fibrotic scarring, size of the fibers, as defined as the width and area, adipose tissue, as defined by the amount of fat surrounding the muscle, were measured to assess level of regeneration.

Young muscle regeneration after acute focal injury had the highest regenerative index (measured as the number of new myofibers with centrally located nuclei per millimeter squared). Aged muscle regeneration following acute injuries performed on average 30-50% less than young muscle regeneration, in part due to the reduction of mitogenic muscle precursor/progenitor cell activity (FIG. 2B). It was predicted that systemic treatment of aged animals, injured animals, animals with genetic diseases causing muscle wasting, or animals injured by radiation or other tissue damaging treatment, the heparin-associated polypeptides, individually or in various combinations, will improve skeletal muscle regeneration by 20-50%, approaching comparable levels to young healthy animals. It was also predicted that the composition of fibrous scar tissue and fat tissue will be reduced to levels comparable to younger animals by treatment with the heparin-associated polypeptides. And indeed, treatment with the heparin-associated polypeptides did improve the skeletal muscle regeneration of sarcopenic mice to level indistinguishable from the young by both the number of new myoblasts and the reduction in fibrous scar tissue (FIG. 2B).

Sarcopenia/Chronic Administration Model

After arrival, animals will be kept under standard animal husbandry condition. Animals will be fed standard chow, and have ad libitum access to food and water. Temperature will be kept at 22° C. and 12 h light/12 h dark cycles. Animals will be acclimated prior to study initiation, including any in vivo assay acclimation, if necessary. The experimental design was C57BL/6J male mice, N=18; Young: 12-13 week old (3-month-old) mice, n=6; Aged: 77-78 week old (18-month-old) mice, n=12. This design can be used to test any single factor identified and validated in in vitro assays or complex mixtures of 2 or more factors.

TABLE 8

Design of sarcopenia/chronic administration model.

Dose

Blood
Tissue

No
Group
n
Test
(mg/kg)
Administration
In vivo assay
collection
collection

1
Young,
6
vehicle
n/a
i.p, q.d; on day
2 sets of:
terminal
TA/GA

Vehicle

−8 to +5
Animal

muscles

2
Aged,
6
vehicle
n/a

weight, grip

into 25%

Vehicle

strength,

sucrose;

3
Aged,
6
Test
0.1

running wheel

Brain,

Test

factor

performance;

liver,

factor

horizontal bar

heart, and

1 set of: In

lung into

capacitance

4% PFA

On Day −10, mice will have the following in vivo health span measurements will be performed over 1 day as a baseline for age-based parameters: Weight, running wheel performance, grip strength, and horizontal bar. Each assay should be run for 4 trials per assay per animal. These health span assays will be repeated on day −1. After one day of rest on day −9, mice will begin 1× daily injections (0.1 mg/kg) of vehicle or factor A for the remainder of the experiment until sacrifice (days −8 to +5, 13 days of dosing). On day −4, 6 days after dosing begins, mice will undergo a repeat of the health span assays. On day 0, 5 days prior to sacrifice, mice will undergo muscle injury with focal injection of cardiotoxin (Ctx; 10 μg, Sigma-Aldrich) in the Tibialis anterior (TA; Day 0) of the right hindleg only. On day 2, the Gastrocnemius (GA; Day 2) muscle of the right hind leg will then receive cardiotoxin (Ctx; 10 μg, Sigma-Aldrich). BrdU will be administered (100 mg/kg, i.p.) once daily for 3 days, day 2-4, before sacrifice. On day +5, prior to take-down, the animals will have an in vivo in capacitance assay run. On day +5, animals will be sacrificed and animal weight recorded. Collect 0.5 ml of blood via cardiac puncture, process to plasma and store plasma samples at 80° C. The animals will then be perfused with 1×PBS. Carefully dissect the skin from the GA/TA muscles of each hind leg and take photos (prior to excision). After excision of exclusively the GA or TA muscle, weigh the muscles, then place muscles into 25% sucrose in PBS at 4° C. for 4 hr. Then rinse the muscles in 1×PBS, adding Tissue-TEK OCT and storing the muscles tissues frozen at 80° C. Perform cryosectioning and H&E, ensuring muscle injury site is appropriately visualized. Carefully excise the inguinal white adipose tissue (WAT) and weigh tissue. Discard WAT post-weighing.

Collected brain, liver, heart and lung can be post-fixed in 4% PFA for 72 hours, after 72 hours, transferred into 30% sucrose in 1×PBS and stored at −4° C. (brain, liver, heart, lung).

Muscle tissue composition, from new skeletal muscle fibers, fibrotic tissue, and adipose (fat), will be measured. Muscle regeneration, as defined as the number of number of new myofibers with centrally located nuclei per millimeter, fibrosis, as defined as the area of fibrotic scarring, size of the fibers, as defined as the width and area, adipose tissue, as defined by the amount of fat surrounding the muscle, will be measured to assess level of regeneration. Weights of the animals during the duration of treatment with heparin-associated polypeptide(s), as well as health span assays including performance on a running wheel (speed, distance, duration), grip strength, and performance on a horizontal bar will take into account the phenotypic outcomes of treatment of the aged animals systemically with the heparin-associated polypeptides for sarcopenia.

The horizontal bar test is performed as described previously (Malinowska et al. 2010) at 8 months (n=6 WT, n=7 MPS IIIB) and 10 months (n=3 WT, n=4 MPS IIIB) of age. In brief, a 300-mm metal wire, 2 mm in diameter, was secured between two posts 320 mm above a padded surface. The mouse was allowed to grip the center of the wire and the time to fall or reach the side was recorded, and after 2 min the test was stopped. Crossing the bar in x seconds was scored as 240-x, remaining on the bar was scored as 120, and falling off the bar after y seconds was recorded as the value of y. The test was repeated three times as a practice run followed by a 10-min rest prior to three tests where the score was recorded.

Young muscle regeneration after acute focal injury has the highest regenerative index (measured as the number of new myofibers with centrally located nuclei per millimeter squared). Aged muscle regeneration following acute injuries performs on average 30-50% less than young muscle regeneration, in part due to the reduction of mitogenic muscle precursor/progenitor cell activity. We predict systemic treatment of aged animals, injured animals, animals with genetic diseases causing muscle wasting, or animals injured by radiation or other tissue damaging treatment, the heparin-associated polypeptides, individually or in various combinations, will improve skeletal muscle regeneration by 20-50%, approaching comparable levels to young healthy animals. We also predict the composition of fibrous scar tissue and fat tissue will be reduced to levels comparable to younger animals by treatment with the heparin-associated polypeptides.

Animals will also have better health span outcomes: reduced weight, fat composition, scar tissue around muscles, increased running speed, duration, and distance, increased grip strength, and enhanced performance on the horizontal bar test.

Example 5—Additonal Tests for Pro-Regenerative Factors

Mechanistic insight into a given heparin-associated polypeptide factor's pathway of action will be gained by establishing and screening against a panel of assays for cellular age. Assays include measurements of reactive oxygen species (ROS) production or tolerance cytoplasmically and in the mitochondria, telomerase activity, measurements of proteostasis capacity via lysosomal, autophagy, and proteasomal routes, epigenetic re-patterning, and cellular energy balance (e.g., ATP/ADP and NAD/NADH ratios). Many of these assay leverage high-throughput automated microscopy to make these measurements in a variety of cell types, including fibroblast, endothelial cells, mesenchymal stem cells, and chondrocytes. Collectively these metrics can inform both the pathway and the mechanisms by which the heparin-associated hPSC secretome or its individual components enact their regenerative effects. These deep profile vectors can be crucial for approaching combinations of factors rationally, and for machine learning predictions.

To test the cellular effects of secretomes toward reversing the hallmarks of aging, high-throughput automated imaging and quantification of single cells to achieve deep population level statistical power can be employed. Cellular component state profiles of Young, Aged, and Aged+Treatment in human fibroblasts and epithelial cells, myoblasts, mesenchymal stem cells, chondrocytes, and neural progenitor cells will be compared. Some examples of tests and methods include:

- 1) Epigenetic reprogramming: repressive mark H3K9me3, the heterochromatin-associated protein HP1γ, nuclear lamina support protein LAP2α
- 2) Nuclear membrane Folding/Blebbing: immunofluorescence of the nuclear membrane protein Lamin A/C
- 3) Proteolytic Activity: Cleavage of fluorescent-tagged chymotrypsin like substrate corresponds to proteasome 20S core particle activity. Wells are first stained with PrestoBlue Cell Viability dye (Life Technologies) for 10 minutes. Well signals are read using a TECAN fluorescence plate reader as a measure of cell count. Then cells are washed with HBSS/Ca/Mg before switching to original media containing the chymotrypsin like fluorogenic substrate LLVY-R110 (Sigma) which is cleaved by the proteasome 20S core particle. Cells are then incubated at 37° C. in 5% CO2 for 2 hours before signals are again read on the TECAN fluorescence plate reader. Readings are then normalized by PrestoBlue cell count.
- 4) Formation of autophagosomes: Autophagosome number and volume are measured by staining with CellTracker Deep Red (Sigma). The cells are then incubated at 37° C. in 5% CO2 for 20 minutes, washed 2 times using HBSS/Ca/Mg, and stained for 15 minutes using CellTracker Deep Red cell labeling dye. Cells are then switched to HBSS/Ca/Mg for single cell imaging using the Operetta High Content Imaging System (Perkin Elmer).
- 5) Energy Metabolism: ATP in the cells is measured using colorimetric assay using an ATP assay kit (ab83355; Abcam, Cambridge, MA) following manufacturer's instructions. Cells are washed in cold phosphate buffered saline and homogenized and centrifuged to collect the supernatant. The samples are loaded with assay buffer in triplicate. ATP reaction mix and background control (50 μL) is added to the wells and incubated for 30 min in dark. The plate is read at OD 570 nm using SpectraMax M2e (Molecular Devices, Sunnyvale, CA). The mean optical density is used to estimate of the intracellular ATP concentration relative to the standard curve.
- 6) Mitochondrial Activity: To measure Mitochondria Membrane Potential, cells are washed twice with Ham's F10 (no serum or pen/strep). Subsequently, MuSCs are stained with MitoTracker Green FM (ThermoFisher, M7514) and DAPI for 30 minutes at 37° C., washed three times with Ham's F10, and analyzed using a BD FACSAria III flow cytometer. To measure
- 7) Mitochondrial ROS Measurement. Cells are washed with HBSS/Ca/Mg and then switched to HBSS/Ca/Mg containing MitoSOX (Thermo), a live cell permeant fluorogenic dye that is selectively targeted to mitochondria and fluoresces when oxidized by superoxide. Cells are incubated for 10 minutes at 37° C. in 5% CO2. Cells are then washed twice with HBSS/Ca/Mg, and stained for 15 minutes using CellTracker Deep Red. Finally, cells are imaged in fresh HBSS/Ca/Mg using the Operetta High Content Imaging System (Perkin Elmer).
- 8) Deregulated Nutrient Sensing: levels of SIRT1 are measured.
- 9) Senescence: Senescence-associated beta-galactosidase staining is measured in cells washed twice with PBS then fixed with 15% Paraformaldehyde in PBS for 6 minutes. Cells are rinsed 3 times with PBS before staining with X-gal chromogenic substrate, which is cleaved by endogenous Beta galactosidase. Plates are kept in the staining solution, Parafilmed, to prevent from drying out, and incubated overnight at 37° C. with ambient CO2. The next day, cells are washed again with PBS before switching to a 70% glycerol solution for imaging under a Leica brightfield microscope.
- 10) Secretome of the cells: Mass-Spec or O-Link for inflammatory cytokines profiles Soft Tissue Deposition: Immunofluorescence for SOX9, MMP3, MMP13, and COL2A1 expression, the decrease of which is characterized by cartilage loss, pain, cleft-lip, and joint destruction.

Example 6—Identification of Pro-Regenerative Factors by Mass Spectroscopy

Factors enriched in the secretome of undifferentiated hPSCs can be determined by Mass spectroscopy. A schematic of a type of mass spectroscopy experiment employed herein is shown in FIG. 3A.

Five confluent, 15 cm plates of cells per biological replicate were washed with OptiMEM—a basal, synthetic medium-, and then incubated in OptiMEM for 16 hours, yielding roughly 100 ml of media. The media, now containing secreted factors, was collected, cells and cell debris removed by centrifugation, and flash frozen for storage at −80 C until processing. The target factors were enriched via affinity purification for heparin binding using heparin-agarose bead columns. Heparin-agarose beads (Sigma) were washed with water twice, and once with OptiMEM (minus phenol red), before incubating with factor containing culture media for 2 h at 4° C. shaking at 100 rpm. The ratio of bead slurry (˜50% beads) to media can be effective at 1:10, 1:20, 1:30, 1:40, and 1:50. Heparin-agarose beads were then collected into a column by centrifugation in an Amicon Pro Purification System column set in a 50 ml conical tube at 1000 g for 5 min, washed with 10× column volumes of PBS+0.05% tween at 4° C. twice. Factors were eluted via two repeats of the following: addition of a high salt solution (1.5M NaCl, 0.01M HEPES, pH 7.2, at ratio of 0.4 ml elution buffer per milliliter of bead slurry), incubated at 4° C. for 10 minutes at 100 rpm, and centrifugation at 1000 g for 5 min into a fresh collection tube.

Protein concentration in the eluted fraction was assayed by silver stain densitometry as shown in FIG. 3B, and a BCA assay against standard curves for bovine serum albumin. Protein disulfide bonds were reduced by incubation in 5 mM tris-(2-carboxyethyl)-phosphine (TCEP) for 25 min, and the free cysteines alkylated with 10 mM iodoacetamide at room temperature for 30 min in the dark. Excess iodoacetamide was quenched with 15 mM dithiothreitol during a 15 min incubation. The eluates from all samples were then further purified by protein precipitation using trichloroacetic acid, prior to resuspending in digest buffer and 16 hr of digestion using a mixture of modified Trypsin and Lys-C to yield peptides predominantly with terminal arginine or lysine residues. The resulting peptide concentration were measured using a quantitative colorimetric peptide assay (Promega), and equimolar amounts of peptides from each biological replicate labeled at their free amines with tandem mass tags (TMT) using manufacturer recommended conditions before mixing the peptides. The mixed sample was desalted via reverse phase separation on a C18 StageTip prior to analysis via nHPLC-SPSMS3 on a Fusion Lumos (Thermo Fisher). A TOP10 method was used to select up to 10 MS2 precursors for identification by CID-MS2 analyzed in the ion trap. For synchronous precursor selection of up to 10 ion windows, the FTMS3 isolation window was 0.4 m/z, max ion time 150 ms, automatic gain control 1.5E5, and FTMS3 resolution was 50,000. Resulting spectra were searched using commercial MS analysis software against the Uniprot human database (2018) protein sequences (Swiss-Prot and TrEMBL) concatenated with their reversed sequences as decoys for FDR determination, appended to common contaminant sequences. Searches restricted the precursor ion tolerance to 50 ppm and the product ion tolerance window to 0.9 m/z (or 50 ppm), allowed no more than two missed cleavages, included static modification of lysine residues, arginine residues and peptide N-termini with TMT tags (+229.163 Da), static carbamidomethylation of cysteine residues (+57.021 Da), and variable oxidation of methionine residues (+15.995 Da).

Results were filtered to a 1% FDR at the peptide and then protein level using the target-decoy strategy. Peptides were assigned to protein groups, and individual proteins by the parsimony principle. Proteins were quantified by summing reporter ion intensities across all PSMs with greater than 70% of their spectral intensity deriving from matched ions and a summed signal to noise intensity greater than 200, normalizing channel level intensities, and computing the percent contribution of a given channel to the total signal. These values were then used for additional statistical modelling of differential abundance.

Heparin-associated proteins from undifferentiated and differentiated supernatants generated distinct sets of secreted factors as indicated by FIGS. 3C, 3D and 3E. Combined results fro m such experiments are summarized in Table 2 shown previously herein, by the gene name, UniProt ID, Entrez Gene ID, and Ensembl ID.

Example 7—Validation of Pro-Regenerative Factors In Vitro Using High-Throughput Imaging

Mass spectroscopy can define candidate pro-regenerative factors, however, as shown in example 6, these experiments can generate large amounts of data that need to be further validated in relevant in vitro and in vivo models. The use of high-throughput imaging can help define individual factors and mixtures of factors that possess regenerative potential. Mouse muscle progenitor cells can be cultured with BrdU or Edu, in the presence or absence of specific potential pro-regenerative factors, and the degree of proliferation determined using high-throughput microscopy. BrdU or Edu staining indicates proliferation, while embryonic Myosin Heavy-Chain (eMyHC) staining indicates terminal differentiation of the progenitor cells. FIGS. 4A and 4B shows an example of data generated using high-throughput imaging.

Many of the factors detailed in Table 2 were tested individually for their ability to promote proliferation and/or fusion of mouse muscle progenitor cells in vitro FIG. 5 and FIG. 6.

The effect of the candidate factors on myogenic activity was assayed in biological triplicate across a range of concentrations centered around expected physiological levels by adding each factor to mouse myoblasts for 48 hours or human myoblasts for 72 hours with daily media changes (DMEM+2% horse serum) and a second pulse of factors. After 24 hours, cells were pulsed for 2-5 hours with EdU (30 uM), ethanol fixed, stained with Hoescht 3342, immunostained for proliferation—as measured by the percent of cells staining positive for EdU (% EdU)-, and immunostained for differentiation—as measured by the increase in cellular area staining positive for embryonic myosin heavy chain (% eMyHC) relative to the negative controls, which received media and vehicle only. Wells were imaged on a Keyence BZ-100 at 4×, the images quantified in Cell Profiler, and the statistics were computed in R. FIGS. 7A-7B show an example of the proliferation dose response for two of the factors tested. Results for additional factors are summarized below in Table 9.

TABLE 9

Effect of individual factors on mouse myoblast growth and fusion

Proliferation (% EdU)
Fusion (% eMyHC)

Effect Size (%
Statistical
Effect Size (%
Statistical

Factor
Concentration
relative to -
Significance
relative to -
Significance

Name
(ug/mL)
control)
(p-value)
control)
(p-value)

FST
0.33
72%
0.001
202%
0.005

CTGF
5

154%
0.00005

THBS1
5

157%
0.004

THBS2
0.33

161%
0.006

IGFBP3
0.33
131%
0.03

IGFBP5
2
69%
0.04

IGFBP7
0.33
78%
0.03

STC2
2.5
133%
0.02
−31%
0.003

SPON1
0.33
139%
0.04

MST1
0.33
144%
0.02

POSTN
0.33
139%
0.01

RARRES2
0.33
141%
0.03

AGRN
2.5
148%
0.008

CHRDL1
1.25
150%
0.00009

VTN
5
125%
0.004

FGF17
0.5
244%
0.0004

ANOS1
1
165%
0.03

FGF4
0.3
239%
4.6E−13

HGF
0.56
114%
1.6E−10

IGF2
1
97%
1.3E−5

FGF1
1
96%
2.3E−7

FGF6
0.002
115%
1.8E−5

MST1
0.33
79%
0.002

PDGFD
0.1
89%
4E−5

The effect of the combination of candidate factors on myogenic activity was assayed in biological triplicate across a range of concentrations centered around expected physiological levels by adding each factor to mouse myoblasts for 48 hours or human myoblasts for 72 hours with daily media changes (DMEM+2% horse serum) and a second pulse of factors. After 24 hours, cells were pulsed for 2-5 hours with EdU (30 uM), ethanol fixed, stained with Hoescht 3342, immunostained for proliferation—as measured by the percent of cells staining positive for EdU (0% EdU)-, and immunostained for differentiation—as measured by the increase in cellular area staining positive for embryonic myosin heavy chain (0% eMyHC) relative to the negative controls, which received media, individual factors, or vehicle only. Wells were imaged on a Keyence BZ-100 at 4×, the images quantified in Cell Profiler, and the statistics were computed in R. FIGS. 7C-7M show examples of the proliferation dose response for two or more of the factors tested individually and as a combination to test for synergy. Statistical metrics for increased myogenetic activity from the pair of factors relative to the controls are summarized below in Tables 10-14. Each polypeptide was produced using the method listed in Table 1. Each polypeptide was produced using the method listed in Table 1. The magnitude of the combinations' effects relative to control (FM—negative control, hESC factors—positive control) is shown. The Combination Index (CI) for synergy was calculated using the Highest Single Agent (HAS) model due to the linear dose responses for the individual factor, e.g. FIG. 7B.

TABLE 10

Synergistic combinations of heparin-associated polypeptides.

Factor 1
Factor 2
Factor 3

Name
ug/mL
Name
ug/mL
Name
ug/mL
p-value
CI (HSA)

THBS2
0.125
THBS4
0.25
VTN
1
<0.05
0.886

THBS2
0.125
THBS4
0.25
ANOS1
1
<0.005
0.532

THBS2
0.125
THBS4
0.25

<0.005
0.633

THBS1
0.0625
FGF17
0.025

<0.005
0.667

THBS1
0.125
FGF17
0.1

<0.005
0.679

THBS2
0.125
THBS4
0.25
IL-15
1
<0.005
0.680

THBS2
0.125
THBS4
0.25
IGF2
0.05
<0.05
0.733

THBS2
0.0625
VTN
1.25

<0.005
0.763

THBS2
0.125
VTN
1.25

<0.005
0.763

THBS2
0.125
VTN
0.3125

<0.005
0.771

THBS2
0.0625
THBS4
0.125

<0.005
0.772

THBS2
0.125
THBS4
0.0625

<0.005
0.779

THBS1
0.0625
FGF17
0.1

<0.005
0.796

THBS1
0.0625
VTN
0.315

<0.005
0.840

THBS2
0.0625
THBS4
0.25

<0.005
0.850

THBS1
0.25
THBS2
0.25

<0.05
0.859

THBS2
0.0625
FGF17
0.1

<0.005
0.871

THBS2
0.0625
VTN
0.625

<0.005
0.876

THBS2
0.125
THBS4
0.125

<0.005
0.878

THBS1
0.0625
VTN
1.25

<0.05
0.880

THBS1
0.25
THBS4
0.0625

<0.005
0.888

THBS2
0.0625
FGF17
0.025

<0.005
0.890

THBS1
0.0625
THBS2
0.0625

<0.05
0.900

THBS1
0.25
VTN
1.25

<0.005
0.907

THBS2
0.125
FGF17
0.025

<0.005
0.913

VTN
0.3125
FGF17
0.025

<0.05
0.915

THBS4
0.25
VTN
0.3125

<0.05
0.922

THBS2
0.125
FGF17
0.1

<0.005
0.923

THBS1
0.25
VTN
0.625

<0.005
0.930

THBS2
0.0625
THBS4
0.0625

<0.05
0.942

THBS4
0.25
FGF17
0.1

<0.005
0.945

THBS4
0.0625
VTN
0.625

<0.05
0.950

VTN
0.625
FGF17
0.1

<0.005
0.952

THBS4
0.25
VTN
1.25

<0.05
0.954

TABLE 11

Additional data regarding synergistic combinations of heparin-associated polypeptides

(mouse myoblasts)

Single

Combo

Dose

Dose

Single
Single
% EdU

% EdU

Dose @
Dose
Fold
Single
Combo
Combo
Fold
Combo

Factor
saturation
% of
Change
Dose
Dose
Dose %
Change
Dose

Name
(ug/mL)
EB
to FM
% EdU
(ug/mL)
of EB
to FM
% EdU
HSA CI

THB S1
2
50%
1.7
15%
0.125
64%
1.16
14%

FGF17
0.5
239%
4.5
69%
0.1
148%
2.89
33%

Combo

163%
3.63
29%
0.679091

THB S2
2
50%
1.25
13%
0.125
46%
0.88
10%

THB S4
2
40%
1.87
10%
0.25
53%
1.11
12%

Combo

71%
1.39
17%
0.632548

THB S1
2
50%
1.7
15%
0.0625
44.08%
0.75
10.63%

VTN
10
50%
1.5
16%
10
59.18%
1.01
14.27%

Combo

69.47%
1.19
16.75%
0.851842

THB S2
2
50%
1.25
13%
0.125
31.08%
0.85
7.86%

THB S4
2
40%
1.87
10%
0.25
29.33%
0.8
7.41%

IL15
0.5
52%
1.4
12.50%
1
47.25%
1.28
11.90%

Combo

57.91%
1.66
16.21%
0.679578

THB S2
2
50%
1.25
13%
0.125
45.08%
0.79
9.64%

THB S4
2
40%
1.87
10%
0.25
61.15%
1.08
13.08%

VTN
10
50%
1.5
16%
10
54.46%
0.94
12.67%

TABLE 12

Additional data regarding synergistic combinations of heparin-associated polypeptides

(mouse myoblasts)

Combo

Dose

Single
Single

Combo
Combo
% EdU Fold
Combo

Dose
Dose %
Single Dose
Dose
Dose % of
Change to
Dose

Factor
(ug/mL)
of Eb
% EdU
(ug/mL)
EB
FM
% EdU

THB S1
2
50%
15%
0.125
64%
1.16
14%

FGF17
0.5
239%
69%
0.1
148%
2.89
33%

Combo

163%
3.63
29%

THB S2
2
50%
13%
0.125
46%
0.88
10%

THB S4
2
40%
10%
0.25
53%
1.11
12%

Combo

71%
1.39
17%

THB S1
2
50%
15%
0.0625
44.08%
0.75
10.63%

VTN
10
50%
16%
10
59.18%
1.01
14.27%

Combo

69.47%
1.19
16.75%

THB S2
2
50%
13%
0.125
31.08%
0.85
7.86%

THB S4
2
40%
10%
0.25
29.33%
0.8
7.41%

IL15
0.5
52%
12.50%
1
47.25%
1.28
11.90%

Combo

57.91%
1.66
16.21%

THB S2
2
50%
13%
0.125
45.08%
0.79
9.64%

THB S4
2
40%
10%
0.25
61.15%
1.08
13.08%

VTN
10
50%
16%
1
54.46%
0.94
12.67%

Combo

69.02%
1.22
14.76%

THB S2
2
50%
13%
0.125
58.62%
0.86
15.23%

THB S4
2
40%
10%
0.25
62.99%
0.93
16.37%

IGF2
2
89%
23%
0.5
85.78%
1.27
22.29%

Combo

116.95%
1.72
30.39%

TABLE 13

Additional data regarding synergistic combinations of heparin-associated polypeptides

(human myoblasts)

Single

Combo

Dose

Dose

Single
Single
% EdU

% EdU

Dose @
Dose
Fold
Single
Combo
Combo
Fold
Combo

Factor
saturation
% of
Change
Dose
Dose
Dose %
Change
Dose
HSA

Name
(ug/mL)
EB
to FM
% EdU
(ug/mL)
of EB
to FM
% EdU
CI

THBS1
7.5
98.93
1.61
10.99
0.5
78.22
0.85
8.95

FGF17
0.25
222.09
3.62
24.67
0.05
121.74
1.33
13.93

Combo

157.29
1.72
18
0.77

THBS2
7.5
112.84
1.2
12.53
0.125
57.09
0.95
7.82

69

448

THBS4
0.5
126.70
2.07
14.07
0.25
62.67
1.04
8.59

02

323

IL15
0.1
67.81
1.13
9.29
0.1
67.81
1.13
9.29

Combo

69
1.15
9.46
0.98

TABLE 14

Additional data regarding synergistic combinations of heparin-associated polypeptides

(human myoblasts)

Combo

Dose

Single

Single Dose

% EdU

Dose @
Single
% EdU Fold
Single
Combo
Combo
Fold
Combo

Factor
saturation
Dose %
Change to
Dose
Dose
Dose %
Change
Dose

Name
(ug/mL)
of EB
FM
% EdU
(ug/mL)
of EB
to FM
% EdU

THB S1
7.5
98.93
1.61
10.99
0.5
78.22
0.85
8.95

FGF17
0.25
222.09
3.62
24.67
0.05
121.74
1.33
13.93

Combo

157.29
1.72
18

Example 8—In Vivo Testing of hPSC Factors Increases Regenerative Index and Reduces Fibrotic Index in an Acute Injury Model in Aged Mice

FIGS. 9A-9F show that aged mice (18 months) administered isolated, heparin-agarose bead purified hPSC show improved regenerative index and reduced fibrotic index. FIG. 9A shows a schematic of the experiment in this example. This experiment shows that hPSC derived factors can improve histological metrics of muscle health and function. As shown in FIG. 9B heparin-associated polypeptides isolated from human pluripotent stem cells increase regenerative potential and reduce muscle fibrosis in aged mice subjected to a model of acute muscle injury. As shown in FIG. 9C, there was increased muscle regeneration for injured, aged mouse muscle treated with THBS1 (2 ug/mL) compared to young and vehicle-treated, aged mouse muscle.

FIG. 9D shows the experimental schematic of time-points for dosing and analysis using an acute injury model in aged mice of the effects of individual heparin-associated polypeptides with fusion enhancing effects in vitro. Square denote injury inducing intramuscular injection (IM) with Barium Chloride while circles denote administration of treatment or vehicle. FIG. 9E shows the results of the experiment outlined in FIG. 9D shows that administration of 20 ul of heparin-associated polypeptides PPDGFRL (5 ug/mL, p<3.85E-2) and IGFBP7 (1 ug/mL, p<6.63E-3) resulted in improved new fiber formation (regenerative index compared to vehicle treated aged mice. Stars indicate degree of significance from one-way ANOVA tests. FIG. 9F provides representative images of immunofluorescence staining of sectioned mouse muscle (tibialis anterior) demonstrating increased muscle regeneration for injured, aged mouse muscle treated with POSTN (1 ug/mL) or IGFBP7 (1 ug/mL) compared to vehicle-treated, aged mouse muscle.

Other models for in vivo testing of hSPC factors include:

Disuse-Reload Injury Model

This mouse model is a way to observe muscle atrophy in a non-invasive way by contracting the hind limbs of a mouse and preventing extension and flexion, thus reducing the size and strength. The model will serve as an important measurement of muscle regeneration with biologic candidates.

The hind limb will be immobilized with Cast Tape extended position using sports tape to prevent flexion of the limb. Once the sports tape is in place, a strip of casting tape will be wrapped over the sports tape from the ankle upward, and air dried. The extension of the hind limb should stay rigid in its position of the duration of the study parameters.

The study begins after mice are acclimated and on Day −3, in which mice from all groups will be weighed. Assigned animals will be given daily i.p. injections of Vehicle control or Candidate Biologic for 3 days before undergoing hind limb immobilization on Day 0 for 7 days with continuous daily i.p. injections. Hind limbs will be observed for any adverse effects due to immobilization. On Day 7 of the study, all animals will be sacrificed and muscle tissue weighed and harvested for further analysis.

Force Measurement

This study will be used to measure the force of pull in the hind limbs that the animal exerts upon skeletal muscle injury of the tibialis anterior (TA) and gastrocnemius (GA) muscles after injury induction with Barium chloride (BaCl2). This model will serve to determine which of our biological candidates are efficacious in muscle regeneration.

Skeletal Muscle Injury Induction: Under anesthesia, BaCl2 will be administered in two sites on the TA and four sites on the GA (as previously described). Hair will be shaved on the left and right hind limbs prior to injection with small animal hair clippers. On Day 0 of the study, the TA muscle will undergo BaCl2 induced injury on two sites (previously described). On Day 4 of the study, the GA muscle will follow with BaCl2 induced injury on four sites. Candidate biologic will be administered on Days 0 and 2 in the injury sites of the TA and GA muscles. BrdU will be injected via IP (QD) on days 4-7 to label proliferating muscle precursor and fibrotic cells in order to measure their regenerative potential.

On terminal day 7, animals will be deeply anesthetized and a force transducer will be used to measure twitch reactions in the hind limbs of each mouse being tested in the study, via a small incision in the TA to a small metal hook. This will be a terminal procedure. Grip strength measurements: the mice will rest on an angled mesh, facing away from the force meter and with its hind limbs at least one-half of the way down the length of the mesh. The mouse's tail is pulled directly toward the meter and parallel to the mesh. During this procedure, the mouse resists by grasping the mesh with all four limbs. Pulling is continued toward the meter until the hind limbs release.

Ex Vivo Regenerative Measurement

To confirm these data with age matched, primary muscle stem cells, injury-activated satellite cells associated with myofibers will be isolated from young and old muscle by dissecting the muscle groups of interest and dissociating the tissue to single cell suspensions by incubating in digestion medium (250 U/mL Collagenase type II in DMEM medium, buffered with 30 mM HEPES, pH 7.4) at 37 C for 1 hr., triturating the cell suspension, the myofibers were collected by centrifugation and myofibers further digested with 1 U/mL Dispase and 40 U/mL Collagenase type II in 30 mM HEPES at 37 C for 1 hr to free muscle stem cells. Muscle stem cells can then be plated and cultured growth media containing serum (2-5%) from the same mouse. The regenerative and fusion potential of the cells will then be assayed as described above in in Example 7 and as demonstrated in FIGS. 10B, 10C, 11B, and 11C. This has the advantage of testing the effect of treatment while maintaining the exogenous, often inhibitory extracellular environmental ques contributed by the age appropriate serum.

Example 9—Modelling Treatment of a Muscular Dystrophy with Pro-Regenerative Factors In Vitro Using High-Throughput Imaging

Muscular dystrophies (MD) encompass a variety of muscular degeneration diseases typically due to genetic mutations in genes encoding proteins responsible for forming and stabilizing skeletal muscle. The phenotypic consequence of these genetic mutations is the progressive loss of muscle mass and strength over time, similar to sarcopenia but with different underlying causes. As heparin-associated polypeptides provided phenotypic improvements on sarcopenic muscle, we tested for similar improvements in a model for MD.

Many of the factors detailed in Table 2 were tested individually for their ability to promote proliferation and/or fusion of human muscle progenitor cells from a patient with myotonic dystrophy type 1 (hMD)—a muscular dystrophy caused by mutations in the DMPK1 gene.

The effect of the candidate factors on myogenic activity was assayed in biological triplicate across a range of concentrations centered around expected physiological levels by adding each factor to hMD myoblasts for 72 hours with daily media changes (DMEM+2% horse serum) and a second pulse of factors at the first media change. After 72 hours, cells were pulsed for 2-5 hours with EdU (30 uM), ethanol fixed, stained with Hoescht 3342, immunostained for proliferation—as measured by the percent of cells staining positive for EdU (% EdU)-, and immunostained for differentiation—as measured by the increase in cellular area staining positive for embryonic myosin heavy chain (% eMyHC) relative to the negative controls, which received media and vehicle only. Wells were imaged on a Keyence BZ-100 at 4×, the images quantified in Cell Profiler, and the statistics were computed in R. FIGS. 12A and 12B show examples of the quantitation of the proliferation response and fusion response for several of the factors tested, respectively. Results those and additional factors are summarized below in Table 15.

TABLE 15

Effect of individual factors on dystrophic human myoblast growth and fusion

Proliferation (% EdU)
Fusion (% eMyHC)

Effect Size
Statistical
Effect Size
Statistical

Factor
Concentration
(% relative
Significance
(% relative
Significance

Name
(ug/mL)
to -control)
(p-value)
to -control)
(p-value)

FGF17
0.2
208%

<9E−14

FGF4
0.0125
269%
9.52E−13

FGF4
0.025
244%
6.83E−12

FGF4
0.05
235%
7.22E−10

FGF4
0.1
213%
8.11E−07

FGF4
0.2
184%
1.46E−02

IGF2
0.2
53%
2.57E−02

FGF1
0.05
157%
1.65E−06

FGF1
0.1
217%
2.87E−06

FGF1
0.2
213%
1.10E−10

FGF6
0.0125
277%
1.34E−09

FGF6
0.025
272%
4.54E−09

FGF6
0.05
261%
4.75E−08

FGF6
0.1
243%
1.03E−07

FGF6
0.2
237%
8.49E−06

PDGFRL
0.03125

2580%
1.47E−06

PDGFRL
0.0625

2240%
6.34E−07

PDGFRL
0.125

1410%
4.53E−03

PDGFRL
0.25

2570%
1.86E−08

PDGFRL
0.5

3440%
5.75E−11

Example 10 Assess hPSC Factors In Vivo Using Rodent Models of Becker Muscular Dystrophy for their Ability to Improve Muscle Regeneration and Muscle Mass

Mdx−/− mice will receive intramuscular injections of the top 3 select hPSC secreted factors selected from the in vitro screen. Indications of enhanced functional regeneration will be assessed through quantification of twitch force measurements and walking track analysis. The Mdx−/− mouse model for BMD is chosen as it has a spontaneous point mutation in the dystrophin gene leading to near complete absence of dystrophin protein. Despite having phenotypic markers of myopathy there are only mild skeletal muscle defects, suggesting that the model best reflects Becker muscular dystrophy. This animal model also mimics the complex paracrine signaling environment, where immune cells and other systemic factors would be involved. Thus, a screen in injured dystrophic muscle for regeneration will efficiently narrow the candidate list for those proteins needed for the ultimate goal of restoring muscle mass and strength to the BMD patients. Myogenesis in a muscle regeneration model will be compared between controls (vehicle-treated) and with the top 3-5 efficacious, dose-optimized factors. Hind limb muscles, the Tibialis anterior (TA) and gastrocnemius (GA) muscle will receive i.m. injection of vehicle control or candidate factor every day for 7 days (t=5 days). BrdU will also be injected 3 days prior to tissue collection for ex vivo analysis. Muscle regeneration will be assessed in 10 micrometer muscle cryosections. The histological analysis of hematoxylin and eosin staining and immunodetection of eMyHC and BrdU will be used to quantify the numbers of de-novo eMyHC+ myofibers with centrally-located BrdU+ nuclei throughout the injury site. Additionally, myofiber size and muscle weights will also be assessed. For twitch for measurements, mice hindlimbs will be immobilize to a frame. A small incision will be made in the skin directly above the tibialis anterior (TA) muscle to hook to a thin metal hook and then attached to a 300C-LR force transducer (Aurora Scientific). A bipolar electrical stimulation cuff will wrap around the TA and stimulate with a single 0.1-ms pulse for 3 seconds.

It is expected that administration of select pro-myogenic factors will increase Delta/Notch and MapK signaling, dependent on BMP signaling in Mdx−/− myogenic cells, resulting in increased proliferation, allowing the injury site to heal similar to wildtype muscle—with new muscle fibers—instead of filling with fibrotic scar tissue or adipose tissue as is common in dystrophic muscle. Administration of candidate factors to Mdx−/− injured TA muscle is expected to improve regeneration indicated by quantification of muscle fiber repair and twitch force measurement.

Example 11—Clinical Testing of Pro-Regenerative Factors

The purpose of this study is to determine the efficacy of repeat dosing with multiple dose levels of heparin-associated proteins on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study will generate data on the safety, tolerability, and pharmacokinetics of heparin-associated proteins in older adults with sarcopenia. Individuals will administered placebo or heparin-associated binding proteins and monitored for 25 weeks of study. The following primary and secondary outcome measures will be assessed:

Primary Outcome Measures:

Short Physical Performance Battery (SPPB) [Time Frame: Baseline, week 25]. Change from baseline to week 25.

Secondary Outcome Measures:

Safety and tolerability as assessed by various measures such as adverse events. Assessed by various measures such as adverse events over 24 weeks.

Change in 6-minute walk test [Time Frame: baseline, week 25]. Change from baseline to week 25.

Gait speed [Time Frame: baseline, week 25]. Change from baseline to week 25.

Change in total lean body mass and appendicular skeletal muscle index measured by DXA from baseline to week 25.

Inclusion Criteria:

Otherwise healthy adults aged at least 70 years; Low muscle mass as confirmed by DXA; Low gait speed; SPPB score less than or equal to 9; Weigh at least 35 kg; with adequate dietary intake as determined by patient interview.

Protocol

Patients will be i.v.-administered placebo (5% dextrose solution) or heparin-associated binding proteins (in 5% dextrose). Starting on day 1, week 1 and repeated every other week (day one of weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. At the end of week 12 and 24 patients will be assessed by the above methods for improvement. Doses will be selected from a traditional 3+3 design, and selected as the top two-doses that lack dose-limiting toxicity.

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention.

All publications, patent applications, issued patents, and other documents referred to in this specification are herein incorporated by reference as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions that are contained in text incorporated by reference are excluded to the extent that they contradict definitions in this disclosure.

	Number	Date	Country
	62690796	Jun 2018	US
	62809479	Feb 2019	US

	Number	Date	Country
Parent	17072636	Oct 2020	US
Child	18448054		US
Parent	16455445	Jun 2019	US
Child	17072636		US

Heparin-Associated Polypeptides and Uses Thereof

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

PRIORITY

Provisional Applications (2)

Continuations (2)